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ABSTRACT 
Dyslipidaemia, a major risk factor of cardiovascular disease (CVD), is prevalent not only in 
diabetic patients but also in individuals with impaired glucose tolerance (IGT) or impaired 
fasting glucose (IFG). The aims of this study were: 1) to investigate lipid levels in relation 
to glucose in European (I) and Asian (II) populations without a prior history of diabetes; 2) 
to study the ethnic difference in lipid profiles controlling for glucose levels (III); 3) to 
estimate the relative risk for cardiovascular mortality (IV) and morbidity (V) associated 
with dyslipidaemia in individuals with different glucose tolerance status. 
Data of 15 European cohorts with 19 476 subjects (I and III) and 13 Asian cohorts with 19 
763 individuals (II and III) from 21 countries aged 25-89 years, without a prior history of 
diabetes at enrollment, representing Asian Indian, Chinese, European, Japanese and 
Mauritian Indian, were compared. The lipid-CVD relationship was studied in 14 European 
cohorts of 17 763 men and women which provided with follow-up data on vital status, with 
871 CVD deaths occurred during the average 10-year follow-up (IV). The impact of 
dyslipidaemia on incidence of coronary heart disease (CHD) in persons with different 
glucose categories (V) was further evaluated in 6 European studies, with 9087 individuals 
free of CHD at baseline and 457 developed CHD during follow-up. Z-scores of each lipid 
component were used in the data analysis (I, II, IV and V) to reduce the differences in 
methodology between studies. Analyses of cardiovascular mortality and morbidity were 
performed using Cox proportional hazards regression analysis adjusting for potential 
confounding factors. 
Within each glucose category, fasting plasma glucose (FPG) levels were correlated with 
increasing levels of triglycerides (TG), total cholesterol (TC), TC to high-density 
lipoprotein (HDL) ratio and non-HDL cholesterol (non-HDL-C) (p<0.05 in most of the 
ethnic groups) and inversely associated with HDL-C (p<0.05 in some, but not all, of the 
populations). The association of lipids with 2-h plasma glucose (2hPG) followed a similar 
pattern as that for the FPG, except the stronger association of HDL-C with 2hPG. 
Compared with Central & Northern (C&N) Europeans, multivariable adjusted odd ratios 
(95% CIs) for having low HDL-C were 4.74 (4.19-5.37), 5.05 (3.88-6.56), 3.07 (2.15-4.40) 
and 2.37 (1.67-3.35) in Asian Indian men but 0.12 (0.09-0.16), 0.07 (0.04-0.13), 0.11 (0.07-
0.20) and 0.16 (0.08-0.32) in Chinese men who had normoglycaemia, prediabetes, 
undiagnosed and diagnosed diabetes, respectively. Similar results were obtained for women. 
The prevalence of low HDL-C remained higher in Asian Indians than in others even in 
individuals with LDL-C < 3 mmol/l. Dyslipidaemia was associated with increased CVD 
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mortality or CHD incidence in individuals with isolated fasting hyperglycaemia or IFG, but 
not in those with isolated post-load hyperglycaemia or IGT.   
In conclusion, hyperglycaemia is associated with adverse lipid profiles in Europeans and 
Asians without a prior history of diabetes. There are distinct patterns of lipid profiles 
associated with ethnicity regardless of the glucose levels, suggesting that ethnic-specific 
strategies and guidelines on risk assessment and prevention of CVD are required. 
Dyslipidaemia predicts CVD in either diabetic or non-diabetic individuals defined based on 
the fasting glucose criteria, but not on the 2-hour criteria. The findings may imply 
considering different management strategies in people with fasting or post-load 
hyperglycaemia. 
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TIIVISTELMÄ 
Dyslipidemia, sydän-ja verisuonitautien (cardiovascular disease, CVD) merkittävä 
riskitekijä, on yleinen paitsi diabeetikoilla mutta myös henkilöillä, joilla on alentunut 
glukoosinsietokyky (impaired glucose tolerance, IGT) tai alentunut paastoverensokeri 
(impaired fasting glucose, IFG). Tutkimuksen tarkoituksena oli: 1) tutkia rasva-arvoja 
suhteessa glukoosiin eurooppalaisissa (I) ja aasialaisissa (II) väestöissä, joilla ei ole 
aiemmin todettu diabetesta, 2) tutkia eroja lipidiprofiilileissa etnisten ryhmien välillä 
huomioiden plasman glukoosipitoisuus (III), 3) arvioida dyslepidemiaan liittyvän CVD-
kuolleisuuden (IV) ja -sairastuvuuden (V) suhteellinen riski eri glukoosinsietokyvyn 
omaavilla henkilöillä. 
Tutkimuksen aineisto koostuu 15 eurooppalaisesta kohortista, joihin osallistui yhteensä 19 
476 tutkimushenkilöä (I ja III) ja 13 aasialaisesta kohortista, joihin osallistui 19 763 
tutkimushenkilöä (II ja III). Näitä tutkimuksia, joissa tutkittiin 25-89-vuotiaita 
lähtökohtaisesti intialaisia, kiinalaisia, eurooppalaisia, japanilaisia ja Mauritiuksen 
intialaisia yhteensä 21 maasta, vertailtiin keskenään. Lipidi-CVD suhdetta tutkittiin 14 
eurooppalaisessa kohortissa, joihin osallistui 17 763 miestä ja naista, joista selvisi myös 
kuolleisuusluvut. Keskimäärin 10 vuoden seurannan aikana (IV) havaittiin 871 CVD-
peräistä kuolemaa. Kuudessa eurooppalaisessa tutkimuksessa arvioitiin dyslipidemian 
vaikutusta sepelvaltimotaudin ilmaantuvuuteen glukoositason mukaan (V). Lähtötilanteessa 
oli 9087 ilman sepelvaltimotautia olevaa henkilöä, joista 457:lle kehittyi sepelvaltimotauti 
seurannan aikana. Tutkimusten välisten menetelmäeroja vaikutuksen vähentämiseksi 
kunkin lipidi-komponentin analysoinnissa (I, II, IV ja V) käytettiin Z-score arvoja. 
Sepelvaltimotaudin kuolleisuus- ja sairastuvuusanalyysit suoritettiin käyttäen Coxin 
suhteellisen riskin regressioanalyysi huomioiden mahdolliset sekoittavat tekijät. 
Kaikissa glukoosiluokissa paastoverensokerin (fasting plasma glucose, FPG) tasot 
korreloivat seerumin triglyseridipitoisuuden, kokonaiskolesterolin (total cholesterol, TC), 
TC-kolesterolin ja high-density lipoproteiini (HDL)-kolesterolin suhteen sekä ei-HDL-
kolesterolin kanssa (p<0.05 useimmissa etnisissä ryhmissä) ja olivat käänteisesti yhteydessä 
HDL-kolesteroliin (p<0.05 joissakin, mutta ei kaikkissa populaatioissa). Lipidien ja 2-
tunnin plasman glukoosipitoisuuden (2hPG) välinen yhteys  oli samankaltainen kuin 
lipidien ja FPG:n yhteys, lukuunottamatta voimakkaampaa yhteyttä HDL- kolesterolin ja 
2hPG välillä. Kun tutkittiin riskiä liittyen mataliin HDL-kolesteroliarvoihin käyttäen 
vertailuryhmänä eurooppalaisia henkilöitä, vakioidut riskisuhteet (odds ratio)(95% CI) 
olivat intialaisilla miehillä 4.74 (4.19-5.37), 5.05 (3.88-6.56), 3.07 (2.15-4.40) ja 2.37 (1.67-
3.35) ja kiinalaisilla miehillä 0.12 (0.09-0.16), 0.07 (0.04-0.13), 0.11 (0.07-0.20) ja 0.16 
(0.08-0.32), kun heillä oli joko normoglykemia, IGT tai IFG, diagnosoimaton diabetes tai 
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aikaisemmin diagnosoitu diabetes. Naisille saatiin samansuuntaiset tulokset. Matala HDL-
kolesteroli oli yleisintä intialaisilla, mutta myös henkilöillä, joilla low-density lipoproteiini-
kolesteroli oli yli 3mmol/l. Dyslipidemia oli yhteydessä lisääntyneeseen CVD-
kuolleisuuteen tai sepelvaltimotaudin ilmaantuvuuteen henkilöillä, joilla oli yksinomainen 
paastohyperglykemia tai IFG, mutta ei niillä, joille oli yksinomainen glukoosirasituksen 
jälkeinen hyperglykemia tai IGT. 
Yhteenvetona voidaan todeta, että hyperglykemia on yhteydessä haitallisiin 
lipidiprofiileihin eurooppalaisilla ja aasialaisilla, joilla ei ole aikaisemmin todettua 
diabetesta. Määrätynlaiset lipidiprofiilit ovat yhteydessä etniseen alkuperään veren 
glukoositasoista riippumatta, mikä viittaa siihen, että eri etnisissä ryhmissä tarvitaan omat 
strategiat ja suuntaviivat CVD:n riskinarvioinnissa ja ehkäisyssä. Dyslipidemia ennustaa 
CVD:tä, riippumatta siitä, onko henkilöllä todettavissa diabetes paastoveren 
glukoosikriteerin perusteella, mutta se ei ennusta henkilöllä, joilla on  todettavissa diabetes 
2 tunnin glukoosirasituksen jälkeisen kriteerin mukaan. Tulosten perusteella voidaan 
mahdollisesti harkita eri hoitosuositusten käyttöä ihmisillä, joilla on paastoveren glukoosi 
koholla kuin niillä, joilla on hyperglykemia glukoosirasituksen jälkeen. 
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1 INTRODUCTION 
Cardiovascular disease (CVD) is a major cause of death worldwide (World Health 
Organization 2007). Although mortality from CVD has decreased in many European and 
other western countries over the past decades, the epidemic of CVD is being an increasing 
public health challenge in Asia with growing urbanization and industrialization (Zimmet et 
al. 2001; Ramachandran et al. 2008). Dyslipidaemia is one of the major CVD risk factors 
and plays an important role in the progress of atherosclerosis, the underlying pathology of 
CVD. To control abnormal lipids and lipoproteins levels has been recommended by 
different national, regional, or global (Expert Panel 2001; Graham et al. 2007; World Health 
Organization 2007) guidelines on the prevention and management of CVD. 
Dyslipidaemia often coexists with diabetes, the coronary heart disease (CHD) risk 
equivalent. An atherogenic lipid profile, consisting of high triglycerides (TG) and small 
dense low-density lipoprotein cholesterol (LDL-C) and low high-density lipoprotein 
cholesterol (HDL-C), is common not only in patients with overt diabetes (Barrett-Connor et 
al. 1982) but also in individuals with impaired glucose tolerance (IGT) or impaired fasting 
glucose (IFG) (Meigs et al. 2002; Novoa et al. 2005; Chen et al. 2006; Pankow et al. 2007). 
Nevertheless, none of the cross-sectional studies has evaluated the linear relationship 
between lipid and blood glucose concentrations at levels below the current diagnostic 
thresholds for diabetes in either the Europeans or the major ethnic groups of Asian 
populations.  
The importance of dyslipidaemia on risk of CVD in patients with diabetes has been 
extensively studied in numerous studies. Reduced HDL-C is well documented as an 
independent predictor of CVD events (Wilson et al. 1988; Cooney et al. 2009). In contrast, 
the role of TG as an independent risk factor for CVD is more controversial (Patel et al. 2004; 
Psaty et al. 2004; Barzi et al. 2005; Sarwar et al. 2007; Wang et al. 2007). Recently, the 
interest to use novel parameters such as total cholesterol (TC) to HDL ratio (TC/HDL-C), 
non-HDL-cholesterol (non-HDL-C), apolipoprotein B (apoB) and apolipoprotein A (apoA) 
to assess CVD risk has increased (Barzi et al. 2005; Pischon et al. 2005; Charlton-Menys et 
al. 2009). As a CVD risk predictor, the non-HDL-C has been considered to be superior to 
LDL-C (Cui et al. 2001; Schulze et al. 2004; Liu et al. 2005; Ridker et al. 2005). But little is 
known with regard to the impact of these dyslipidaemic parameters on cardiovascular 
mortality or morbidity in individuals with non-diabetic glucose levels. 
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2 REVIEW OF THE LITERATURE 
2.1 Physiology of lipid metabolism 
Lipids are fats that are either absorbed from blood or synthesized by the liver. All lipids are 
hydrophobic and therefore they are transported associated with proteins as lipoproteins 
(Table 1), which are hydrophilic and with spherical structures.  
Table 1 Physical properties, lipid and apolipoprotein composition of human plasma lipoproteins 
VLDL, very-low density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein. 
2.1.1 Exogenous lipid metabolism 
Over 95% of dietary lipids are TG; the rest are phospholipids, free fatty acids (FFA), 
cholesterol and fat-soluble vitamins. Dietary fats are digested in the stomach and duodenum 
into monoglycerides (MGs) and FFAs by gastric lipase, pancreatic lipase and emulsification 
from vigorous stomach peristalsis (Fig. 1). Dietary cholesterol esters are de-esterified into 
free cholesterol (FC) by the same mechanisms. MGs, FFAs and FC are then solubilized in 
the intestine by bile acid micelles, which shuttle them to intestinal villi for absorption. They 
are reassembled into TGs and packaged with cholesterol into chylomicrons once absorbed 
into the enterocytes. 
Chylomicrons, the largest lipoproteins, transport dietary TG and cholesterol from within 
enterocytes through lymphatics into the circulation. In the capillaries of adipose and muscle 
 Chylomicron VLDL IDL LDL HDL 
Source Intestine Liver Lipolysis of 
VLDL 
Lipolysis of 
VLDL, via IDL 
Liver, 
intestine; 
Diameter (nm) 75-1200 30-80 25-35 18-25 5-12 
Density (kg/l) < 0.96 0.96-1.006 1.006-1.019 1.019-1.063 1.063-1.210 
Composition (%)      
Triglycerides 86 55 23 6 5 
Phospholipids 7 18 19 22 33 
Cholesteryl esters 4 12 29 42 17 
Free cholesterol 2 7 9 8 5 
Protein 2 8 19 22 40-55 
Apolipoproteins 
contained 
A-I, A-IV, B-48, 
C, E 
B-100, C, E B-100, C, E B-100 A-I, A-II, C, E 
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tissues, apolipoprotein C-II (apoC-II) on the chylomicron activates endothelial lipoprotein 
lipase (LPL) (Breckenridge et al. 1978) to convert 90% of chylomicron TG to fatty acids 
and glycerol, which are taken up by adipocytes and muscle cells for energy use or storage 
(Fig. 1). Cholesterol-rich chylomicron remnants are then cleared rapidly from circulation by 
the liver through a process mediated by apolipoprotein E (apoE) (Mahley and Ji 1999).  
 
 
Figure 1 Summary of exogenous and endogenous lipid metabolism. FFA: free fatty acid; LDL: low-density 
lipoprotein; IDL: intermediate-density lipoprotein; HDL: high-density lipoprotein; LCAT:  lecithin-cholesterol 
acyl transferase; LPL: lipoprotein lipase; ApoC-II: apolipoprotein C-II; SRBI: scavenger receptor class B type 
I; CETP: cholesteryl ester transfer protein 
 
2.1.2 Endogenous lipid metabolism 
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on the VLDL surface activates endothelial LPL to hydrolyze TGs into FFAs and glycerol, 
which are taken up by cells. 
Intermediate-density lipoproteins (IDL) are the product of LPL processing of VLDL and 
chylomicrons (Eisenberg 1984). IDL are cholesterol-rich VLDL and chylomicron remnants 
that are either cleared by the liver or metabolized by hepatic lipase into LDL, which retains 
apoB (Poapst et al. 1985; Steiner et al. 1987). 
LDL, the products of VLDL and IDL catabolism, are the most cholesterol-rich of all 
lipoproteins. About 40-60% of all LDL are cleared by the liver in a process mediated by 
apoB and hepatic LDL receptors (Attie et al. 1982); the rest are taken up by either non-
hepatic LDL or non-hepatic scavenger receptors. Hepatic LDL receptors are down-
regulated by delivery of cholesterol to the liver and by increased dietary saturated fat 
(Spady and Dietschy 1985; Fox et al. 1987). Non-hepatic scavenger receptors, most notably 
on macrophages, take up excess oxidized LDL not processed by hepatic receptors. 
Monocytes rich in oxidized LDL migrate into the subendothelial space and become 
macrophages, which takes up more oxidized LDL and form foam cells within 
atherosclerotic plaques. There are 2 forms of LDL: large, buoyant and small, dense LDL 
(Austin et al. 1988b; Barakat et al. 1990). Small, dense LDL is especially rich in cholesterol 
esters, associated with metabolic disturbances such as hypertriglyceridaemia, insulin 
resistance and atherogenesis (Austin et al. 1988a; Aguilera et al. 2008). The increased 
atherogenicity of small, dense LDL derives from less efficient hepatic LDL receptor 
binding, leading to prolonged circulation and exposure to endothelium and increased 
oxidation (Nigon et al. 1991). 
The overall role of HDL, synthesized in both enterocytes and the liver, is to obtain 
cholesterol from peripheral tissues and other lipoproteins and transport it to other cells, 
other lipoproteins (using cholesteryl ester transfer protein [CETP]) and the liver. Efflux of 
FC from cells (Johnson et al. 1986) is mediated by adenosine triphosphate-binding cassette 
transporter A1 (ABCA1), which combines with apoA-I to produce nascent HDL. FC in 
nascent HDL is then esterified by the lecithin-cholesterol acyl transferase (LCAT), 
producing mature HDL (Rye et al. 1999; Santamarina-Fojo et al. 2000). HDL exerts various 
anti-atherogenic properties, including reverse transport of cholesterol from cells of the 
arterial wall to the liver (Miller et al. 1985; Tall 1998), inhibition of LDL oxidation by 
HDL-bound paraoxonase-1 (Mackness et al. 1993; Mackness et al. 1996), regulation of 
coagulation and fibrinolysis and inhibition of platelet activation (Nofer et al. 2002), 
neutralization of endotoxin or lipopolysaccharide (Huuskonen et al. 2001), inhibition of the 
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chemotaxis of monocytes and the adhesion of leukocytes to the endothelium (Nofer et al. 
2002) and promotion of endothelial progenitor cell-mediated endothelial repair (Sumi et al. 
2007). 
Lipoprotein(a) [Lp(a)] is LDL that contains apolipoprotein(a), characterized by 5 cysteine-
rich regions called kringles. One of these regions is homologous with plasminogen and is 
thought to competitively inhibit fibrinolysis and thus predispose to thrombus (Jialal 1998; 
Maher and Brown 1995). Because Lp(a) has LDL as its component, oxidized Lp(a) is 
avidly taken up by the scavenger receptor pathway and promotes cholesterol delivery into 
the artery wall (Jialal 1998), inducing atherosclerosis. 
2.2 Epidemiology of dyslipidaemia 
2.2.1 Prevalence and ethnic variation 
Lipids and lipoproteins abnormalities are major metabolic disorders, commonly including 
elevated levels of TC, LDL-C, Lp(a) and TG and reduced levels of HDL-C. In patients with 
type 2 diabetes, a CHD equivalent (Juutilainen et al. 2005), it is most commonly 
characterized by elevated TG and reduced HDL-C (Goldberg 2001; Krauss 2004; Kendall 
2005). These abnormalities can be present alone or in combination with other metabolic 
disorders. The prevalence of dyslipidaemia varies depending on the population studied, 
geographic location, socioeconomic development and the definition used (Wood et al. 1972; 
Onat et al. 1992; Berrios et al. 1997; Ezenwaka et al. 2000; Foucan et al. 2000; Hanh et al. 
2001; Zaman et al. 2001; Li et al. 2005; Pang et al. 2006; Zhao et al. 2007; Erem et al. 2008; 
Azizi et al. 2003; Pongchaiyakul et al. 2006; Mann et al. 1988; Hertz et al. 2006; Tekes-
Manova et al. 2006; Steinhagen-Thiessen et al. 2008; Florez et al. 2005). Caucasians 
generally have higher mean TC concentrations than do populations of Asian or African 
origin (Fuentes et al. 2003; Tolonen et al. 2005). In general populations, the highest 
prevalence of hypercholesterolaemia (TC ≥ 6.5mmol/l) has been seen in Malta (up to 50% 
in women) and the lowest in China (2.7% in men) in the World Health Orgnization (WHO) 
Inter-Health Programme (Berrios et al. 1997). However, inhabitants of the developing 
world now have had access to more fats in their diets and more sedentary lives; therefore 
the disease is becoming an increasing problem there.  
There is a large body of evidence showing that diabetes is associated with a high prevalence 
of dyslipidaemia (Kannel 1985; Cowie et al. 1994; UKPDS Investigators 1997; Jacobs et al. 
2005; Bruckert et al. 2007; Okafor et al. 2008; Surana et al. 2008; Ahmed et al. 2008; 
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Abdel-Aal et al. 2008; Jurado et al. 2009; Papazafiropoulou et al. 2009; Roberto Robles et 
al. 2009; Seyum et al. 2010; Agarwal et al. 2009; Temelkova-Kurktschiev et al. 2009; 
Zhang et al. 2009). In the Framingham Heart Study (Kannel 1985), the prevalence of low 
HDL-C (21% vs. 12% in men and 25% vs. 10% in women, respectively) and high TG levels 
(19% vs. 9% in men and 17% vs. 8% in women, respectively) in people with diabetes was 
almost twice as high as the prevalence in non-diabetic individuals. By contrast, TC and 
LDL-C levels did not differ from those of non-diabetic counterparts. A similar pattern of 
lipid profiles was observed in the UK Prospective Diabetes Study (UKPDS) (UKPDS 
Investigators 1997). In this study, the plasma TG levels were substantially increased 
whereas HDL-C levels were markedly reduced in both men and women with diabetes 
compared with the non-diabetic controls. Higher prevalence has been reported in other 
studies. Data from a primary care-based 7692 patients with type 2 diabetes in the United 
States showed nearly half of the patients had low HDL-C (Grant and Meigs 2007). The 
figure was even worse in an urban Indian cohort of 5088 type 2 diabetes patients, with more 
than half having low HDL-C (52.3%) or high TG (57.9%) (Surana et al. 2008). In addition 
to the traditional lipid measurement, increased levels of apoB were also seen in patients 
with diabetes compared with non-diabetic individuals (Bangou-Bredent et al. 1999). 
It has been shown that the prevalence of lipid and/or glucose abnormality differs between 
ethnic groups. It is clear that certain ethnic groups have differences in lipid profiles in 
general. Elevated TG and reduced HDL-C, as the components of the metabolic syndrome 
and atherogenic dyslipidaemia, was seen more common in Asian Indians than in the whites 
(Anand et al. 2000; Razak et al. 2005; Chandalia et al. 2008; Mulukutla et al. 2008), 
Chinese (Tan et al. 1999; Anand et al. 2000; Razak et al. 2005; Karthikeyan et al. 2009; The 
DECODA Study Group 2007), Japanese (Karthikeyan et al. 2009; The DECODA Study 
Group 2007) or Africans (Mulukutla et al. 2008). In a nationally representative sample of 
seven ethnic groups in the UK (Zaninotto et al. 2007), the prevalence of low HDL-C was 
highest in south Asian groups such as Bangladeshi, Indian and Pakistani, followed by 
Chinese, Irish and those from the general population living in private households; In 
contrast, the lowest prevalence was seen in black Caribbean. Similar finding was reported in 
another study where the comparison was made between non-South-Asians and South 
Asians (France et al. 2003). In addition, African Americans have been reported to have less 
adverse lipid profiles than Whites or Hispanics despite the presence of diabetes (Sharma 
and Pavlik 2001; Cowie et al. 1994; Werk et al. 1993). The causes of ethnic difference in 
levels of CVD risk factor are complex and may include genetic, environmental and cultural 
factors (Zaninotto et al. 2007). However, little is known about such ethnic differences in 
lipid profiles at comparable glucose tolerance status. 
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2.2.2 Risk factors  
There are several factors that contribute to the development of dyslipidaemia (Expert Panel 
2001), including genetic factors (Cohen et al. 1994) and acquired factors (Chait and 
Brunzell 1990; Devroey et al. 2004; Ruixing et al. 2008) such as overweight and obesity 
(Denke et al. 1993; Denke et al. 1994; Brown et al. 2000), physical inactivity (Berg et al. 
1997; Hardman 1999), cigarette smoking (Criqui et al. 1980; Cade and Margetts 1989; 
Umeda et al. 1998; Fisher et al. 2000; Wu et al. 2001; Maeda et al. 2003; Mammas et al. 
2003; Venkatesan et al. 2006; Grant and Meigs 2007; Batic-Mujanovic et al. 2008; Arslan 
et al. 2008), high fat intake (Millen et al. 2002; Hennig et al. 2001; Tanasescu et al. 2004), 
very high carbohydrate diets (> 60 percent of total energy) (McNamara and Howell 1992) 
and certain drugs (Lehtonen 1985; Fogari et al. 1988; Roberts 1989; Middeke et al. 1990; 
Stone 1994) (such as beta-blockers, anabolic steroids, progestational agents, et al.). Excess 
alcohol intake is also documented as a risk factor (Umeda et al. 1998; Wu et al. 2001; 
Mammas et al. 2003) despite that moderate alcohol consumption may have a beneficial 
effect on improving HDL-C concentrations (De Oliveira et al. 2000; Shai et al. 2004b). In 
addition, glycaemic control is an important determinant of dyslipidaemia in patients with 
diabetes (Ismail et al. 2001; Grant and Meigs 2007; Ahmed et al. 2008; Gatti et al. 2009). 
Among these acquired factors, overweight, obesity and physical inactivity appear to be 
most important (Denke et al. 1993; Denke et al. 1994; Hardman 1999; Berg et al. 1997; 
Brown et al. 2000). They are also the most important lifestyle variables that decrease insulin 
action and increase the risk of diabetes. 
2.3 Dyslipidaemia in individuals with hyperglycaemia: the role in the 
progress of atherosclerosis 
The origins of the diabetic dyslipidaemia derive from specific abnormalities in lipoprotein 
metabolism and abnormalities in insulin action. The most fundamental defect in these 
patients is resistance to cellular actions of insulin, particularly resistance to insulin-
stimulated glucose uptake (Ginsberg 2000; Avramoglu et al. 2006). In both fasting and 
postprandial states, deficient action of insulin on adipocytes results in reduced suppression 
of lipolysis of stored TG, increasing the release of FFA. Higher uptake of FFAs in the liver 
results in an increased hepatic production of VLDL (Howard 1987; Lewis 1997). The 
reduced action of insulin also impairs LPL action, resulting in impaired clearance of VLDL 
from the circulation. The final result is an elevation of circulating TG concentration.  
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A low level of HDL-C is closely linked to the overproduction of TG-rich lipoproteins such 
as VLDL and chylomicrons (Bakogianni et al. 2001; Semenkovich 2006). In the 
hypertriglyceridaemic, insulin resistant states, it is enhanced that TG-rich lipoproteins 
actively exchange their core lipid with both HDL and LDL, a process facilitated by CETP 
(Hayek et al. 1993). This results in TG enrichment of HDL and LDL. Although the 
mechanisms are not entirely clear, available data suggest TG-enrichment of HDL particles 
leading to particle instability and degradation, enhancing catabolism of HDL (Rashid et al. 
2003). ApoA-I may dissociate from TG-enriched HDL and is then cleared rapidly from 
plasma, further reducing the availability of HDL for reverse cholesterol transport. It is also 
possible that insulin resistance and low HDL-C levels may have a common mediator such 
as tumor necrosis factor-α that is found to down-regulate the apoA-I gene expression and 
can lower serum HDL-C levels (Haas et al. 2003). On the other hand, TG-enriched LDL 
particles due to the hypertriglyceridaemia and increased CETP activity undergo lipolysis 
and thus convert into small dense LDL (Kendall 2005).   
Diabetic dyslipidaemia is a major predisposing factor to the development of atherosclerosis 
(Syvanne and Taskinen 1997). Small dense LDL particles penetrate the endothelial barrier 
1.7 times more easily than do larger LDL particles, and they remain longer in the 
subendothelial matrix (de Graaf et al. 1991). Moreover, small dense LDL particles are more 
easily modified by oxidation and, particularly in type 2 diabetes, by glycation, and are more 
atherogenic (Brinton 2005). Oxidative modification of LDL particles results in rapid uptake 
by macrophages, with subsequent formation of foam cells (Pastromas et al. 2008). LDL 
particles can promote inflammatory and immune changes via cytokine released from 
macrophages (Hammad et al. 2009). Foam cells can rupture and release oxidized LDL 
particles, intracellular enzymes and oxygen-free radicals that can further damage the vessel 
wall. The increased synthesis of VLDL particles are taken up by receptors located on 
macrophages, thus promoting the accumulation of lipids within macrophages and 
contributing to the formation of foam cells in vessel walls as well. Furthermore, 
hypertriglyceridaemia is associated with prothrombotic and inflammatory changes that may 
contribute to the increased risk of CVD (Krentz 2003). HDL from patients with type 2 
diabetes may have substantially impaired endothelial-protective effects compared with HDL 
from healthy subjects (Sorrentino et al. 2010). In addition, low HDL may disturb reverse 
cholesterol transport, a process by which excess amounts of cholesterol located in cells and 
atherosclerotic plaques are removed (Gotto and Brinton 2004). 
 21 
 
2.4 Relationship between dyslipidaemia and cardiovascular risk in 
individuals with different glucose levels 
In the past decades, genetic, histopathologic and epidemiological studies have established 
the primary role of lipids and lipoproteins in the development of CVD, either in general 
population or in patients with diabetes. It is well-established that TC, LDL-C, low HDL-C 
and calculated indices such as TC/HDL-C or non-HDL-C are predictors of cardiovascular 
events. Whether fasting TG is an independent predictor of CVD, however, remains 
unsettled. 
2.4.1 Lipids and cardiovascular risk in general populations 
The link between levels of TC and the risk of CHD has been well established. There is a 
strong and graded positive association between TC as well as LDL-C and the risk of CHD 
(Neaton et al. 1992; Nobili et al. 1994). Data from the the Multiple Risk Factor Intervention 
Trial (MRFIT) study (LaRosa et al. 1990) demonstrate a curvilinear relation between TC 
level and CHD mortality. Clinical trials using lipid-modifying drugs have unequivocally 
demonstrated that lowering LDL-C yields significant reductions in both morbidity and 
mortality from CHD in people with or without established CHD (Mills et al. 2008; 
Thavendiranathan et al. 2006), supporting that the reduction of LDL-C should be of prime 
concern in both primary and secondary prevention of atherosclerotic disease. 
The role of HDL-C as an independent and powerful inverse predictor of CHD has been well 
established (Gordon et al. 1977; Rywik et al. 1999; Cui et al. 2001; Mazza et al. 2005; Bass 
et al. 1993; The DECODE Study Group 2006; Barzi et al. 2005; Tanko et al. 2005; 
Tunstall-Pedoe et al. 1997; Laakso et al. 1993; Ridker et al. 2005; Pischon et al. 2005; 
Zaninotto et al. 2007; Cooney et al. 2009). An analysis of data from the Framingham study, 
the Coronary Primary Prevention Trial (CPPT), and the MRFIT study indicates that the risk 
for CHD decreases by 2%-3% for each 0.03 mmol/l increase in HDL-C, after controlling 
for other risk factors (Gordon et al. 1989). In the Lipid Research Clinics Prevalence 
Mortality Follow-up Study (LRCF), the same increment (0.03 mmol/l) in HDL-C was 
associated with a significant CVD mortality decrement of 3.7% in men and 4.7% in women 
(Gordon et al. 1989). Although the benefits of raising HDL-C levels remain to be confirmed 
in randomized clinical trials, it appears in a most recent report that the modest improvement 
in HDL-C levels (per 0.13 mmol/l) is associated with a 21% reduction in cardiovascular risk 
independent of the effect on other lipid measures (Grover et al. 2009).  
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The association between hypertriglyceridaemia and risk of CVD is not as strong as it is for 
TC and HDL-C. High TG is consistently shown to be a significant CVD risk factor in most 
of the univariate analyses (Stampfer et al. 1996; Cremer et al. 1997; Dunder et al. 2004a; 
Eberly et al. 2003; Hulley et al. 1980; Iso et al. 2001; Jeppesen et al. 2001; Pirro et al. 2002; 
Pischon et al. 2005; Psaty et al. 2004; Shai et al. 2004a; Sharrett et al. 2001; Talmud et al. 
2002; Yarnell et al. 2001; Bansal et al. 2007)  and in some of the multivariate models 
including HDL-C (Eberly et al. 2003; Iso et al. 2001; Jeppesen et al. 2001; Sharrett et al. 
2001; Stampfer et al. 1996; Talmud et al. 2002; Yarnell et al. 2001; Bansal et al. 2007) but 
not in others (Avins and Neuhaus 2000; Cremer et al. 1997; Dunder et al. 2004a; Eberly et 
al. 2003; Hulley et al. 1980; Pirro et al. 2002; Pischon et al. 2005; Shai et al. 2004a; Sharrett 
et al. 2001; Talmud et al. 2002; Walldius et al. 2001; Yarnell et al. 2001; Bansal et al. 2007). 
In many early prospective studies, the predictive value of fasting TG tended to diminish or 
even disappear when other lipid or non-lipid risk factors were considered. This failure may 
result from the large number of intercorrelated variables associated with elevated TG. 
Renewed interest in the importance of elevated TG has been, however, stimulated by the 
publication of meta-analyses that found that raised TG is in fact an independent risk factor 
for CHD (Austin et al. 1998; Assmann et al. 1998). A number of epidemiological studies 
published in the past few years (Dunder et al. 2004a; Eberly et al. 2003; Pischon et al. 2005; 
Shai et al. 2004a) have also supported the role of TG as an independent risk factor. Thus, 
many persons with elevated TG are at increased risk for CHD, even when this greater risk 
cannot be independently explained by TG.  
Recently, the use of TC/HDL-C (Barzi et al. 2005; Ridker et al. 2005) and non-HDL-C (Cui 
et al. 2001) for CVD risk assessment has increased. The Framingham Heart Study and the 
Quebec Cardiovascular Study have demonstrated that TC/HDL-C appears to predict CHD 
events better than than any single lipid parameter (Natarajan et al. 2003; Lemieux et al. 
2001). Non-HDL-C is also shown to be a better predictor of CVD mortality than LDL-C 
(Cui et al. 2001; Schulze et al. 2004; Liu et al. 2005; Ridker et al. 2005) because it includes 
all atherogenic lipoprotein particles.   
In addition, ApoB and apoB/apoA-I are useful indicators of risk of atherosclerosis. Data 
from the Health Professionals Follow-up Study, a nested case-control study with a 6-year 
follow up of 18,225 male participants, showed that apoB is more predictive in development 
of CHD than non-HDL-C (Pischon et al. 2005). The finding from the INTERHEART study, 
another case-control study with 21,465 participants from 262 centres in 52 countries, 
strengthened the predictive ability of apoB/apoA1 for myocardial infarction (MI) 
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(McQueen et al. 2008). This has been supported by recent reports from prospective studies, 
such as Apolipoprotein Mortality Risk study (Walldius et al. 2001), the European 
Prospective Investigation of Cancer-Norfolk study (Vaessen et al. 2006), Uppsala 
Longitudinal Study of Adult Men (Dunder et al. 2004b) and the MONItoring of trends and 
determinants in Cardiovascular disease Augsburg/KOoperative Gesundheitsforschung in 
der Region Augsburg (Meisinger et al. 2005). In a most recent report from the Third 
National Health and Nutrition Examination Survey mortality study, the predictive ability of 
apoB to detect CHD death was better than any of the routine clinical lipid measurement and 
as powerful as apoB/apoA-I (Sierra-Johnson et al. 2009). Whereas, standardized apoB 
measures are not widely available and apoB is not included in the current recommendations 
for assessing cardiovascular risk. 
2.4.2 Lipids and cardiovascular risk in individuals with hyperglycaemia 
It is well known that the risk of morbidity and mortality from CVD is increased by two- to 
four-fold in diabetic patients compared with the general population (Kannel 1985; Morrish 
et al. 1991b; Almdal et al. 2004). A number of studies have determined the association of 
dyslipidaemia with cardiovascular risk in people with hyperglycaemia, and most of them 
were conducted in patients with diabetes. There is a large body of evidence linking 
dyslipidaemia and cardiovascular risk in patients with diabetes against quite few negative 
reports (Roselli della Rovere et al. 2003; Vlajinac et al. 1992) on this issue. Cross-sectional 
studies have found positive associations of atherosclerotic vascular disease with TC 
(Ronnemaa et al. 1989; Jurado et al. 2009), LDL-C (Reckless et al. 1978; Jurado et al. 2009; 
Agarwal et al. 2009), non-HDL-C (Jurado et al. 2009), TG (Santen et al. 1972; Ronnemaa 
et al. 1989; Gomes et al. 2009), apoB (Ronnemaa et al. 1989) and Lp(a) (Mohan et al. 1998; 
Murakami et al. 1998; Smaoui et al. 2004), but inverse associations with HDL-C (Reckless 
et al. 1978; Ronnemaa et al. 1989; Smaoui et al. 2004; Grant and Meigs 2007; Jurado et al. 
2009; Gomes et al. 2009) and apoA-I (Seviour et al. 1988; Ronnemaa et al. 1989).  
Prospective data have provided with further evidence. The UKPDS study (Turner et al. 
1998) has demonstrated that high LDL-C and low HDL-C are potentially modifiable risk 
factors for coronary artery disease (CAD) in patients with type 2 diabetes. TG, however, 
was not independently associated with CAD risk in this study, possibly because of its close 
inverse relationship with HDL-C. Results from the MRFIT (Stamler et al. 1993), in which 
356,499 nondiabetic and 5163 diabetic men without CHD at baseline were followed for 12 
years, indicated that serum cholesterol is an independent predictor of CHD mortality in men 
with diabetes. Rosengren et al. (Rosengren et al. 1989) showed similar results in a 
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prospective study of 6897 middle aged diabetic men. Patients with TC > 7.3 mmol/l had a 
significantly higher incidence of CHD during the 7-year follow up than those with TC ≤ 5.5 
mmol/l (28.3% vs. 5.4%, p<0.05). Long term follow-up of the London cohort of the WHO 
Multinational Study of Vascular Disease in Diabetics, consisting of 254 type 2 diabetic 
patients, has showed that TC was associated with incidence of MI (Morrish et al. 1991a) 
and overall cardiovascular mortality (Morrish et al. 1990). The role of TC in predicting 
CHD was also confirmed in women patients with diabetes (Schulze et al. 2004).   
In general, the lipid profile in patients with type 2 diabetes is most commonly characterized 
by hypertriglyceridaemia and reduced HDL-C. Most of the studies consistently addressed 
the role of HDL-C in predicting CVD in patients with hyperglycaemia. In the Honolulu 
Heart Program (Laws et al. 1993), both HDL-C and TC were significant predictors of 
incident CHD in men with diabetes (diagnosis based on use of oral hypoglycaemic agent) or 
abnormal glucose tolerance (1-h glucose ≥ 12.5 mmol/l after 50 g oral glucose challenge), 
independently of age, body mass index (BMI), systolic blood pressure (SBP), smoking and 
alcohol consumption. In the Helsinki Heart Study, both low HDL-C and high LDL-C were 
independently related to CHD incidence in 135 diabetic patients during a 5-year follow-up 
(Koskinen et al. 1992). Laakso et al. (Laakso et al. 1993) gave further evidence in a Finnish 
cohort that low HDL-C and HDL2 cholesterol are powerful risk indicators for CHD events 
in 313 diabetic patients during a 7-year follow-up.  
Although the role of TG in predicting cardiovascular events remains controversial in the 
general population, the evidence in diabetic populations is better established (Janka 1985; 
Koskinen et al. 1992; Laakso et al. 1993; Uusitupa et al. 1993; Turner et al. 1998; Bos et al. 
2003; Chan et al. 2005; Tseng et al. 2006; Fontbonne et al. 1989; West et al. 1983; Giorda 
et al. 2008). In the WHO multinational study, ischaemic heart disease was more strongly 
associated with TG than with TC concentrations, particularly in obese diabetic patients 
(West et al. 1983). During an 11-year follow-up of 943 patients with either IGT or diabetes 
in the Paris Prospective Study, TG was the only factor significantly associated with 
coronary deaths in multivariate regression analysis (Fontbonne et al. 1989). In the 
Schwabing Study of 542 diabetic patients, TG was shown to be a significant predictor of 5-
year incidence of major macrovascular complications such as cardiovascular death, 
gangrene or MI (Janka 1985). Data from a Finnish study (Laakso et al. 1993) showed that 
both high total and VLDL-TG were predictive for CHD events in 313 diabetic patients who 
were followed up for 7 years. In another Finnish study, LDL-TG but not total TG was found 
to be associated with cardiovascular death (Uusitupa et al. 1993). This may be due to the 
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impact of LDL particles enriched with TG on atherogenesis. The role of TG was also 
confirmed separately in women patients with type 2 diabetes enrolled in the Nurses’ Health 
Study (Schulze et al. 2004). In addition, data from diabetic populations other than 
Caucasian patients confirmed the predictive value of TG. Chan and colleagues (Chan et al. 
2005), following 517 Chinese patients with newly diagnosed type 2 diabetes for 4.6 years, 
found that TG was significantly associated with cardiovascular mortality in these patients. 
These epidemiological findings have been supported by randomized clinical trials in which 
reduction of TG was related to decreased risk of CVD in patients with low HDL-C (Rubins 
et al. 1999; Keech et al. 2005).  
In the Hoorn Study (Bos et al. 2003), high TG was shown to be a risk factor for CVD in 
subjects with diabetes or prediabetes, but only in those with high non-HDL-C. This finding, 
together with other raising evidence, implies that non-HDL-C may be a useful marker for 
CVD not only in the general population (Cui et al. 2001; Liu et al. 2005; Pischon et al. 2005; 
Rallidis et al. 2005) but also in diabetic patients (Lu et al. 2003; Jiang et al. 2004; Schulze et 
al. 2004). In the Strong Heart study, a 9-year follow-up study of 2108 American-Indian 
patients with diabetes but free of CVD at baseline, non-HDL-C (highest vs. lowest tertile) 
was strongly associated with incidence of overall CVD in both male [HR 2.23 (1.41–3.43)] 
and female [1.80 (1.32–2.46)] patients (Lu et al. 2003). The finding was further confirmed 
in diabetic men in the Health Professionals’ Follow-up Study (Jiang et al. 2004). However, 
among diabetic women in the Nurses’ Health Study (Schulze et al. 2004), non-HDL-C 
predicted CHD risk only among those with elevated TG levels, implying that non-HDL-C 
may provide little additional power to predict CHD at lower TG levels. 
Recently, the utility of TC/HDL-C as CVD predictor is increasing in diabetic population 
and has been evaluated in several studies. TC/HDL-C is as good as non-HDL-C in the 
Strong Heart Study (Lu et al. 2003) and is shown to be the best predictor in diabetic men in 
the Health Professionals’ Follow-up Study (Jiang et al. 2004), but failed to be predictive in 
diabetic women in the Nurses’ Health Study (Schulze et al. 2004).  
Previous studies have shown that patients with diabetes have elevated apoB (Bangou-
Bredent et al. 1999; Thomas et al. 2006), apoC-III/C-II, apoE and decreased concentrations 
of apoA-I (Thomas et al. 2006). In two prospective studies, apoB seems to be a potent 
predictor of CVD in both diabetic men (Jiang et al. 2004) and women (Schulze et al. 2004). 
Nevertheless, a large body of evidence is still limited concerning the role of apoB in 
predicting CVD risk in diabetic patients. 
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Although the role of lipid parameters in predicting cardiovascular risk has, as above 
summarized, been well addressed in either general or diabetic populations, it is still unclear 
that whether lipids predict CVD/CHD events in people with prediabetes (i.e., IGT and IFG), 
who are already exposed to a cluster of risk factors.   
2.5 Management of dyslipidaemia 
Epidemiological investigations of human populations have revealed a robust relationship 
between lipids and CVD risk. Furthermore, the benefit of lipid-modifying strategy on 
cardiovascular events has been demonstrated from a large number of randomized clinical 
trials (Mills et al. 2008; Thavendiranathan et al. 2006), especially from those using 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (i.e., statins) (Colhoun et 
al. 2004; Pyorala et al. 2004; Collins et al. 2003; Goldberg et al. 1998; Shepherd et al. 2006; 
Sever et al. 2005; Knopp et al. 2006). Intensive control of dyslipidaemia has been greatly 
emphasized in the prevention and management of CVD. Current guidelines from the 
National Cholesterol Education Program Adult Treatment Panel III (ATP III) (Adult 
Treatment panel III 2002), the European Society of Cardiology (Graham et al. 2007) and 
the American Diabetes Association (American Diabetes Association 2009) consistently 
recommend that LDL-C should be the primary target of therapy not only in patients with 
CHD or diabetes but also in persons with increased cardiovascular risk. In addition, non-
HDL-C is set by ATP III as a secondary target of therapy and HDL-C and TG as potential 
target.  
Despite current guidelines aimed at achieving targets for LDL-C, blood pressure and 
glycaemia, patients remain at high residual risk of vascular events (Fruchart J 2008). 
Dyslipidaemia may play a role in residual vascular risk. LDL-C, however, is not the sole 
lipid that defines the risk. Therapies which aim to raise HDL-C are currently under intense 
consideration. Recent evidence (Grover et al. 2009) supports the further evaluation of 
therapies to raise HDL-C levels to prevent cardiovascular events. In a most recent study, 
extended-release niacin (ERN) therapy is shown to not only increase plasma HDL-C levels 
but also substantially improve endothelial-protective properties of HDL in diabetic patients 
(Sorrentino et al. 2010). Moreover, ERN therapy in combination with a statin induces 
regression of carotid intima-media thickness in patients with CHD or CHD equivalent 
(Villines et al. 2010). The current evidence implies that pharmacological HDL-raising 
therapies should be examined in the way their ability to restore the vascular-protective 
function of HDL. 
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3 AIMS OF THE STUDY 
The aims of this study are: 
1) To investigate lipid profiles in relation to plasma glucose levels in European men 
and women without a prior history of diabetes (Study I); 
2) To study blood lipid levels in relation to plasma glucose levels in 7 Asian 
populations without a prior history of diabetes (Study II); 
3) To compare the ethnic difference in lipid profiles controlling for plasma glucose 
levels in European and Asian populations (Study III); 
4) To assess the impact of dyslipidaemia on CVD mortality in relation to plasma 
glucose levels in European men and women (Study IV); 
5) To estimate the impact of dyslipidaemia on CHD incidence in European men and 
women with different plasma glucose levels (Study V). 
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4 POPULATIONS AND METHODS 
4.1 Study populations 
The DECODE (Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in 
Europe) study was initiated in 1997 and the DECODA (Diabetes Epidemiology: 
Collaborative analysis Of Diagnostic criteria in Asia) study 1998. Briefly, researchers who 
had carried out population-based or large occupational epidemiological studies on diabetes 
in Europe or Asia, using a standard 2-h 75-g oral glucose tolerance test (OGTT), were 
invited to participate. Individual data on fasting plasma glucose (FPG) and 2-h plasma 
glucose (2hPG) concentrations as well as TC, HDL-C and TG and a number of other 
variables were sent to the Diabetes Prevention Unit of the National Institute for Health and 
Welfare in Helsinki, Finland for collaborative data analysis. The Ethics Committee of the 
National Institute for Health and Welfare had approved the data analysis plans for both the 
DECODE and the DECODA studies. The two studies consisted of 64 cohorts of mainly 
population-based from 24 countries and regions around the world, with about 84 000 
Europeans and 84 207 Asians of Chinese, Japanese, Indians, Mongolians and Filipinos. The 
age ranges from 25-99 years. 23 European cohorts and 8 Asian cohorts provide with follow-
up data on vital status, comprising 12 283 all-cause deaths and 5811 CVD deaths in 
Europeans and 1024 and 455 in Asians, respectively. The existing database has been 
updated continuously.  
4.2 Inclusion and exclusion criteria 
The inclusion and exclusion criteria for the data analysis of each study are summarized in 
the Table 2. A total of 19 476 subjects (8960 men and 10 516 women with a mean age of 55 
years) from 15 DECODE studies were included in the data analysis for Study I and 19 763 
(8933 men and 10 830 women with a mean age of 55 years) from 13 DECODA study 
cohorts for Study II. Further, 52 355 subjects (24 760 men and 27 595 women with a mean 
age of 50 years) from 31 (18 in DECODE and 13 in DECODA) study cohorts of 12 
countries, representing Asian Indians, Chinese (divided into subgroups of Hong Kong 
Chinese and Qingdao Chinese), Europeans (divided into subgroups of Central & Northern 
European and Southern European), Japanese, and Mauritian Indians, met the inclusion 
criteria for Study III. 
Among 14 DECODE cohorts (including 9132 men and 8631 women aged 25-89 years) 
which provided data on CVD mortality and required covariates for Study IV, 6 (including 
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4818 men and 4269 women from 4 Finnish and 2 Swedish cohorts) with eligible data on 
cause-specific morbidity and all variables required were jointly analysed in Study V.  
 Table 2 Inclusion/Exclusion criteria of the study populations 
4.3 Blood lipids and glucose assays 
In all cohorts, blood samples were collected after overnight fasting. Plasma glucose was 
measured in each of the studies with an oxidase or dehydrogenase method. Detailed 
information on lipids and lipoproteins assays in each study was shown in Appendix 1. 
Briefly, TC and TG were determined using enzymatic techniques (McGowan et al. 1983; 
Stein and Steiner 1989; Warnick and Remaley 2001; Dowse et al. 1995; Soderberg et al. 
2005) in all and HDL-C measured enzymatically after a precipitation of apoB-containing 
lipoproteins with established methods (Langlois and Blaton 2006) in most of the 
laboratories, except in the Qingdao 2006 study from China, the Funagata study from Japan 
and two Indian studies in India applying direct method for HDL-C assay (Appendix 1). 
 Data source Inclusion criteria Exclusion criteria 
Study I DECODE 1) Participants aged 35-74 years; 2) Studies 
including both sexes; 3) Baseline examination 
performed after 1980; 4) The availability of TC, 
HDL-C, TG, FPG and 2hPG data 
Participants with a prior 
history of diabetes 
Study II DECODA 1) Participants aged 30-74 years; 2) Studies 
including both sexes; 3) Baseline examination 
performed after 1980; 4) The availability of TC, 
HDL-C, TG, FPG and 2hPG data 
Participants with a prior 
history of diabetes 
Study III DECODE and 
DECODA 
1) Participants aged 25 to 74 years old; 2) Studies 
including both sexes; 3) Baseline examination 
performed after 1980; 4) Data on TC, HDL-C, TG, 
FPG, 2hPG and BMI available 
 
Study IV DECODE 1) Cohort study with data on cause-specific 
mortality; 2) Baseline measurement of TC, HDL-C, 
TG, FPG, 2hPG, blood pressure and smoking status 
available 
Participants with a prior 
history of diabetes; 
Participants lost to the 
follow-up 
Study V DECODE 1) Cohort study with data on cause-specific 
morbidity; 2) Baseline measurement of TC, HDL-C, 
TG, FPG, 2hPG, blood pressure and smoking status 
available 
Participants with either a 
prior history of diabetes or 
history of CHD at baseline; 
Participants lost to the 
follow-up 
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Non-HDL-C levels were calculated by subtracting HDL-C from TC levels. In Study III, 
LDL-C was calculated among individuals with a TG value of less than 4.5 mmol/l 
(n=51,521) using the Friedewald formula (Friedewald et al. 1972) as follows: LDL-C (in 
mmol/l) = TC - (HDL-C) - (0.45*TG). Individuals with a TG ≥ 4.5 mmol/l (n=834) were 
excluded from the analysis related to the LDL-C in this sub-study.   
4.4 Classification of hyperglycaemia 
According to the WHO 1999 criteria (Alberti and Zimmet 1998), a person with a prior 
history of diabetes was classified as previously diagnosed diabetes regardless of the glucose 
levels, and were included only in the data analysis for study III. Those without previously 
diagnosed diabetes were classified based on either FPG or 2hPG levels. Classification into 
newly diagnosed diabetes, IGT and normal glucose tolerance (NGT) was determined by 
2hPG levels of ≥ 11.1, ≥ 7.8 - < 11.1, and < 7.8 mmol/l, respectively. FPG levels of ≥ 7.0, ≥ 
6.1 - < 7.0, and < 6.1 mmol/l classified subjects into newly diagnosed diabetes, IFG, and 
normal fasting glucose (NFG), respectively. According to the both criteria combined, 
subjects were further classified into: i) normoglycaemia (NFG&NGT), isolated fasting 
hyperglycaemia (FPG ≥ 6.10 mmol/l and 2hPG < 7.80 mmol/l), isolated post-load 
hyperglycaemia (FPG<6.10 mmol/l and 2hPG ≥ 7.80 mmol/l) and combined fasting and 
post-load hyperglycaemia (CH, FPG ≥ 6.10 mmol/l and 2hPG ≥ 7.80 mmol/l) or ii) 
NFG&NGT, isolated IFG (FPG 6.1-6.9 mmol/l and 2hPG < 7.8 mmol/l), isolated IGT (FPG 
< 6.1 mmol/l and 2hPG 7.8-11.0 mmol/l) and combined IFG and IGT (FPG 6.1-6.9 mmol/l 
and 2hPG 7.8-11.0 mmol/l), respectively, for different study objectives. 
4.5 Classification of dyslipidaemia 
According to the definition for the metabolic syndrome proposed by the International 
Diabetes Federation (Alberti et al. 2005), elevated TG was defined as TG ≥ 1.7 mmol/l, and 
reduced HDL-C was defined as HDL-C < 1.03 mmol/l for men and < 1.29 mmol/l for 
women. High LDL-C was defined as LDL-C ≥ 3.0 mmol/l according to the European 
guidelines on CVD prevention (Graham et al. 2007). 
4.6 Definition of fatal and nonfatal cardiovascular events 
Vital status and the date and the cause of death for those deceased were recorded for each 
subject attending the baseline examination. Subjects who had emigrated and for whom the 
vital status could not be confirmed were treated as censored at the time of emigration. The 
International Classification of Diseases (ICD) was used for coding the causes of death. 
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CVD deaths were defined using ICD codes 401-448 for the eighth or ninth revision and 
codes I10-I79 for the tenth revision. Participants who died, but for whom information on the 
causes of death was not available, were considered as missing and were excluded in the 
calculation of CVD mortality.  
Incident CHD events during the follow-up were ascertained through computerized record 
linkage of the unique national identification numbers of the subjects to the National Death 
Registry and the National Hospital Discharge Registry in all Finnish and Swedish studies. 
The ICD was used for coding incident CHD events during the follow up. In the present 
analysis, we used ICD codes 410-411 for the eighth or ninth revision and code I21 for the 
tenth revision for the first ever nonfatal MI, and 410-414 and I20-I25 for fatal CHD. 
Individuals (n=468) with a prior history of CHD before the baseline survey or those (n=41) 
lost to follow-up were excluded from the data analyses. 
4.7 Statistical analysis 
4.7.1 Cross-sectional studies (Studies I, II and III) 
TG was logarithmically transformed for data analysis because of its skewed distribution. In 
Studies I and II, the sex-specific mean lipid and lipoprotein concentrations were calculated 
for subjects of each ethnic group by different glucose categories, adjusted for age and study 
cohort. Multiple linear regression analysis with standardized coefficient (β) was used in 
both Study I and II to examine the relationship between each lipid component (dependent 
variable) and blood glucose (independent variable) adjusting for age, study cohort, BMI, 
smoking, and SBP. A χ2 test was used for categorical variables. In Study III, we estimated 
the ethnic- and sex-specific mean concentration of each lipid variable with 95% confidence 
interval (CI), adjusting for age, study cohort and BMI. Within each glucose category, 
pairwise comparisons between ethnic groups were made with Bonferroni method to adjust 
for multiple comparisons. Logistic regression analysis was used to estimate odds of having 
low HDL-C, high LDL-C or high TG for each ethnic group as compared with that for 
Central & Northern Europeans (reference group) at a given glucose category, adjusting for 
age, study cohort, BMI, SBP and smoking status. Waist was not adjusted in the multivariate 
analysis because it was not available for every study. The proportions of individuals with 
different dyslipidaemia between ethnicities were compared using χ2 test. 
4.7.2 Prospective studies (Studies IV and V)  
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Hazard ratios (HRs) and 95% CIs for CVD mortality (Study IV) or CHD incidence (Study 
V) in relation to lipids were estimated in each blood glucose category using Cox 
proportional hazard model analysis for all studies pooled together, with adjustment for age, 
sex, study cohort, hypertension at baseline, smoking status, waist circumference (BMI in 
Study V) and lipid parameters. χ2 log-likelihood ratio test was applied to determine whether 
TG or HDL-C (or non-HDL-C) were independent of each other in predicting CHD. 
4.7.3 Z-scores 
To reduce the bias derived from differences in methodology between studies, cohort- and 
sex-specific Z-scores (standard deviation scores) were also calculated for each lipid 
component (Studies I, II, IV and V) using the formula: Z= (X-µ) /σ, where X represents the 
value of the element with mean µ and S.D. σ (Rimm AA 1980). Both the original values 
and the Z-scores of lipid components were analyzed. HRs for CVD mortality or CHD 
incidence were estimated corresponding to a one unit increase in the Z-scores for each lipid 
variable. Data were analyzed using SPSS for Windows (version 15.0). 
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5 RESULTS 
5.1 Blood lipid levels in relation to glucose in Europeans and Asians 
without a prior history of diabetes (Studies I and II) 
Characteristics of study cohorts included in the cross-sectional studies (studies I, II and III) 
were summarized in the Table 4. In subjects without a prior history of diabetes (study I and 
II), multivariable adjusted linear regression analyses showed positive associations of FPG 
with TG [β ranging from 0.06 (average change of 0.06 mmol/l in TG per 1 mmol/l change 
in FPG, p<0.01) for Hong Kong Chinese in men to  0.19 (p<0.01) for Asian Indian in men], 
non-HDL-C, TC/HDL-C and TC in most of the ethnic groups, but an inverse association of 
FPG with HDL-C in only five groups of women and in Qingdao Chinese men (Table 5). 
The relationship between lipid and 2hPG (Table 6) followed a similar pattern as that for 
FPG except for HDL-C (significant change observed in all female groups and in 4 male 
groups). There were significant interactions between ethnicity and FPG or ethnicity and 
BMI with regard to each lipid component (p<0.05 for all terms), the interaction term 
between ethnicity and 2hPG was also significant for HDL-C (p<0.05) and TC/HDL-C 
(p<0.05). 
The linear regression analyses were repeated in a subgroup of the population having data on 
fasting insulin and waist, with further adjustment for fasting insulin and/or waist (data not 
shown). The standardized β coefficient and the model fitness fitted with waist did not differ 
substantially from that fitted with BMI, but the additional adjustment for fasting insulin 
attenuated the association between glucose and the lipid profiles and slightly improved the 
model fitness (the increase in R2 ranged from 0.01 for HDL-C to 0.03 for TG in men and 
0.02 to 0.04 in women), although the β coefficients still remained statistical significance for 
all sex-specific analyses except for the association between FPG and lipid variable in 
women. 
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Table 4 Characteristics of study cohorts included in the studies (Studies I, II and III) 
 
Ethnic group Study cohort Year of 
survey 
No. Mean 
age 
(years) 
 Diabetes (%) 
 
IFG 
and/or 
IGT 
BMI 
(kg/m2) 
TC 
(mmol/l) 
LDL-C a 
(mmol/l) 
HDL-C 
(mmol/l) 
TG 
(mmol/l) 
 
    
Undiagnosed Diagnosed (%) 
     
Men 
            
Chinese,  
Hong Kong, 
China 
HK-wscvdrf b 1991 831 38±8 3.7 1.9 8.3 23.3±2.9 5.3±1.0 3.39±0.90 1.25±0.31 1.35±0.88 
HK-cvrfps c 1995-1996 1361 46±13 6.8 3.5 15.3 24.3±3.4 5.1±0.9 3.22±0.87 1.16±0.30 1.38±0.87 
Chinese, 
Qingdao, China 
Qingdao 2002 2002 697 53±11 11.2 2.0 18.1 26.6±3.4 5.6±1.1 3.34±0.95 1.50±0.28  1.75±1.32 
Qingdao 2006 2006 1614 49±10 13.8 6.9 25.1 25.8±3.2 5.3±1.0 2.99±0.95 1.59±0.44 d 1.49±1.13 
Asian Indian, 
India 
Chennai 94 1994-1995 255 49±7 11.8 15.3 13.7 22.4±3.9 5.1±1.0 3.09±0.82 1.04±0.25 1.92±1.26 
Chennai 97 1996-1998 397 44±12 6.0 10.3 8.6 22.2±4.1 4.5±1.0 2.82±0.85 0.96±0.22 1.50±1.00 
 CURES 2003-2004 959 42±11 11.7 8.8 11.1 23.2±3.8 4.7±1.0 2.91±0.86 1.04±0.24 d 1.64±1.12 
 Chennai 2006 2006 2624 41±11 5.9 11.5 8.3 22.9±4.2 4.3±1.0 2.40±0.78 1.07±0.24 d 1.63±1.11 
Mauritian Indian, 
Mauritius 
Mauritius 87 1987 1518 42±12 9.3 5.6 15.3 22.8±3.7 5.6±1.6 3.47±1.46 1.27±0.36 1.83±1.35 
Mauritius 92 1992 846 42±11 9.7 7.7 20.8 24.0±4.8 4.9±0.8 2.90±0.75 1.23±0.33 1.62±1.12 
 Mauritius 98 1998 355 43±11 13.0 9.6 15.5 24.5±4.1 5.1±1.1 3.35±0.99 0.90±0.34 1.70±1.00 
Japanese, Japan Funagata 1995-1997 802 56±11 3.2 5.6 12.5 23.6±3.0 5.2±0.9 3.05±0.84 1.41±0.37 d 1.53±1.47 
 Hisayama 1988 978 55±9 8.1 10.4 23.8 22.9±2.9 5.1±1.0 3.21±1.00 1.26±0.31 1.68±1.49 
Italian, Italy   Cremona 
Study 
1990-1991 742 55±8 3.0 8.2 10.5 26.8±3.7 6.0±1.1 3.98±0.97 1.25±0.38 1.67±1.36 
Cypriot, Republic 
of Cyprus 
Nicosia 
Diabetes Study 
2003-2004 542 49±12 7.0 11.4 12.0 27.7±4.1 5.5±1.1 3.57±0.95 1.15±0.29 1.78±1.56 
Spanish, Spain The Guia 
Study 
1997 246 52±13 8.5 9.3 19.5 27.5±3.5 5.9±1.1 3.73±0.86 1.23±0.32 1.75±1.09 
 The Viva 
Study 
1995-1998 902 49±8 4.2 2.3 13.6 27.6±3.7 5.8±1.1 3.89±0.99 1.19±0.32 1.54±1.10 
Finnish, Finland East-West men 1989 156 71±1 14.1 7.1 28.8 26.3±3.9 5.8±1.1 3.93±0.99 1.16±0.27 1.44±0.65 
 National 
FINRISK 
STUDY 87, 92 
1987-1992 877 54±6 5.9 4.0 25.5 27.7±3.8 6.0±1.0 3.82±0.92 1.24±0.32 1.94±1.24 
 National 
FINRISK 
Study 2002 
2002 1799 58±7 11.1 8.1 34.0 28.0±4.0 5.8±1.1 3.59±0.96 1.34±0.36 1.73±1.08 
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 Oulu Study 1992 325 55 22.2 5.8 43.4 26.7±3.4 5.6±1.3 3.82±1.21 1.17±0.33 1.35±0.98 
 Savitaipale 1996-1999 584 53±7 7.0 6.5 36.3 26.4±3.9 5.6±1.0 3.56±0.87 1.35±0.36 1.49±1.11 
 Vantaa Study 1990-1991 272 65±0.4 4.4 11.4 30.1 26.9±3.7 5.8±1.0 3.83±0.93 1.16±0.30 1.58±0.94 
Polish, Poland POLMONICA 1992-1993 168 58±8 8.3 0 32.7 26.5±4.1 5.5±0.9 3.43±0.85 1.39±0.29 1.49±0.98 
Swedish, Sweden MONICA 
1986 
1986 218 44±11 1.8 11.0 6.9 25.4±3.7 5.9±1.1 4.12±1.00 1.13±0.25 1.41±0.96 
 MONICA 
1990 
1990 364 45±11 1.9 2.7 11.3 25.8±3.3 6.2±1.2 4.14±1.08 1.28±0.31 1.66±1.02 
 MONICA 
1994 
1994 497 50±13 3.6 5.4 13.3 27.3±3.7 6.2±1.3 4.12±1.09 1.22±0.30 1.70±1.24 
 ULSAM 1991-1995 1176 70±0.6 10.6 5.9 30.5 26.3±3.4 5.8±1.0 3.82±0.88 1.28±0.35 1.45±0.77 
Dutch, The 
Netherlands 
The Hoorn 
Study 
1989-1991 1080 60±6 6.9 3.1 18.5 26.2±3.0 6.4±1.1 4.42±1.02 1.18±0.31 1.68±1.02 
 Zutphen 1990 211 71±1 10.4 7.6 24.2 25.9±2.9 6.2±1.1 4.28±1.03 1.15±0.31 1.57±0.87 
British, U.K. ELY 1990-1992 473 54±8 8.2 0 34.2 26.1±3.2 6.5±1.2 4.43±1.05 1.29±0.32 1.49±0.71 
 Newcastle 
Heart Project 
1993-1994 376 54±12 8.5 2.7 31.4 26.3±3.9 5.7±1.0 3.61±0.94 1.35±0.39 1.51±0.79 
 The Goodinge 
Study 
1990-1991 446 54±10 9.4 0 43.0 25.5±4.1 6.3±1.2 4.17±1.13 1.29±0.38 1.70±1.29 
Women        
     
Chinese,  
Hong Kong, 
China 
HK-wscvdrf b 1991 551 40±8 3.1 2.0 8.7 23.5±3.5 4.8±0.9 2.85±0.82 1.52±0.38 0.89±0.64 
HK-cvrfps c 1995-1996 1409 45±12 6.4 4.3 17.3 24.0±3.8 5.0±1.0 3.16±0.91 1.35±0.32 1.09±0.71 
Chinese, 
Qingdao, China 
Qingdao 2002 2002 1192 52±11 9.2 2.5 18.0 26.3±3.8 5.7±1.1 3.51±0.91 1.52±0.28  1.48±0.95 
Qingdao 2006 2006 2368 49±10 12.0 7.4 26.7 25.8±3.6 5.3±1.1 3.04±0.92 1.65±0.40 d 1.27±0.86 
Asian Indian, 
India 
Chennai 94 1994-1995 215 50±8 12.6 19.1 19.5 24.0±4.7 5.4±1.1 3.34±0.91 1.13±0.30 1.82±0.92 
Chennai 97 1996-1998 566 44±13 5.8 6.9 7.8 23.5±4.5 4.7±1.0 2.95±0.88 1.10±0.27 1.30±0.74 
CURES 2003-2004 1116 40±11 9.8 5.1 11.4 23.6±4.0 4.8±1.0 2.93±0.83 1.18±0.25 d 1.33±0.80 
Chennai 2006 2006 3250 40±10 5.1 9.2 8.5 23.9±5.0 4.4±1.0 2.52±0.82 1.16±0.25 d 1.45±0.88 
Mauritian Indian, 
Mauritius 
Mauritius 87 1987 1692 42±13 7.0 4.8 21.4 23.9±4.7 5.3±1.5 3.37±1.39 1.31±0.31 1.29±0.87 
Mauritius 92 1992 960 43±12 8.0 12.2 17.7 25.6±5.2 4.8±0.9 2.84±0.75 1.33±0.29 1.26±0.75 
Mauritius 98 1998 436 42±10 8.7 8.9 18.1 25.2±4.8 4.7±1.1 3.05±0.93 0.99±0.32 1.24±0.62 
Japanese, Japan Funagata 1995-1997 1121 56±11 2.2 3.8 12.7 23.9±3.5 5.4±0.9 3.31±0.86 1.53±0.36 d 1.15±0.63 
 Hisayama 1988 1312 55±9 4.9 5.6 22.3 23.1±3.2 5.6±1.1 3.69±0.99 1.34±0.29 1.21±0.76 
Italian, Italy   Cremona 1990-1991 876 56±8 2.4 5.6 8.3 26.4±4.9 6.2±1.2 4.13±1.10 1.46±0.36 1.25±0.62 
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Study 
Cypriot, Republic 
of Cyprus 
Nicosia 
Diabetes Study 
2003-2004 558 50±13 2.5 5.6 12.2 27.0±5.9 5.5±1.0 3.38±0.92 1.48±0.36 1.27±0.89 
Spanish, Spain The Guia 
Study 
1997 322 51±12 4.0 11.2 18.6 28.6±5.4 6.0±1.0 3.91±0.91 1.38±0.33 1.41±0.81 
 The Viva 
Study 
1995-1998 1107 49±9 4.2 2.3 13.6 28.2±4.9 5.7±1.1 3.72±0.96 1.40±0.33 1.13±0.61 
Finnish, Finland National 
FINRISK 
STUDY 87, 92 
1987-1992 1043 54±6 4.0 3.3 14.5 27.2±4.8 5.9±1.1 3.75±0.95 1.50±0.34 1.41±0.90 
 National 
FINRISK 
Study 2002 
2002 2065 57±8 6.2 5.9 23.7 27.9±5.1 5.8±1.0 3.48±0.92 1.65±0.43 1.35±0.72 
 Oulu Study 1992 411 55 13.1 2.2 42.8 26.5±4.3 5.9±1.3 3.89±1.29 1.48±0.43 1.05±0.55 
 Savitaipale 1996-1999 583 54±7 5.8 4.8 37.9 26.6±4.8 5.7±1.1 3.46±0.93 1.58±0.41 1.26±0.80 
 Vantaa Study 1990-1991 337 65±0.4 8.0 8.0 28.2 27.6±4.6 6.3±1.0 4.15±0.99 1.40±0.33 1.53±0.97 
Polish, Poland POLMONICA 1992-1993 190 57±8 5.8 2.6 28.9 29.3±4.9 5.9±1.0 3.69±0.88 1.46±0.26 1.54±0.81 
Swedish, Sweden MONICA 
1986 
1986 204 44±11 1.1 4.4 9.8 24.4±4.5 6.0±1.3 4.09±1.17 1.38±0.41 1.08±0.67 
 MONICA 
1990 
1990 410 44±11 1.5 1.7 10.5 25.1±4.4 6.1±1.3 3.89±1.19 1.55±0.35 1.33±0.70 
 MONICA 
1994 
1994 521 49±14 4.4 3.6 11.9 25.9±4.7 6.2±1.4 3.96±1.21 1.49±0.40 1.44±0.81 
Dutch, The 
Netherlands 
The Hoorn 
Study 
1989-1991 1238 61±6 6.0 3.4 15.3 26.8±4.0 6.9±1.2 4.66±1.10 1.45±0.37 1.55±0.96 
British, U.K. ELY 1990-1992 619 53±8 6.0 0 28.3 25.9±5.0 6.6±1.4 4.39±1.25 1.58±0.38 1.28±0.68 
 Newcastle 
Heart Project 
1993-1994 354 53±11 4.8 1.7 23.7 26.4±5.0 5.9±1.2 3.56±1.07 1.61±0.39 1.46±0.78 
 The Goodinge 
Study 
1990-1991 559 54±10 8.6 0 30.1 26.0±5.3 5.6±1.4 4.31±1.24 1.54±0.40 1.48±0.83 
Data are n, means ± S.D, or %.  
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein 
cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides. a Calculated only in individuals with TG<4.5mmol/l 
b
 Hong Kong Workforce Survey on CVD Risk Factors 
c
 Hong Kong Cardiovascular Disease Risk Factor Prevalence Study 
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Table 5 Age- and study-adjusted mean lipid concentrations by fasting plasma glucose categories (Studies I and II) 
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; NFG, normal fasting glucose; IFG, impaired fasting glucose; 
DM, newly diagnosed diabetes classified based on fasting plasma glucose; 
* Standardized coefficients (β) from multiple linear regression model where lipid as dependent variable and fasting plasma glucose as  
independent variable, after adjusting for age, cohort, body mass index, systolic blood pressure and smoking status;  
a
 p<0.05 for the difference between IFG and NFG groups;  
b
 p<0.05, c p<0.01, d p<0.001 for β 
 
 
 
 TC  
(mmol/l)  
HDL-C  
(mmol/l)  
TG 
 (mmol/l)  Non-HDL-C (mmol/l)  TC/HDL-C  
Ethnic group No. NFG IFG DM Beta* NFG IFG DM Beta* NFG IFG DM Beta* NFG IFG DM Beta* NFG IFG DM Beta* 
Men                      
Qingdao Chinese 2033 5.31 5.52a 5.61 0.10d 1.60 1.49a 1.49 -0.09d 1.41 1.87a 2.23 0.19d 3.71 4.03a 4.12 0.14d 3.45 3.79a 3.85 0.17d 
Hong Kong Chinese 1837 5.23 5.35 5.26 0.01 1.20 1.10a 1.06 -0.02 1.37 1.68a 1.91 0.06c 4.04 4.25a 4.20 0.01 4.64 5.11a 5.16 0.02 
European 8960 5.95 6.10a 6.07 0.06d 1.27 1.26 1.26 -0.02 1.55 1.77a 2.21 0.14d 4.68 4.83a 4.91 0.06d 5.02 5.14a 5.58 0.06d 
Japanese 1696 5.10 5.28a 5.25 0.07c 1.34 1.31 1.34 -0.002 1.50 2.02a 2.40 0.12b 3.76 3.97a 3.91 0.07b 4.04 4.33a 4.14 0.06b 
Asian Indian 1267 4.71 5.03a 5.10 0.12d 1.03 0.97 0.97 -0.03 1.57 2.01a 2.48 0.19b 3.68 4.05a 4.12 0.13d 4.78 5.35a 5.36 0.10d 
Mauritian Indian 2100 5.31 5.51a 5.65 0.06c 1.22 1.20 1.16 -0.01 1.66 2.09a 2.35 0.11d 4.09 4.31a 4.49 0.06c 4.79 4.96 5.43 0.05b 
Women                      
Qingdao Chinese 3125 5.40 5.51a 5.81 0.11d 1.64 1.54a 1.57 -0.06d 1.26 1.34a 1.82 0.15d 3.76 3.98a 4.24 0.14d 3.40 3.66a 3.77 0.15d 
Hong Kong Chinese 1708 5.00 5.33a 5.26 0.09d 1.41 1.21a 1.30 -0.08c 1.02 1.37a 1.45 0.10d 3.59 4.13a 3.97 0.12d 3.77 4.71a 4.29 0.13d 
European 10 516 6.11 6.17 6.20 0.03c 1.54 1.47a 1.36 -0.03b 1.28 1.50a 1.80 0.12d 4.55 4.77a 4.84 0.03c 4.21 4.51a 4.93 0.05d 
Japanese 2326 5.46 5.64a 5.75 0.06c 1.44 1.38a 1.33 -0.06c 1.13 1.52a 1.61 0.10d 4.02 4.26a 4.42 0.08d 3.97 4.39a 4.60 0.11d 
Asian Indian 1308 4.76 5.06a 5.26 0.16d 1.17 1.03a 1.05 -0.07b 1.28 1.81a 2.11 0.21d 3.59 4.03a 4.21 0.18d 4.24 5.19a 5.13 0.13d 
Mauritian Indian 2363 5.05 5.31a 5.83 0.12d 1.27 1.22a 1.18 -0.04 1.22 1.37a 2.05 0.13d 3.78 4.09a 4.65 0.13d 4.21 4.64a 5.33 0.17d 
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Table 6 Age- and study-adjusted mean lipid concentrations by 2-h plasma glucose categories (Studies I and II) 
TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; NGT, normal glucose tolerance; IGT, impaired glucose 
tolerance; DM, newly diagnosed diabetes classified based on 2-h plasma glucose; 
* Standardized coefficients (β) from multiple linear regression model where lipid as dependent variable and 2-h plasma glucose as  
independent variable, after adjusting for age, cohort, body mass index, systolic blood pressure and smoking status;  
a
 p<0.05 for the difference between IGT and NGT groups;  
b
 p<0.05, c p<0.01, d p<0.001 for β 
 
 TC  
(mmol/l)  
HDL-C  
(mmol/l)  
TG  
(mmol/l)  Non-HDL-C (mmol/l)  TC/HDL-C  
Ethnic group No. NGT IGT DM Beta* NGT IGT DM Beta* NGT IGT DM Beta* NGT IGT DM Beta* NGT IGT DM Beta* 
Men                      
Qingdao Chinese 2033 5.34 5.38 5.66 0.06c 1.58 1.51a 1.60 -0.01 1.44 1.88a 2.09 0.14d 3.75 3.87a 4.06 0.07c 3.50 3.67a 3.72 0.08c 
Hong Kong Chinese 1837 5.21 5.37a 5.29 0.03 1.21 1.12a 1.09 -0.07c 1.30 1.74a 1.90 0.16d 4.01 4.26a 4.20 0.05b 4.58 5.11a 5.12 0.08d 
European 8960 5.99 5.91a 6.05 -0.01 1.27 1.21a 1.17 -0.08d 1.56 1.86a 2.27 0.15d 4.72 4.70 4.88 0.02 5.03 5.23a 5.57 0.08d 
Japanese 1696 5.09 5.24a 5.29 0.05 1.35 1.27a 1.34 -0.05b 1.45 2.00a 2.46 0.15d 3.74 3.98a 3.96 0.07c 4.01 4.39a 4.24 0.08c 
Asian Indian 1267 4.67 5.00a 5.06 0.10d 1.03 1.00 0.97 -0.07b 1.52 1.92a 2.30 0.19d 3.63 3.99a 4.09 0.12d 4.72 5.20a 5.36 0.13d 
Mauritian Indian 2100 5.29 5.53a 5.61 0.08d 1.22 1.18a 1.18 -0.01 1.63 2.08a 2.26 0.15d 4.07 4.35a 4.43 0.09d 4.74 5.13a 5.32 0.08d 
Women                      
Qingdao Chinese 3125 5.41 5.47 5.76 0.08d 1.63 1.57a 1.58 -0.05c 1.23 1.46a 1.80 0.15d 3.78 3.90a 4.18 0.10d 3.42 3.56a 3.71 0.11d 
Hong Kong Chinese 1708 4.96 5.23a 5.25 0.10d 1.43 1.30a 1.19 -0.14d 0.96 1.27a 1.58 0.23d 3.53 3.94a 4.06 0.15d 3.67 4.26a 4.69 0.18d 
European 10 516 6.12 6.10 6.11 -0.004 1.51 1.40a 1.27 -0.11d 1.26 1.56a 1.83 0.15d 4.57 4.67a 4.77 0.03c 4.20 4.54a 4.91 0.10d 
Japanese 2326 5.44 5.59a 5.73 0.07c 1.45 1.38a 1.31 -0.07c 1.11 1.36a 1.69 0.15d 4.00 4.21a 4.42 0.09d 3.94 4.29a 4.55 0.11d 
Asian Indian 1308 4.74 4.96a 5.13 0.15d 1.18 1.10a 1.02 -0.14d 1.23 1.53a 2.05 0.32d 3.55 3.87a 4.11 0.19d 4.16 4.71a 5.17 0.23d 
Mauritian Indian 2363 5.04 5.12 5.71 0.11d 1.28 1.22a 1.21 -0.05b 1.17 1.39a 1.88 0.23d 3.76 3.90a 4.51 0.12d 4.18 4.42a 5.14 0.12d 
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5.2 Ethnic differences in lipid profiles by glucose status (Study III) 
5.2.1 Lipid distributions in relation to ethnicity and glucose categories 
Age-, cohort- and BMI adjusted mean TC, LDL-C and TG increased while the mean HDL-
C decreased with more pronounced glucose intolerance in most of the ethnic groups in 
individuals without a prior history of diabetes (Fig. 2 a-h). Subjects with undiagnosed 
diabetes, however, had a worse lipid profile than those with known disease. Within 
individuals with normoglycaemia, mean lipid and lipoprotein concentrations differed 
among the ethnic groups. The Europeans had highest TC (Fig. 2 a-b) and LDL-C (Fig. 2 c-
d), while Qingdao Chinese had highest HDL-C levels among all ethnic groups (Fig. 2 e-f). 
In contrast, Asian Indians had the lowest TC (Fig. 2 a-b), LDL-C (Fig. 2 c-d) and HDL-C 
(Fig. 2 e-f) but the highest TG (Fig. 2 g-h) among the ethnic groups (p <0.05 for all 
comparisons). These ethnic differences were consistently found in all glucose categories. 
5.2.2 Dyslipidaemia in relation to ethnicity by glucose levels 
The multivariate-adjusted odds ratio (95% CI) of having low HDL-C was significantly 
higher for Asian Indians, Mauritian Indians, Hong Kong Chinese and Southern Europeans 
but lower for Qingdao Chinese compared with C&N Europeans, across all glucose 
categories from normal to diabetes (Table 7). Asian Indians and Mauritian Indians tended to 
have higher but Southern Europeans lower odds ratios for having high-TG compared with 
the reference group. Unlike that for HDL-C or TG, the odds ratio for having high LDL-C 
was consistently lower in all Asian ethnic groups compared with the reference, across most 
of the glucose categories.  
In contrast to the lower HDL-C and higher TG profiles, Asian Indians had considerably 
lower TC and LDL-C concentrations than others. As shown in Table 3, 71% non-diabetic 
and 57.6% diabetic Asian Indians had low LDL-C (< 3.0 mmol/l), while the corresponding 
figures were 19.2% and 24.6% (p < 0.01) for C&N Europeans and 46.6% and 38.8% (p < 
0.01) for Qingdao Chinese. However, even within the low LDL-C category, there was still a 
higher proportion of Asian Indians having low HDL-C compared with others (Table 8). The 
results were confirmed in the same analysis conducted separately for men and women. 
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Figure 2 Age-, study cohort- and body mass index-adjusted mean lipid (geometric means for triglycerides) and  
lipoprotein concentrations and 95% CIs (vertical bars) in men (figure 1-a, c, e and g) and women (figure 1-b, d, 
f and h) by ethnicities and glucose categories. Abbreviations as in Table 4 and 5. * p for trend < 0.05 within 
each glucose category. 
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Table 7 Odds ratio (95% confidence interval) of having dyslipidaemia in relation to ethnicity by glucose categories (Study III) 
Model adjusted for age, study cohort, body mass index, systolic blood pressure and smoking status. 
NFG, normal fasting glucose; NGT, normal glucose tolerance; other abbreviations as in Table 4. 
a
 Reference group 
 HDL-C < 1.03 in men and < 1.29 in women (mmol/l) TG ≥ 1.7 mmol/l LDL-C  ≥ 3 mmol/l 
 NFG and  IFG and/or  Undiagnosed Diagnosed NFG and  IFG and/or  Undiagnosed Diagnosed NFG and  IFG and/or  Undiagnosed Diagnosed 
 NGT IGT diabetes diabetes NGT IGT diabetes diabetes NGT IGT diabetes diabetes 
Men             
Central & 
Northern 
European a 
1  1 1 1 1 1 1 1 1 1 1 1 
Hong Kong 
Chinese 
1.63  
(1.41-1.87) 
2.75  
(2.09-3.62) 
1.82  
(1.20-2.76) 
2.57  
(1.48-4.46) 
0.75  
(0.64-0.87) 
1.16  
(0.88-1.53) 
1.05  
(0.70-1.58) 
0.63  
(0.36-1.12) 
0.51 
(0.44-0.58)  
0.61 
(0.46-0.82)  
0.51 
(0.33-0.78)  
0.86 
(0.49-1.52)  
Qingdao 
Chinese 
0.12  
(0.09-0.16) 
0.07  
(0.04-0.13) 
0.11  
(0.07-0.20) 
0.16  
(0.08-0.32) 
0.68  
(0.58-0.79) 
0.81  
(0.66-1.00) 
0.81  
(0.61-1.09) 
0.40  
(0.26-0.63) 
0.23  
(0.20-0.26) 
0.30  
(0.24-0.37) 
0.44  
(0.32-0.60) 
0.57 
(0.37-0.86) 
Asian Indian 4.74  
(4.19-5.37) 
5.05  
(3.88-6.56) 
3.07  
(2.15-4.40) 
2.37  
(1.67-3.35) 
1.40  
(1.23-1.58) 
1.53  
(1.19-1.97) 
1.24  
(0.88-1.75) 
1.42  
(1.01-2.00) 
0.12 
(0.10-0.13)  
0.17 
(0.13-0.22)  
0.23 
(0.16-0.33)  
0.29 
(0.20-0.41)  
Mauritian 
Indian 
1.82  
(1.58-2.09) 
2.04  
(1.58-2.63) 
1.27  
(0.89-1.81) 
1.16  
(0.78-1.74) 
1.47  
(1.28-1.69) 
1.55  
(1.23-1.98) 
1.18  
(0.85-1.65) 
1.06  
(0.72-1.57) 
0.39 
(0.34-0.45) 
0.38 
(0.30-0.49) 
0.49 
(0.34-0.70) 
0.75 
(0.50-1.12) 
Japanese 0.87 
(0.73-1.03) 
1.29 
(0.98-1.70) 
0.73  
(0.44-1.20) 
0.57 
(0.36-0.90) 
0.99  
(0.84-1.15) 
1.31 
(1.02-1.68) 
1.36 
(0.88-2.09) 
1.02 
(0.68-1.53) 
0.26  
(0.23-0.30) 
0.35 
(0.27-0.44) 
0.36 
(0.23-0.57) 
0.77 
(0.51-1.16) 
Southern 
European 
1.21  
(1.06-1.37) 
1.49  
(1.15-1.93) 
1.79  
(1.19-2.70) 
1.13  
(0.78-1.63) 
0.78  
(0.69-0.88) 
0.83  
(0.65-1.07) 
1.16  
(0.77-1.75) 
0.58  
(0.40-0.84) 
0.87 
(0.75-1.00)  
0.99 
(0.73-1.36)  
1.80 
(1.01-3.23)  
1.52 
(0.99-2.31)  
Women             
Central & 
Northern 
European a 
1 1 1 1 1 1 1 1 1 1 1 1 
Hong Kong 
Chinese 
2.23  
(1.93-2.57) 
3.79  
(2.88-4.98) 
3.02  
(1.88-4.85) 
3.03  
(1.68-5.48) 
0.86  
(0.69-1.08) 
1.16  
(0.85-1.58) 
0.98  
(0.61-1.57) 
0.69  
(0.39-1.21) 
0.41 
(0.35-0.47) 
0.64 
(0.48-0.86) 
0.61 
(0.36-1.04) 
1.21 
(0.66-2.22) 
Qingdao 
Chinese 
0.66  
(0.57-0.76) 
0.52  
(0.41-0.65) 
0.27  
(0.19-0.38) 
0.20  
(0.13-0.31) 
1.29  
(1.11-1.50) 
1.06  
(0.87-1.30) 
0.99  
(0.73-1.36) 
0.57  
(0.39-0.84) 
0.40 
(0.36-0.45) 
0.45 
(0.37-0.55) 
0.48 
(0.33-0.69) 
0.67 
(0.45-0.99) 
Asian Indian 10.91  
(9.68-12.30) 
7.80  
(5.99-9.94) 
8.64  
(5.62-13.29) 
4.34  
(2.93-6.44) 
2.76  
(2.39-3.18) 
2.21  
(1.71-2.87) 
3.13  
(2.15-4.55) 
1.29  
(0.90-1.85) 
0.22  
(0.20-0.25) 
0.36  
(0.28-0.47) 
0.36  
(0.24-0.54) 
0.41  
(0.28-0.60) 
Mauritian 
Indian 
4.41  
(3.88-5.02) 
3.80  
(3.05-4.74) 
2.65  
(1.82-3.88) 
2.26  
(1.53-3.35) 
1.38  
(1.16-1.65) 
1.15  
(0.91-1.47) 
1.54  
(1.07-2.23) 
0.81  
(0.56-1.19) 
0.48 
(0.42-0.55) 
0.50 
(0.40-0.63) 
0.78 
(0.51-1.21) 
0.85 
(0.57-1.27) 
Japanese 2.40 
(2.12-2.73) 
3.07 
(2.44-3.87) 
2.65 
(1.62-4.34) 
1.07 
(0.67-1.72) 
0.92  
(0.77-1.09) 
1.19 
(0.93-1.53) 
0.72 
(0.43-1.21) 
0.41 
(0.25-0.68) 
0.58  
(0.51-0.66) 
0.67 
(0.52-0.87) 
0.56 
(0.31-0.99) 
2.24 
(1.27-3.93) 
Southern 
European 
1.50  
(1.34-1.68) 
1.62  
(1.26-2.08) 
0.93  
(0.56-1.52) 
1.70  
(1.13-2.56) 
0.70  
(0.60-0.81) 
0.80  
(0.61-1.05) 
0.60  
(0.36-1.01) 
0.53  
(0.35-0.79) 
0.98 
(0.87-1.11) 
1.39 
(1.01-1.93) 
1.38 
(0.70-2.72) 
2.67 
(1.62-4.42) 
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Table 8 Proportions (%) of individuals according to lipid levels stratified by diabetic status in each ethnic group (Study III) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations as in Table 4. 
a
 < 1.03 mmol/l in men and < 1.29 mmol/l in women 
b
 ≥ 1.70 mmol/l 
 
 
 LDL-C < 3 mmol/l  LDL-C ≥ 3 mmol/l 
 Normal HDL-C 
 and normal TG, % 
Low HDL-
C a alone, % 
High TG b 
alone, % 
both, %  Normal HDL-C  
and normal TG, % 
Low HDL-C a 
alone, % 
High TG b 
alone, % 
both, % 
Non-diabetic population          
Hong Kong Chinese 29.3 9.9 1.6 4.2  32.1 12.9 3.7 6.2 
Qingdao Chinese 31.0  5.4  8.3  1.9   40.5  2.4  9.8  0.7  
Asian Indian 23.2  33.6  3.2  11.0   9.2  10.7 2.8  6.4 
Mauritian Indian 23.9 15.8 5.0 4.7  23.2 14.7 5.7 7.0 
Japanese 25.2 6.4 3.4 3.5  38.2 13.0 5.0 5.3 
Central & Northern European 13.3 2.3 2.0 1.6  48.6 9.7 12.6 10.0 
Southern European 14.2 4.3 1.1 2.1  45.5 15.1 7.8 10.0 
Diabetic population          
Hong Kong Chinese 12.4 9.6 1.4 11.0  22.6 18.1 7.6 17.2 
Qingdao Chinese 21.1 3.5 11.1 3.1  37.9 2.7 19.1 1.5 
Asian Indian 12.8 17.4 6.0 21.4  8.1 12.4 7.2 14.7 
Mauritian Indian 12.4 8.6 6.4 10.2  21.2 15.5 10.2 15.5 
Japanese 14.3 6.0 7.1 5.1  34.3 11.6 12.2 9.4 
Central & Northern European 10.5 2.8 4.9 6.4  30.4 9.3 16.4 19.4 
Southern European 7.5 3.3 6.0 10.2  24.4 11.2 12.8 14.8 
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5.3 Dyslipidaemia and CVD mortality in the Europeans without a prior 
history of diabetes (Study IV) 
Among the 17 763 European subjects of 14 cohorts, 1286 (7.2%) were identified as having 
newly diagnosed diabetes at baseline examination, 2690 (15.1%) IFG, 2557 (14.4%) IGT, 
and 4390 (24.7%) IFG and/or IGT. During an average of 10 years of follow-up, there were 
861 deaths (686 men and 185 women) from CVD accumulated (Table 9).  
Multivariate-adjusted Cox proportional hazards analysis showed that, HDL-C was inversely 
associated with CVD death in all glucose categories except for IGT (Table 10) or isolated 
post-load hyperglycaemia (Table 11). TG was positively associated with CVD death only in 
those with newly diagnosed diabetes or CH. Non-HDL-C and TC/HDL-C were 
significantly associated with increased risk of CVD death in subjects with IFG (Table 10) as 
well as in those with isolated fasting hyperglycaemia (Table 11), but none of these lipid 
variables significantly predicted CVD death in individuals with IGT (Table 10) or in those 
with isolated post-load hyperglycaemia (Table 11). No significant interaction between lipid 
and glucose was observed in any group. Due to the relatively low number of deaths from 
CVD in women, gender-specific analyses were only able to do in men and results for men 
were not different from the combined data analysis. 
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Table 9 Baseline characteristics of subjects and number of deaths from cardiovascular disease during follow-up (Study IV) 
Countries and Studies No. 
(men/women) 
Mean age  
in years 
(range) 
IFG 
 (%) 
IGT  
(%) 
 
Diabetes 
(%) 
 
Hypertension 
(%) 
Current 
Smoking  
(%) 
Follow-up 
year  
(Max) 
No. of CVD 
Deaths 
(men/women) 
Finland          
  East-West men 354/- 76 (69-89) 15.8 27.1 12.7 81.9 14.1 17.1 137/- 
  National FINRISK Study 87, 92 841/1007 54 (44-64) 13.6 11.1 5.1 64.5 20.6 15.0 54/18 
  National FINRISK Study 2002 1640/1934 57 (45-74) 20.3 16.8 8.7 64.6 28.3 4.9 22/5 
  Oulu Study 304/401 55 (55-55) 30.6 28.7 17.6 71.3 23.3 15.0 13/7 
  Vantaa Study 240/308 65 (64-66) 10.8 27.9 6.6 80.7 16.6 13.9 29/10 
Italy          
  Cremona Study 731/927 57 (40-88) 4.4 8.7 3.4 58.7 22.7 15.7 76/65 
Poland          
  POLMONICA   163/181 57 (43-73) 13.7 22.7 7.3 47.4 25.6 6.6 13/2 
Sweden          
  MONICA 993/1077 46 (25-74) 5.5 7.2 2.5 32.1 21.6 20.6 36/19 
  ULSAM 1095/- 70 (69-73) 9.3 28.4 11.1 73.9 20.8 12.4 119/- 
The Netherlands          
  The Hoorn Study  1081/1269 61 (49-77) 10.9 9.5 6.9 49.4 33.7 10.2 66/32 
  Zutphen Study 442/- 75 (69-89) 17.9 10.0 10.6 67.4 22.6 4.8 46/- 
U.K.          
  Isle of ELY Diabetes Project 425/599 54 (40-69) 22.7 15.4 6.6 32.5 16.8 15.7 22/6 
  Newcastle Heart Project 375/360 54 (30-76) 21.2 13.3 7.2 34.6 28.0 10.6 25/8 
  The Goodinge Study 448/568 54 (39-76) 31.9 9.3 8.9 21.9 37.7 9.7 28/13 
Total 9132/8631 57 (25-89) 15.1 14.4 7.2 54.1 25.3 20.6 686/185 
Abbreviations as in Table 4.
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Table 10 Number of subjects and percentage of deaths from cardiovascular disease, and 
multivariate-adjusted hazard ratios (95% CIs) for cardiovascular mortality corresponding to a one 
unit increase in the Z-score for lipid according to fasting or 2-hour glucose criteria in subjects 
without a prior history of diabetes (Study IV) 
 FPG (mmol/l) category  2hPG (mmol/l) category  New-DM 
 NFG (<6.10) IFG (6.10-6.99) 
 
NGT (<7.80) IGT (7.80-11.09)  
(FPG≥7.80 and/or 
2hPG≥11.10mmol/l) 
No. 13 787 2690  13 920 2557  1286 
CVD death (%) 4.4 5.5  4.1 7.4  9.2 
HDL-C a 0.88 (0.80-0.98) 0.66 (0.50-0.87)  0.83 (0.74-0.92) 0.96 (0.79-1.16)  0.68 (0.52-0.88) 
TG a 1.03 (0.92-1.15) 1.09 (0.88-1.34)  1.05 (0.93-1.19) 1.00 (0.83-1.19)  1.12 (1.01-1.28) 
TC b 0.96 (0.87-1.06) 1.10 (0.88-1.37)  1.01 (0.91-1.12) 0.92 (0.77-1.11)  1.05 (0.83-1.31) 
Non-HDL-C b 1.01 (0.91-1.11) 1.20 (1.00-1.50)  1.07 (0.97-1.19) 0.94 (0.78-1.13)  1.17 (0.93-1.46) 
TC/HDL-C b 1.09 (0.99-1.20) 1.36 (1.11-1.67)  1.18 (1.07-1.31) 1.01 (0.85-1.09)  1.26 (1.04-1.53) 
a
 Adjusted for age, sex, cohort, hypertension, smoking status, waist circumference and total 
cholesterol 
b Adjusted for age, sex, cohort, hypertension, smoking status and waist circumference 
 
 
 
Table 11 Number of subjects and percentage of deaths from cardiovascular disease, and 
multivariate-adjusted hazard ratios (95% CIs) for cardiovascular mortality corresponding to a one 
unit increase in the Z-score for lipid according to both fasting and 2-hour glucose criteria in subjects 
without a prior history of diabetes (Study IV) 
 
FPG (mmol/l) <6.10 ≥6.10 <6.10 ≥6.10 
2hPG (mmol/l) <7.80 <7.80 ≥7.80 ≥7.80 
No. 12 087 2048 1896 1732 
CVD death (%) 4.0 4.7 7.5 8.7 
HDL-C a 0.84 (0.75-0.94) 0.66 (0.48-0.92) 1.03 (0.84-1.27) 0.67 (0.51-0.89) 
TG a 1.05 (0.92-1.20) 1.10 (0.85-1.44) 0.95 (0.75-1.19) 1.12 (1.00-1.27) 
TC b 0.97 (0.87-1.08) 1.29 (0.99-1.68) 0.91 (0.74-1.12) 1.02 (0.83-1.25) 
Non-HDL-C b 1.03 (0.92-1.15) 1.40 (1.08-1.81) 0.91 (0.73-1.12) 1.11 (0.90-1.36) 
TC/HDL-C b 1.14 (1.03-1.27) 1.44 (1.13-1.84) 0.94 (0.77-1.15) 1.26 (1.05-1.50) 
a
 Adjusted for age, sex, cohort, hypertension, smoking status, waist circumference and total 
cholesterol 
b Adjusted for age, sex, cohort, hypertension, smoking status and waist circumference 
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5.4 Dyslipidaemia and CHD incidence in the Europeans without a prior 
history of diabetes (Study V) 
Among the 9087 subjects of 6 European cohorts who were free of CHD at baseline, 622 
(6.8%) were identified as having diabetes, 979 (10.8%) isolated IGT, 797 (8.8%) isolated 
IFG, and 429 (4.7%) had combined IFG and IGT. During a median follow-up of 10.2 years, 
a total of 457 incident CHD cases (379 men and 78 women) were identified (Table 12).  
 
 
 Table 12 Demographic and follow-up information of the participants (Study V) 
Abbreviations as in Table 4. 
 
 
 
 
Studies 
No. 
(men/ 
women) 
Mean  
age, 
years 
  Prevalence (%) Median of 
follow-up, 
years 
No. of incident 
CHD 
(men/women) 
Diabetes 
 
Isolated 
IGT 
Isolated 
IFG 
Combined 
IFG and IGT 
Finland         
East-West men  295/- 76 13.2 19.7 7.1 8.5 8.0  85/- 
    National 
FINRISK 
Study 87, 92 
789/990 53 4.8 6.5 9.0 4.2 14.9 61/22 
National 
FINRISK 
Study 2002 
1536/1909 58 8.6 10.0 13.8 6.3 4.8 26/17 
Vantaa Study 212/296 65 6.3 20.9 4.1 6.5 13.3  31/21 
Sweden         
MONICA 959/1074 46 2.6 5.8 3.8 1.4 15.8 58/18 
ULSAM 1027/- 70 11.6 23.0 3.9 5.1 9.9  118/- 
Total 9087 57 6.8 10.8 8.8 4.7 10.2 379/78 
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Individuals with hyperglycaemia (isolated IFG, isolated IGT, combined IFG and IGT, or 
diabetes) were older and had worse lipid profiles, higher BMI and waist circumference and 
the higher prevalence of hypertension than those with normoglycaemia (Table 13). In 
general, individuals with IFG and/or IGT had the CVD risk factor profiles falling between 
that observed in the normoglycaemic and diabetic people. In addition, individuals with 
combined IFG and IGT had comparable BMI and prevalence of hypertension with diabetic 
patients.    
 
Table 13 Baseline characteristics of subjects with different glucose categories defined by fasting and 
2-h plasma glucose (Study V) 
 NFG and NGT Isolated IFG Isolated IGT 
Combined IFG 
and IGT Diabetes 
No. 6260 797 979 429 622 
Men (%) 48.5 69.6 55.6 63.2 66.6 
Age (years) 55±0.1 57±0.4 a 62±0.3 a 61±0.5 a 62±0.4 a 
BMI (kg/m2) 26.2±0.1 28.0±0.1 a 27.4±0.1 a 29.4±0.2 a 29.5±0.2 a 
Waist (cm) 88.4±0.1 93.4±0.4 a 92.3±0.4 a 97.5±0.6 a 98.2±0.5 a 
TC (mmol/l) 5.93±0.01 6.03±0.04 b 5.88±0.04 5.89±0.05 5.96±0.04 
TG (mmol/l) 1.36±0.01 1.61±0.03 a 1.62±0.03 a 1.83±0.04 a 1.97±0.03 a 
HDL-C (mmol/l) 1.45±0.01 1.41±0.01 a 1.36±0.01 a 1.30±0.02 a 1.28±0.02 a 
Non-HDL-C (mmol/l) 4.48±0.01 4.61±0.04 a 4.52±0.04 4.59±0.05 4.68±0.05 a 
TC/HDL-C 4.38±0.02 4.56±0.05 a 4.60±0.04 a 4.81±0.07 a 4.95±0.05 a 
Hypertension (%) 52.1 69.8 a 73.4 a 81.4 a 82.4 a 
Smoking (%) 23.4 30.4 a 19.1 a 20.1 22.5 
Data are age-, sex- and cohort-adjusted means ± SE, or %; NFG, normal fasting glucose; NGT, 
normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; HDL-C, 
high-density lipoprotein cholesterol; TG, triglycerides; TC, total cholesterol; Non-HDL-C, non-
HDL cholesterol 
a
 P<0.01 compared with NFG and NGT 
b
 P<0.05 compared with NFG and NGT 
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In individuals with normoglycaemia each lipid variable was associated with incident CHD 
events; the age-, sex-, and cohort-adjusted HRs (95% CIs) were 1.22 (1.08-1.38), 0.71 
(0.62-0.82), 1.35 (1.20-1.53), 1.42 (1.29-1.58) and 1.23 (1.09-1.39) for TC, HDL-C, non-
HDL-C, TC/HDL-C and TG, respectively (Table 14). Similarly in people with diabetes, TC, 
non-HDL-C and TC/HDL-C and TG were directly associated while HDL-C inversely 
associated with CHD risk. In contrast, none of these was significant in people with isolated 
IGT or with combined IFG and IGT, and only TC and non-HDL-C predicted incident CHD 
in those with isolated IFG. 
After multivariate adjustment for known non-lipid risk factors (Table 14), the results 
remained significant in normoglycaemic and diabetic groups. Further addition of HDL-C or 
non-HDL-C to the model with TG improved the model prediction in the diabetic individuals 
(χ2 = 6.13 for HDL-C, 1 df, p < 0.05 or χ2 = 6.64 for non-HDL-C, 1 df, p < 0.05). TG also 
improved the prediction of the model with HDL-C (χ2 = 3.90 for TG, 1 df, p < 0.05), but did 
not contribute to the prediction in the model with non-HDL-C (χ2 = 2.54 for TG, 1 df, p > 
0.05). Since TG was not a significant predictor of the CHD in other non-diabetic glycaemic 
groups, the log-likelihood ratio test was not performed in other groups. No interaction was 
observed for the term of TG*HDL-C*glucose category (χ2 = 2.35, 4 df, p > 0.05) or 
TG*non-HDL-C*glucose category (χ2 = 3.68, 4 df, p > 0.05). We reported results from 
multivariate Cox regression analysis by pooling men and women together because sex-
specific analysis for women was not allowed due to a low number of cases. There was no 
significant interaction between sex and each lipid component except for HDL-C in the 
normoglycaemic group (χ2 = 5.33, 1 df, p < 0.05). 
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Table 14 Multivariate-adjusted hazard ratios (95% CIs) for coronary heart disease morbidity 
corresponding to a one unit increase in the Z-score for each lipid according to fasting and 2-h 
plasma glucose criteria in people without a prior history of diabetes (Study V) 
 NFG and NGT Isolated IFG Isolated IGT 
Combined  
IFG and IGT Diabetes 
No. 6260 797 979 429 622 
No. of Incident CHD 
 (rate per 1,000 person-year) 254 (3.8) 37 (5.8) 74 (8.4) 30 (8.7) 62 (13.0) 
Age-, sex- and  
cohort-adjusted model      
TC 1.22 (1.08-1.38) 1.46 (1.06-2.00) 1.13 (0.89-1.45) 1.35 (0.89-2.06) 1.31 (1.03-1.67) 
TG 1.23 (1.09-1.39) 1.07 (0.76-1.49) 1.04 (0.84-1.29) 1.11 (0.82-1.51) 1.18 (1.05-1.33) 
HDL-C 0.71 (0.62-0.82) 1.29 (0.90-1.85) 1.06 (0.82-1.38) 0.98 (0.63-1.52) 0.64 (0.45-0.91) 
Non-HDL-C 1.35 (1.20-1.53) 1.39 (1.01-1.93) 1.11 (0.88-1.41) 1.35 (0.90-2.04) 1.43 (1.13-1.83) 
TC/HDL-C 1.42 (1.29-1.58) 1.13 (0.81-1.59) 1.04 (0.83-1.32) 1.02 (0.71-1.46) 1.54 (1.22-1.95) 
Multivariate-adjusted model a      
TC 1.21 (1.06-1.37) 1.53 (1.10-2.15) 1.03 (0.80-1.34) 1.42 (0.90-2.27) 1.39 (1.08-1.80) 
TG 1.14 (0.99-1.30) 1.09 (0.78-1.52) 0.98 (0.78-1.22) 1.07 (0.76-1.49) 1.21 (1.07-1.37) 
HDL-C 0.76 (0.66-0.87) 1.32 (0.91-1.93) 1.05 (0.81-1.38) 1.05 (0.64-1.73) 0.57 (0.39-0.84) 
Non-HDL-C 1.31 (1.16-1.49) 1.47 (1.05-2.08) 1.02 (0.80-1.31) 1.39 (0.88-2.19) 1.56 (1.21-2.01) 
TC/HDL-C 1.36 (1.22-1.53) 1.18 (0.83-1.69) 0.98 (0.77-1.25) 0.97 (0.65-1.45) 1.74 (1.34-2.26) 
Mutually adjusted model 1 a      
TG  1.02 (0.88-1.19) 1.18 (0.83-1.67) 0.99 (0.78-1.26) 1.11 (0.76-1.62) 1.16 (1.01-1.33) 
HDL-C  0.76 (0.66-0.89) 1.38 (0.94-2.03) 1.05 (0.79-1.40) 1.13 (0.65-1.98) 0.62 (0.42-0.92) 
Mutually adjusted model 2 a      
TG  1.02 (0.87-1.19) 0.89 (0.58-1.36) 0.95 (0.73-1.25) 0.91 (0.61-1.32) 1.14 (0.99-1.32) 
Non-HDL-C  1.31 (1.14-1.49) 1.56 (1.05-2.32) 1.05 (0.78-1.42) 1.50 (0.86-2.65) 1.44 (1.10-1.90) 
Abbreviations as in Table 13. 
a
 Adjusted for age, sex, cohort, body mass index, hypertension status and smoking status 
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6 DISCUSSION 
6.1 Relationship between lipids and lipoproteins and glucose 
It is well established that lipid profiles are worse in diabetic than in non-diabetic individuals 
(Barrett-Connor et al. 1982; Wilson 1994; Betteridge 1999). Our study in the Europeans 
(Study I) and Asians (Study II), along with others (Harris et al. 2002; Novoa et al. 2005; 
Chen et al. 2006; Pankow et al. 2007), indicated that subjects with IFG/IGT were also 
associated with a poor lipid profile compared with those with NFG/NGT. With worsening 
glucose tolerance, levels of TG and TC/HDL-C markedly deteriorated in both sexes. TG, 
non-HDL-C and TC/HDL-C were positively associated with FPG or 2hPG in subjects 
without a prior history of diabetes. An inverse relationship between HDL-C and glucose 
was more pronounced for 2hPG that for FPG. The association of glucose with TC was not 
as clear as that with TG. This may be due to the different compositional changes in LDL 
particles in the hyperglycaemic states. VLDL-C and IDL-C levels are higher, whereas 
HDL-C levels are lower in diabetic than in non-diabetic individuals. Despite the increased 
risk of CHD in diabetes, LDL-C concentrations are often similar to those of control subjects 
(Howard 1999). TC, finally, is the sum of VLDL-C, IDL-C, LDL and HDL-C.  
The diabetic dyslipidaemia may be the exhibition of the underlying insulin resistance, a 
central pathophysiological feature of type 2 diabetes. Insulin resistance appears to cause 
hyperinsulinaemia, enhanced hepatic gluconeogenesis and glucose output, reduced 
suppression of lipolysis in adipose tissue leading to a high FFA flux and increased hepatic 
VLDL secretion causing hypertriglyceridaemia and reduced levels of HDL-C (Avramoglu 
et al. 2006). Individuals with IGT have been reported having more atherogenic lipid profiles, 
with higher TG and lower HDL-C levels than those with NGT or IFG (Blake et al. 2004; 
Wasada et al. 2004). The association of 2hPG with HDL-C compared with that of FPG with 
HDL-C, along with current evidence suggests that IFG and IGT may have different 
pathophysiologies (Bock et al. 2006) and different clinical consequences (The DECODE 
Study Group 2001). Subjects with IFG have severe hepatic insulin resistance and normal or 
nearly-normal muscle insulin sensitivity combined with impairment in first-phase insulin 
release, while people with IGT have marked muscle insulin resistance but only mild hepatic 
insulin resistance combined with impairment in first- and second-phase insulin release 
(Blake et al. 2004; Abdul-Ghani et al. 2006; Meyer et al. 2006). This implies that IGT is 
more closely related to insulin resistance than IFG (Wasada et al. 2004). In contrast with 
men, women with IFG were associated with worse HDL-C levels than were women with 
NFG in our study. A recent study has also shown an inverse relationship between FPG and 
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HDL-C in a Chinese population older than 50 years consisting of over 70% of female 
participants (Thomas et al. 2006). Further studies are needed on the issue whether gender 
difference in insulin resistance exists for the given range of glucose.  
Insulin resistance as well as abdominal obesity has been considered underlying cause of 
hyperglycaemia. Each of them is feature of the metabolic syndrome and plays an important 
role in lipid and glucose metabolism (Thomas et al. 2004; Katzmarzyk et al. 2006; Onat et 
al. 2007). This raises the question that to what extent is the relationship between lipid and 
blood glucose mediated through insulin resistance or abdominal obesity. We also carried 
out the regression analyses with further adjustment for fasting insulin levels and waist in 
both European and Asian populations. The consistent results suggest that the relationship 
between glucose and the lipid profiles, to some extent, is mediated through fasting insulin 
levels, a surrogate indicator of the insulin resistance, but the association could not be fully 
explained by fasting insulin levels. 
6.2 Distinct ethnic differences in lipid profiles across glucose categories 
In the collaborative analysis of seven ethnic groups of European and Asian populations 
(Study III), considerable ethnic differences in lipid profiles were observed within each 
glucose category. Asian Indians exhibited an adverse lipid pattern consisting of low HDL-C 
and high TG across all glucose categories as compared with other ethnic groups. Reduced 
HDL-C is prevalent even in Asian Indians with desirable LDL-C levels regardless of the 
diabetic status. In addition, in most of the ethnic groups, individuals detected with 
undiagnosed diabetes had a worse lipid profile than did diagnosed cases.  
The ethnic differences in lipid profiles given the same glucose levels have not been well 
investigated. In the HeartSCORE and IndiaSCORE studies (Mulukutla et al. 2008) where 
lipids were measured with the same assay procedures for Asian Indians as for whites and 
blacks, Asian Indians had lowest TC and HDL-C and highest TG among all the ethnic 
groups studied. In another multi-ethnic study of the 1992 Singapore National Health Survey 
(Tan et al. 1999), Asian Indians appeared to have lower HDL-C but higher TG levels 
compared with Chinese. The findings of these previous studies are consistent with ours 
although glucose status was not controlled in the previous studies. The causes of ethnic 
difference in cardiovascular risk profile are complex. Possible contributors include genetic, 
environmental, psychosocial, cultural and unmeasured factors and many are not well 
clarified (Zaninotto et al. 2007). It is clear that the observed ethnic differences in lipid 
profiles cannot be explained by genetics alone and may be more indicative of lifestyle-
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related factors such as dietary pattern and physical activity (Ruixing et al. 2008; 
McNaughton et al. 2009; Sisson et al. 2009). To what extent is ethnic-specific lifestyle 
pattern associated with different lipid profiles deserves further investigation. An adverse 
lipid profile in Asian Indians has been reported to be associated with the greater 
susceptibility to insulin resistance (Tan et al. 1999; Anand et al. 2000; Bhalodkar et al. 2005; 
Palaniappan et al. 2007), and a higher percentage of body fat for the same BMI as compared 
with whites (McKeigue et al. 1991), which may contribute to the high prevalence of CVD 
(Kuller 2004) and diabetes (Ramachandran et al. 2008; Snehalatha and Ramachandran 2009) 
in this ethnic group. In addition, it may also reflect the genetic variation, for example, at the 
apoE locus (Tan et al. 2003) and an excess of other risk factors such as homocysteine, Lp(a) 
or dietary fat (France et al. 2003). The difference in HDL-C concentrations between 
Qingdao and Hong Kong Chinese subgroups cannot be simply explained by the difference 
in assay methods. It may largely attribute to the differences in dietary structure and 
preference, geographic and environmental factors. Shellfish and beer, for example, are 
commonly consumed all the year round in Qingdao. Nevertheless, whether other factors 
exist and contribute to the high HDL-C in Qingdao needs to be further investigated. 
Similar to others (Harris and Eastman 2000; Hadaegh et al. 2008), we observed a worse 
lipid profile in individuals with undiagnosed diabetes than that of previously diagnosed 
patients in most of the ethnic groups, indicating individuals with undiagnosed diabetes are 
at increased CVD risk and need to be identified and treated early. On the other hand, 
glycaemic control is shown to be an important determinant of diabetic dyslipidaemia 
(Ismail et al. 2001). The better lipid profile in diagnosed diabetes as compared with 
undiagnosed diabetes might imply a benefit of lifestyle intervention or drug treatment 
targeting favorable metabolic profiles and hemoglobin A1c (HbA1c), a surrogate measure 
for average blood glucose. However, to what extent the levels of HbA1c have contributed to 
the differences is unknown due to the lack of information in the current study. In addition, 
the data on lipid-lowering treatment is not available for most of the earlier studies 
conducted in the 1990s because the statins were not widely prescribed at that time. These 
deserve further investigation in future studies. 
6.3 Lipids and lipoproteins and cardiovascular mortality 
The Study IV, which carried out in European men and women without a prior history of 
diabetes, showed that the low HDL-C and the high TC/HDL-C increased the risk of death 
from CVD independent of the fasting hyperglycaemia, but the relationship was not 
observed in the presence of isolated post-load hyperglycaemia (or IGT). Non-HDL-C was 
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also able to predict CVD death only in the presence of fasting hyperglycaemia and TG only 
in the most advanced stage of prediabetes, i.e., CH, and in newly diagnosed diabetes.  
Our findings on the HDL-C and TC/HDL-C were consistent with previous reports in either 
diabetic patients (Wilson et al. 1988; Laakso 1996; Boden 2000; Hu et al. 2002) or non-
diabetic subjects (Kinosian et al. 1994; Criqui and Golomb 1998; Schulze et al. 2004; Wang 
et al. 2007) where diabetes or pre-diabetic status were defined based on either fasting alone 
(Liu et al. 2005) or on both fasting and post-load glucose criteria, but did not distinguish the 
isolated fasting from the isolated post-load hyperglycaemic categories. The finding that 
non-HDL-C predicted CVD death only in individuals with isolated fasting hyperglycaemia 
or IFG could be explained by the potential significance of postprandial hyperlipidaemia in 
IFG, which is characterized by severe hepatic insulin resistance with normal or near-normal 
muscle insulin sensitivity (Abdul-Ghani et al. 2006). Since non-HDL-C is the sum of 
VLDL-C, IDL-C and LDL-C; and VLDL-C (i.e., TG) and LDL-C (i.e., TC) were not 
significantly associated with CVD death in IFG, it could be speculated that the association 
of non-HDL-C with CVD death in IFG is mainly driven by IDL-C that includes cholesterol-
rich remnants of fasting and postprandial lipoproteins (Rebolledo and Actis Dato 2005). 
Patients with atherosclerosis have postprandial hyperlipidaemia, even in the presence of 
normal fasting TG (Patsch et al. 1992). In postprandial hyperlipidaemia, the increased 
concentration of chylomicron and VLDL remnants seems to play an important role in 
inducing inflammation and oxidative stress in the bloodstream and at the endothelium via 
leucocytes and the complement system (Alipour et al. 2007). In addition, the prolonged 
catabolism of remnant lipoproteins leads to increased production of small, dense LDL, 
thereby further increasing the atherogenicity (Proctor and Mamo 1998; Alipour et al. 2007). 
Recent studies (Nordestgaard et al. 2007; Bansal et al. 2007) have further confirmed the 
role of non-fasting TG in cardiovascular events, suggesting that postprandial TG levels may 
be superior to fasting levels for assessment of CVD risk (Bansal et al. 2007).  
Whether fasting TG is an independent predictor of CVD remains pending. Results from two 
meta-analysis studies, one consisting of 29 western European and North American 
prospective studies of 262 525 subjects (Sarwar et al. 2007) and another including 32 Asia 
Pacific cohort studies of 93 281 subjects (Barzi et al. 2005), showed that TG is associated 
with CHD risk with HRs (95%CI) of 1.72 (1.56-1.90) and 1.61 (1.39-1.86), respectively. 
Our study, along with some other European studies, did not reveal such an association in 
non-diabetic (Wang et al. 2007) or normoglycaemic subjects (Bos et al. 2003), whereas we 
do confirm the importance of TG in predicting CVD death in conditions quite similar to 
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manifest diabetes, like CH or newly diagnosed diabetes (Laakso 1996; Onat et al. 2006; 
Chan et al. 2005; Schulze et al. 2004).  
This is the first study that has investigated the role of dyslipidaemia in predicting CVD 
mortality in subjects with isolated fasting or isolated post-load hyperglycaemia. In the 
present study, none of the lipid variables significantly predicted CVD mortality in the 
presence of isolated post-load hyperglycaemia. This adds up to many other different 
phenotypes (The DECODE Study Group 2003; The DECODE Study Group 2005; The 
DECODE Study Group 2001; Sorkin et al. 2005; Nakagami 2004) between IFG and IGT, 
i.e., age and gender difference in prevalence, less concordance between the two categories 
and difference in insulin resistance and secretion. The finding further suggests that, even 
though both IFG and IGT represent intermediate stages of glucose intolerance, they are 
likely to be distinct conditions with different pathophysiological etiologies. Future 
guidelines for lipid screening and CVD management in individuals with pre-diabetes or 
diabetes should consider these differences. Nevertheless, it should be borne in mind that the 
role of other lipid profiles which were not included in this data analysis such as postprandial 
lipaemia, apoB or small, dense LDL particles (Krauss 2004) is still not clear and needs 
further study. 
6.4 Lipids and lipoproteins and incidence of CHD by glucose categories 
To our knowledge, few studies have been published on the role of lipid parameters in 
predicting CHD in people with different glucose categories, i.e. IFG and/or IGT. Our study 
of Finnish and Swedish data with a median follow-up of 10 years (study V), showed that 
TC, HDL-C, non-HDL-C and TC/HDL-C were associated with risk for incident CHD not 
only in people with diabetes but also in those with normoglycaemia (NFG and NGT), 
independently of other analyzed risk factors. In addition, TC and non-HDL-C predicted 
CHD incidence in those with isolated IFG. In people with IGT or combined IFG and IGT, 
none of these lipid variables significantly predicted CHD risk. TG was not an independent 
predictor once non-HDL-C was taken into account, even in people with diabetes. 
The association of lipids and lipoprotein patterns with CHD risk has been estimated in 
many epidemiological studies. Our findings supported by others (Laakso 1996; Boden 2000; 
Mora et al. 2008) showed that TC, HDL-C and non-HDL-C were similarly powerful risk 
factors for CHD in diabetic as in normoglycaemic individuals. Non-HDL-C, which includes 
all atherogenic lipoproteins, is also a CHD predictor, and may be superior to LDL-C for 
assessment of CVD risk (Pischon et al. 2005; Robinson et al. 2009). Previous studies have, 
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however, not included the glucose tolerance status in their analyses. It is possible that some 
of the effect associated with non-HDL-C is actually due to abnormal glucose tolerance. In 
contrast, the risk related to TG remains controversial in predicting CHD risk (Onat et al. 
2006; Sarwar et al. 2007). The Hoorn study (Bos et al. 2003) showed an association of high 
TG with increased future CVD risk in people with abnormal glucose metabolism defined as 
having IFG, IGT, previously diagnosed or newly diagnosed diabetes, but non-HDL-C was 
not included in their analyses. Our finding that TG was an independent predictor in analyses 
including HDL-C but not in that with non-HDL-C is consistent with the fact that TG is a 
major constituent of VLDL and thus also part of non-HDL-C (Frost et al. 1996). The 
independent role of TG and CHD risk thus needs further investigation. 
The current analysis of subjects free of CHD at baseline shows the lack of lipid-CHD 
association in people with post-load hyperglycaemia. This might be a chance finding or 
suggest a pathophysiological difference between IFG and IGT (Festa et al. 2004; Pankow et 
al. 2007; Nathan et al. 2007). Moreover, our knowledge regarding lipid-CVD association is 
again based on fasting measurements. Patients with atherosclerosis, however, often have 
increased postprandial hyperlipidaemia, even in the presence of normal fasting TG (Patsch 
et al. 1992). It is proposed that the postprandial rather than fasting measurement of TG 
might be a better indicator for CHD risk (Mora et al. 2008; McQueen et al. 2008). Increased 
production of TG-rich lipoproteins in the postprandial state may induce inflammatory 
changes and oxidative stress in the endothelial layer of the vessel walls (Proctor and Mamo 
1998; Alipour et al. 2007), which may have rendered HDL dysfunction and impaired 
protection against CHD (Kontush and Chapman 2006). In addition, decreased HDL-C level 
(Branchi et al. 2006) and its glycoxidation impair the reverse cholesterol transport, 
providing an extra atherogenic mechanism (Rebolledo and Actis Dato 2005). In this 
population, HDL dysfunction may be less marked in diabetic subjects than in those with 
post-load hyperglycaemia (i.e., IGT), characterized by higher levels of remnant lipoproteins, 
oxidative stress and inflammation (Freiberg et al. 2008; Nordestgaard et al. 2007). In 
addition, increasing evidence shows that apoB/apoA-I may provide incremental value when 
traditional lipid variables are weakly predictive (Charlton-Menys et al. 2009; Ingelsson et al. 
2007; Karthikeyan et al. 2009). This deserves further investigations. 
6.5 Strengths and limitations of the study 
The study consisted of large populations of European and Asian origins and all studies were 
population-based with a random sampling approach except for the Hong Kong Workforce 
study (occupational study) and the Hisayama study (community-based study). Information 
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on CVD death or incident CHD events in both Finnish and Swedish cohorts has been 
obtained through national registers which have been approved to be valid and complete and 
uniformly classified according to the ICD coding. Populations of the same ethnicity were 
pooled to increase statistical power and “study cohort” was also considered as a covariate in 
the data analysis.  
Although all blood samples for lipid assays were obtained in the fasting state (The 
DECODA Study Group 2007), a limitation of this study was the lack of standardization in 
assay methods for lipids in different laboratories. This needs to be kept in mind when 
interpreting or comparing the results for, in particular, HDL-C, the measurement of which 
remains a major challenge over time. Except for the direct assays applied in a few of the 
studies, most of the studies have used chemical precipitation methods for HDL-C assays, 
including the heparin/Mn2+, the dextran sulfate MgCl2, the phosphotungstate MgCl2 and the 
polyethylene glycol method. The observed differences in HDL-C among ethnicities, to our 
knowledge, are less likely biased by the laboratory assays. Firstly, there is a good agreement 
and a similar accuracy between the results of most of the precipitation methods (Demacker 
et al. 1997). Secondly, the direct method and the precipitation method are shown to be 
closely correlated (Jensen et al. 2002). On average the HDL-C concentration obtained from 
the direct method is about 0.1-0.2 mmol/l higher than that from the precipitation method 
when TG is < 4.6 mmol/l (Jensen et al. 2002; Okazaki et al. 1997). The mean difference in 
the HDL-C concentration was about 0.4-0.5 mmol/l higher in Qingdao Chinese (direct or 
precipitation method) than in Asian Indians (precipitation method), much greater than that 
could be attributed to the difference in assay methods. Most importantly, our observation is 
consistent with previous reports regarding the adverse lipid profiles in Asian Indians 
compared with western or Chinese populations where the lipids were measured using the 
same assay procedure for Indians as for others (Mulukutla et al. 2008; Tan et al. 1999). 
Moreover the mean lipid levels in our study were similar to others. The mean TC was 4.4 
mmol/l, HDL-C 1.03-1.04 mmol/l and TG 1.53-2.04 mmol/l for Asian Indians in the 
HeartSCORE and IndiaSCORE study (Mulukutla et al. 2008) and the Singapore National 
Health Survey (Tan et al. 1999). This further strengthens the validity of the study. 
Due to the low number of incident CHD cases in women, sex-specific analysis could be 
done only in men but not in women. The results in study V seem to be conclusive for men 
and larger studies are required to confirm these findings in women. In addition, the absence 
of information on apoB and other lipoprotein subgroups limited the evaluation of novel 
atherogenic lipid parameters in relation to CHD risk. 
 57 
 
6.6 Implications for current guidelines on CVD prevention and future 
research 
Regardless of the contribution of insulin resistance, IFG or IGT, as a clinical classification 
of intermediate hyperglycaemia, generally appeared to be associated with worse lipid 
profiles compared with normal glycaemia in our study. Increasing levels of glucose in the 
“high normal” range and the coexistence of other cardiovascular risk factors have been 
shown to be adversely associated with arterial endothelial dysfunction and intima-media 
thickening (Heiss et al. 1980). The cluster of hyperglycaemia and dyslipidaemia in non-
diabetic population should be further emphasized in prevention of atherosclerosis and CVD. 
Current guidelines from the National Cholesterol Education Program Adult Treatment 
Panel III (Expert Panel 2001), the European Society of Cardiology (Graham et al. 2007) and 
the American Diabetes Association (American Diabetes Association 2010), mainly based 
on the data of whites, consistently recommend that LDL-C < 2.6 mmol/l should be the 
primary target of therapy in patients with diabetes. As shown in our study and others’ 
(Mulukutla et al. 2008; Karthikeyan et al. 2009), the Asian Indian population had 
significantly lower TC and LDL-C than did whites. The threshold of LDL-C for treatment 
target for Whites may be too high for Asian Indians. Further studies are warranted to verify 
this hypothesis and determine the threshold applicable to this ethnic group.  
In contrast to LDL-C, HDL-C has been either dropped from (Graham et al. 2007) or set as a 
secondary (American Diabetes Association 2010) or tertiary (Expert Panel 2001) target in 
the major guidelines despite the strong evidence of reduced HDL-C as an independent risk 
factor for CVD (Boden 2000). This may change if more therapy choices developed to 
increase HDL-C levels and improve HDL function are shown to prevent CVD (Singh et al. 
2007; Duffy and Rader 2009; Sorrentino et al. 2010) or reduce the residual cardiovascular 
risk (Fruchart J 2008). Most recently, the ARBITER 6-HALTS (Arterial Biology for the 
Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment 
Strategies in Atherosclerosis) trial has shown a significant improvement in serum HDL-C 
levels and regression of carotid intima-media thickness when ERN was conbined with statin 
therapy in patients with CHD or CHD equivalent (Taylor et al. 2009; Villines et al. 2010). 
Our study demonstrates distinct patterns of lipid profiles between different ethnic groups. 
Considering the high proportion of Asian Indians with adverse HDL-C levels, appropriate 
approaches to increasing HDL-C and/or improving HDL function may become an important 
treatment target in Asian Indians in order to reduce their excess CVD risks. 
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7 CONCLUSIONS 
The findings and conclusions of original studies I to V can be summarized as follows: 
1) Hyperglycaemia is associated with adverse lipid profiles in Europeans and Asians 
without a prior history of diabetes. Dyslipidaemia needs to be considered when 
assessing the risk of CVD in individuals with intermediate hyperglycaemia. 
2) There are distinct patterns of lipid profiles associated with ethnicity regardless of 
the glucose levels, suggesting that ethnic-specific strategies and guidelines for CVD 
risk assessment and prevention are required. 
3) Dyslipidaemia predicts CVD mortality or CHD incidence in either diabetic or non-
diabetic individuals defined based on the fasting glucose criteria, but not on the 2-
hour criteria. The difference between fasting and post-load hyperglycaemia with 
regard to the lipid-CVD relation may suggest different management strategies in 
people with fasting or post-load hyperglycaemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
 
8 ACKNOWLEDGEMENTS 
This work was carried out at the Department of Public Health, Hjelt Institute, University of 
Helsinki and Diabetes Prevention Unit, Department of Chronic Disease Prevention, 
National Institute for Health and Welfare, Helsinki, Finland during the years 2005-2010. I 
hereby wish to thank the both institutes for providing me with excellent research facilities. 
I would like to express my sincere respect and deepest gratitude to my principal supervisor, 
Docent Qing Qiao. I have always benefited from her expert supervision, brilliant ideas, 
continuous enthusiasm, rigorous attitude to science, valuable advice and extensive 
knowledge. I would like also to thank her for providing me with research grants and the 
great opportunity to have received field research training by coordinating the Qingdao 
Diabetes Prevention Project in Qingdao, China during Oct 2007-Jul 2008. 
I am also most grateful to another supervisor, Professor Jaakko Tuomilehto, for his 
constructive guidance, generous support and inspired suggestions on my work during the 
years. He has always had shrewd insight and given valuable detailed comments and 
suggestions which have greatly helped to improve the work and create a better version of 
the manuscripts. I always feel so lucky to have worked with the two excellent supervisors 
over these years.        
I sincerely thank the official reviewers of the dissertation, Professor Ronald P. Stolk and 
Professor Timo Strandberg, for their time, careful work and valuable comments and 
suggestions, and Docent Jorma Lahtela for accepting the role of Opponent in my thesis 
defence. 
I owe my deep gratitude to all the researchers of the DECODE and DECODA Studies and 
all the coauthors of my manuscripts for their genuine interest, prompt response and skillful 
comments that greatly contributed to my manuscripts. A special thank goes to Niklas 
Hammar, who has actively participated in this work and kindly provided me with great help. 
I greatly appreciate Professor Yanhu Dong for his recommendation and introducing me to 
Qing and Jaakko. I also wish to thank Professor Zengchang Pang and Professor Shaojie 
Wang for their kind supports on my work and life during the time I have been in Qingdao, 
China. 
I wish to express my warm thanks to my colleagues and friends, Dr. Regzedmaa Nyamdorj, 
M.Sci Feng Ning, Dr. Xin Song, Dr. Xianghai Zhou, Dr. Jing Zhao, who have always given 
me great help during the years of study. I wish to thank Dr. Weiguo Gao for his generous 
help and supports in my work and life in Finland. Meanwhile, I give my special thank to 
 60 
 
Pirjo Saastamoinen for her kind help in practical matters related to the work and to Fabian 
Hoti and Anni Helldan for their timely help in preparing for the popular abstract of this 
work in Finnish. 
My deepest debt of gratitude is to my parents and my little sister for their unlimited love 
and support. They have encouraged me throughout these years. The most special thanks 
belong to my beloved wife Yan Gu, for her unwavering understanding during all these years 
of my absence, her selfless love and support all along, and her encouragement and 
companionship during the preparation of this thesis. 
 
 
Helsinki, May 2010 
 
Lei Zhang 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
 
9    REFERENCES 
Abdel-Aal NM, Ahmad AT, Froelicher ES, Batieha AM, Hamza MM, Ajlouni KM (2008): 
Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan. Saudi Med J 
29: 1423-1428. 
Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006): Contributions of beta-cell dysfunction 
and insulin resistance to the pathogenesis of impaired glucose tolerance and 
impaired fasting glucose. Diabetes Care 29: 1130-1139. 
Adult Treatment panel III (2002): Third Report of the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 
106: 3143-3421. 
Agarwal AK, Singla S, Singla R, Lal A, Wardhan H, Yadav R (2009): Prevalence of 
coronary risk factors in type 2 diabetics without manifestations of overt coronary 
heart disease. J Assoc Physicians India 57: 135-142. 
Aguilera CM, Gil-Campos M, Canete R, Gil A (2008): Alterations in plasma and tissue 
lipids associated with obesity and metabolic syndrome. Clin Sci (Lond) 114: 183-
193. 
Ahmed N, Khan J, Siddiqui TS (2008): Frequency of dyslipidaemia in type 2 diabetes 
mellitus in patients of Hazara division. J Ayub Med Coll Abbottabad 20: 51-54. 
Alberti KG, Zimmet PZ (1998): Definition, diagnosis and classification of diabetes mellitus 
and its complications. Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation. Diabet Med 15: 539-553. 
Alberti KG, Zimmet P, Shaw J (2005): The metabolic syndrome--a new worldwide 
definition. Lancet 366: 1059-1062. 
Alipour A, Elte JW, van Zaanen HC, Rietveld AP, Cabezas MC (2007): Postprandial 
inflammation and endothelial dysfuction. Biochem Soc Trans 35: 466-469. 
Almdal T, Scharling H, Jensen JS, Vestergaard H (2004): The independent effect of type 2 
diabetes mellitus on ischemic heart disease, stroke, and death: a population-based 
study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 164: 
1422-1426. 
American Diabetes Association (2009): Standards of medical care in diabetes--2009. 
Diabetes Care 32 Suppl 1: S13-61. 
American Diabetes Association (2010): Standards of medical care in diabetes--2010. 
Diabetes Care 33 Suppl 1: S11-61. 
Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, 
Lonn E, Gerstein H, et al (2000): Differences in risk factors, atherosclerosis, and 
cardiovascular disease between ethnic groups in Canada: the Study of Health 
Assessment and Risk in Ethnic groups (SHARE). Lancet 356: 279-284. 
Arslan E, Yakar T, Yavasoglu I (2008): The effect of smoking on mean platelet volume and 
lipid profile in young male subjects. Anadolu Kardiyol Derg 8: 422-425. 
 62 
 
Assmann G, Schulte H, Funke H, von Eckardstein A (1998): The emergence of 
triglycerides as a significant independent risk factor in coronary artery disease. Eur 
Heart J 19 Suppl M: M8-14. 
Attie AD, Pittman RC, Steinberg D (1982): Hepatic catabolism of low density lipoprotein: 
mechanisms and metabolic consequences. Hepatology 2: 269-281. 
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM (1988a): 
Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 
260: 1917-1921. 
Austin MA, King MC, Vranizan KM, Newman B, Krauss RM (1988b): Inheritance of low-
density lipoprotein subclass patterns: results of complex segregation analysis. Am J 
Hum Genet 43: 838-846. 
Austin MA, Hokanson JE, Edwards KL (1998): Hypertriglyceridemia as a cardiovascular 
risk factor. Am J Cardiol 81: 7B-12B. 
Avins AL, Neuhaus JM (2000): Do triglycerides provide meaningful information about 
heart disease risk? Arch Intern Med 160: 1937-1944. 
Avramoglu RK, Basciano H, Adeli K (2006): Lipid and lipoprotein dysregulation in insulin 
resistant states. Clin Chim Acta 368: 1-19. 
Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, Sarbazi N (2003): 
Serum lipid levels in an Iranian adults population: Tehran Lipid and Glucose Study. 
Eur J Epidemiol 18: 311-319. 
Bakogianni MC, Kalofoutis CA, Skenderi KI, Kalofoutis AT (2001): Clinical evaluation of 
plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-
dependent diabetics with coronary artery disease. J Diabetes Complications 15: 265-
269. 
Bangou-Bredent J, Szmidt-Adjide V, Kangambega-Nouvier P, Foucan L, Campier A, 
Pinget M, Donnet JP (1999): Cardiovascular risk factors associated with diabetes in 
an Indian community of Guadeloupe. A case control study. Diabetes Metab 25: 393-
398. 
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007): Fasting compared 
with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298: 
309-316. 
Barakat HA, Carpenter JW, McLendon VD, Khazanie P, Leggett N, Heath J, Marks R 
(1990): Influence of obesity, impaired glucose tolerance, and NIDDM on LDL 
structure and composition. Possible link between hyperinsulinemia and 
atherosclerosis. Diabetes 39: 1527-1533. 
Barrett-Connor E, Grundy SM, Holdbrook MJ (1982): Plasma lipids and diabetes mellitus 
in an adult community. Am J Epidemiol 115: 657-663. 
Barzi F, Patel A, Woodward M, Lawes CM, Ohkubo T, Gu D, Lam TH, Ueshima H (2005): 
A comparison of lipid variables as predictors of cardiovascular disease in the Asia 
Pacific region. Ann Epidemiol 15: 405-413. 
Bass KM, Newschaffer CJ, Klag MJ, Bush TL (1993): Plasma lipoprotein levels as 
predictors of cardiovascular death in women. Arch Intern Med 153: 2209-2216. 
 63 
 
Batic-Mujanovic O, Beganlic A, Salihefendic N, Pranjic N, Kusljugic Z (2008): Influence 
of smoking on serum lipid and lipoprotein levels among family medicine patients. 
Med Arh 62: 264-267. 
Berg A, Halle M, Franz I, Keul J (1997): Physical activity and lipoprotein metabolism: 
epidemiological evidence and clinical trials. Eur J Med Res 2: 259-264. 
Berrios X, Koponen T, Huiguang T, Khaltaev N, Puska P, Nissinen A (1997): Distribution 
and prevalence of major risk factors of noncommunicable diseases in selected 
countries: the WHO Inter-Health Programme. Bull World Health Organ 75: 99-108. 
Betteridge DJ (1999): Diabetic dyslipidaemia. Eur J Clin Invest 29 Suppl 2: 12-16. 
Bhalodkar NC, Blum S, Rana T, Kitchappa R, Bhalodkar AN, Enas EA (2005): 
Comparison of high-density and low-density lipoprotein cholesterol subclasses and 
sizes in Asian Indian women with Caucasian women from the Framingham 
Offspring Study. Clin Cardiol 28: 247-251. 
Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM (2004): Impaired 
glucose tolerance, but not impaired fasting glucose, is associated with increased 
levels of coronary heart disease risk factors: results from the Baltimore Longitudinal 
Study on Aging. Diabetes 53: 2095-2100. 
Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Rizza R 
(2006): Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial 
hyperglycemia in people with impaired fasting glucose and/or impaired glucose 
tolerance. Diabetes 55: 3536-3549. 
Boden WE (2000): High-density lipoprotein cholesterol as an independent risk factor in 
cardiovascular disease: assessing the data from Framingham to the Veterans Affairs 
High--Density Lipoprotein Intervention Trial. Am J Cardiol 86: 19L-22L. 
Bos G, Dekker JM, Nijpels G, de Vegt F, Diamant M, Stehouwer CD, Bouter LM, Heine RJ 
(2003): A combination of high concentrations of serum triglyceride and non-high-
density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects 
with abnormal glucose metabolism--The Hoorn Study. Diabetologia 46: 910-916. 
Branchi A, Torri A, Berra C, Colombo E, Sommariva D (2006): Changes in serum 
triglycerides and high-density lipoprotein concentration and composition after a 
low-fat mixed meal. Effects of gender and insulin resistance. Intern Emerg Med 1: 
287-295. 
Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M (1978): Hypertriglyceridemia 
associated with deficiency of apolipoprotein C-II. N Engl J Med 298: 1265-1273. 
Brinton EA (2005): Controversies in dyslipidemias: atheroprevention in diabetes and 
insulin resistance. Ann N Y Acad Sci 1055: 159-178. 
Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan 
M (2000): Body mass index and the prevalence of hypertension and dyslipidemia. 
Obes Res 8: 605-619. 
Bruckert E, Baccara-Dinet M, Eschwege E (2007): Low HDL-cholesterol is common in 
European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from 
a pan-European survey. Diabet Med 24: 388-391. 
 64 
 
Cade J, Margetts B (1989): Cigarette smoking and serum lipid and lipoprotein 
concentrations. BMJ 298: 1312. 
Chait A, Brunzell JD (1990): Acquired hyperlipidemia (secondary dyslipoproteinemias). 
Endocrinol Metab Clin North Am 19: 259-278. 
Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, Osaki R, Cockram CS, Chan JC 
(2005): Triglyceride predicts cardiovascular mortality and its relationship with 
glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 
21: 183-188. 
Chandalia M, Mohan V, Adams-Huet B, Deepa R, Abate N (2008): Ethnic difference in sex 
gap in high-density lipoprotein cholesterol between Asian Indians and Whites. J 
Investig Med 56: 574-580. 
Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone 
SJ, Neil HA, Newman CB, Szarek M, et al (2009): Apolipoproteins, cardiovascular 
risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes 
Study (CARDS). Diabetologia 52: 218-225. 
Chen LK, Lin MH, Chen ZJ, Hwang SJ, Tsai ST, Chiou ST (2006): Metabolic 
characteristics and insulin resistance of impaired fasting glucose among the middle-
aged and elderly Taiwanese. Diabetes Res Clin Pract 71: 170-176. 
Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R (1994): Variation at the hepatic 
lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically 
determined variation in plasma HDL cholesterol levels. J Clin Invest 94: 2377-2384. 
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, 
Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004): Primary 
prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the 
Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised 
placebo-controlled trial. Lancet 364: 685-696. 
Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003): MRC/BHF Heart Protection Study 
of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised 
placebo-controlled trial. Lancet 361: 2005-2016. 
Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, De Backer G, 
Jousilahti P, Keil U, Thomsen T, et al (2009): HDL cholesterol protects against 
cardiovascular disease in both genders, at all ages and at all levels of risk. 
Atherosclerosis 206: 611-616. 
Cowie CC, Howard BV, Harris MI (1994): Serum lipoproteins in African Americans and 
whites with non-insulin-dependent diabetes in the US population. Circulation 90: 
1185-1193. 
Cremer P, Nagel D, Mann H, Labrot B, Muller-Berninger R, Elster H, Seidel D (1997): 
Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence 
Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. 
Atherosclerosis 129: 221-230. 
Criqui MH, Wallace RB, Heiss G, Mishkel M, Schonfeld G, Jones GT (1980): Cigarette 
smoking and plasma high-density lipoprotein cholesterol. The Lipid Research 
Clinics Program Prevalence Study. Circulation 62: IV70-76. 
 65 
 
Criqui MH, Golomb BA (1998): Epidemiologic aspects of lipid abnormalities. Am J Med 
105: 48S-57S. 
Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL 
(2001): Non-high-density lipoprotein cholesterol level as a predictor of 
cardiovascular disease mortality. Arch Intern Med 161: 1413-1419. 
de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF 
(1991): Enhanced susceptibility to in vitro oxidation of the dense low density 
lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11: 298-306. 
De Oliveira ESER, Foster D, McGee Harper M, Seidman CE, Smith JD, Breslow JL, 
Brinton EA (2000): Alcohol consumption raises HDL cholesterol levels by 
increasing the transport rate of apolipoproteins A-I and A-II. Circulation 102: 2347-
2352. 
Demacker PN, Hessels M, Toenhake-Dijkstra H, Baadenhuijsen H (1997): Precipitation 
methods for high-density lipoprotein cholesterol measurement compared, and final 
evaluation under routine operating conditions of a method with a low sample-to-
reagent ratio. Clin Chem 43: 663-668. 
Denke MA, Sempos CT, Grundy SM (1993): Excess body weight. An underrecognized 
contributor to high blood cholesterol levels in white American men. Arch Intern 
Med 153: 1093-1103. 
Denke MA, Sempos CT, Grundy SM (1994): Excess body weight. An under-recognized 
contributor to dyslipidemia in white American women. Arch Intern Med 154: 401-
410. 
Devroey D, De Swaef N, Coigniez P, Vandevoorde J, Kartounian J, Betz W (2004): 
Correlations between lipid levels and age, gender, glycemia, obesity, diabetes, and 
smoking. Endocr Res 30: 83-93. 
Dowse GK, Gareeboo H, Alberti KG, Zimmet P, Tuomilehto J, Purran A, Fareed D, 
Chitson P, Collins VR (1995): Changes in population cholesterol concentrations and 
other cardiovascular risk factor levels after five years of the non-communicable 
disease intervention programme in Mauritius. Mauritius Non-communicable Disease 
Study Group. BMJ 311: 1255-1259. 
Duffy D, Rader DJ (2009): Update on strategies to increase HDL quantity and function. Nat 
Rev Cardiol 6: 455-463. 
Dunder K, Lind L, Lagerqvist B, Zethelius B, Vessby B, Lithell H (2004a): Cardiovascular 
risk factors for stable angina pectoris versus unheralded myocardial infarction. Am 
Heart J 147: 502-508. 
Dunder K, Lind L, Zethelius B, Berglund L, Lithell H (2004b): Evaluation of a scoring 
scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for 
the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study 
of Adult Men (ULSAM). Am Heart J 148: 596-601. 
Eberly LE, Stamler J, Neaton JD (2003): Relation of triglyceride levels, fasting and 
nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 163: 1077-
1083. 
Eisenberg S (1984): High density lipoprotein metabolism. J Lipid Res 25: 1017-1058. 
 66 
 
Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M (2008): Prevalence of 
dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. 
Endocrine 34: 36-51. 
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults 
(2001): Executive Summary of The Third Report of The National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment 
of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-
2497. 
Ezenwaka CE, Premanand N, Orrett FA (2000): Studies on plasma lipids in industrial 
workers in central Trinidad and Tobago. J Natl Med Assoc 92: 375-381. 
Festa A, D'Agostino R, Jr., Hanley AJ, Karter AJ, Saad MF, Haffner SM (2004): 
Differences in insulin resistance in nondiabetic subjects with isolated impaired 
glucose tolerance or isolated impaired fasting glucose. Diabetes 53: 1549-1555. 
Fisher SD, Zareba W, Moss AJ, Marder VJ, Sparks CE, Hochman J, Liang C, Krone RJ 
(2000): Effect of smoking on lipid and thrombogenic factors two months after acute 
myocardial infarction. Am J Cardiol 86: 813-818. 
Florez H, Silva E, Fernandez V, Ryder E, Sulbaran T, Campos G, Calmon G, Clavel E, 
Castillo-Florez S, Goldberg R (2005): Prevalence and risk factors associated with 
the metabolic syndrome and dyslipidemia in White, Black, Amerindian and Mixed 
Hispanics in Zulia State, Venezuela. Diabetes Res Clin Pract 69: 63-77. 
Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Maiwald C (1988): Effects of 
different beta-blockers on lipid metabolism in chronic therapy of hypertension. Int J 
Clin Pharmacol Ther Toxicol 26: 597-604. 
Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, 
Claude JR, Rosselin GE (1989): Hypertriglyceridaemia as a risk factor of coronary 
heart disease mortality in subjects with impaired glucose tolerance or diabetes. 
Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32: 
300-304. 
Foucan L, Kangambega P, Koumavi Ekouevi D, Rozet J, Bangou-Bredent J (2000): Lipid 
profile in an adult population in Guadeloupe. Diabetes Metab 26: 473-480. 
Fox JC, McGill HC, Jr., Carey KD, Getz GS (1987): In vivo regulation of hepatic LDL 
receptor mRNA in the baboon. Differential effects of saturated and unsaturated fat. J 
Biol Chem 262: 7014-7020. 
France MW, Kwok S, McElduff P, Seneviratne CJ (2003): Ethnic trends in lipid tests in 
general practice. QJM 96: 919-923. 
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG (2008): Nonfasting 
triglycerides and risk of ischemic stroke in the general population. JAMA 300: 2142-
2152. 
Friedewald WT, Levy RI, Fredrickson DS (1972): Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin Chem 18: 499-502. 
Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Jr., Isaacsohn JL, Wassertheil-
Smoller S, Wilson AC, Stamler J (1996): Serum lipids and incidence of coronary 
 67 
 
heart disease. Findings from the Systolic Hypertension in the Elderly Program 
(SHEP). Circulation 94: 2381-2388. 
Fruchart J SF, Hermans M, Assmann, G, Brown W, Ceska R, Chapman M, Dodson P, 
Fioretto P, Ginsberg H (2008): The residual risk reduction initiative: a call to action 
to reduce residual vascular risk in dyslipidaemic patients. Diabetes&Vascular 
Disease Research 5: 319-335. 
Fuentes R, Uusitalo T, Puska P, Tuomilehto J, Nissinen A (2003): Blood cholesterol level 
and prevalence of hypercholesterolaemia in developing countries: a review of 
population-based studies carried out from 1979 to 2002. Eur J Cardiovasc Prev 
Rehabil 10: 411-419. 
Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, Morano S, 
Trischitta V, Filetti S (2009): Poor glycemic control is an independent risk factor for 
low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 32: 1550-1552. 
Ginsberg HN (2000): Insulin resistance and cardiovascular disease. J Clin Invest 106: 453-
458. 
Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, 
Raschetti R, Velussi M, Ferrannini E (2008): Recurrence of cardiovascular events in 
patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care 31: 
2154-2159. 
Goldberg IJ (2001): Clinical review 124: Diabetic dyslipidemia: causes and consequences. J 
Clin Endocrinol Metab 86: 965-971. 
Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole 
TG, Pfeffer MA, Braunwald E (1998): Cardiovascular events and their reduction 
with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors 
with average cholesterol levels: subgroup analyses in the cholesterol and recurrent 
events (CARE) trial. The Care Investigators. Circulation 98: 2513-2519. 
Gomes MB, Giannella-Neto D, Faria M, Tambascia M, Fonseca RM, Rea R, Macedo G, 
Modesto-Filho J, Schmid H, Bittencourt AV, et al (2009): Estimating cardiovascular 
risk in patients with type 2 diabetes: a national multicenter study in Brazil. Diabetol 
Metab Syndr 1: 22. 
Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr., 
Bangdiwala S, Tyroler HA (1989): High-density lipoprotein cholesterol and 
cardiovascular disease. Four prospective American studies. Circulation 79: 8-15. 
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977): High density 
lipoprotein as a protective factor against coronary heart disease. The Framingham 
Study. Am J Med 62: 707-714. 
Gotto AM, Jr., Brinton EA (2004): Assessing low levels of high-density lipoprotein 
cholesterol as a risk factor in coronary heart disease: a working group report and 
update. J Am Coll Cardiol 43: 717-724. 
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De 
Backer G, Ebrahim S, Gjelsvik B, et al (2007): European guidelines on 
cardiovascular disease prevention in clinical practice: executive summary. Fourth 
Joint Task Force of the European Society of Cardiology and other societies on 
 68 
 
cardiovascular disease prevention in clinical practice (constituted by representatives 
of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14 Suppl 2: 
E1-40. 
Grant RW, Meigs JB (2007): Prevalence and treatment of low HDL cholesterol among 
primary care patients with type 2 diabetes: an unmet challenge for cardiovascular 
risk reduction. Diabetes Care 30: 479-484. 
Grover SA, Kaouache M, Joseph L, Barter P, Davignon J (2009): Evaluating the 
incremental benefits of raising high-density lipoprotein cholesterol levels during 
lipid therapy after adjustment for the reductions in other blood lipid levels. Arch 
Intern Med 169: 1775-1780. 
Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NC, Mooradian AD (2003): 
Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and 
IL-1beta. Biochim Biophys Acta 1623: 120-128. 
Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F (2008): High 
prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian 
urban population: Tehran Lipid and Glucose Study. BMC Public Health 8: 176. 
Hammad SM, Twal WO, Barth JL, Smith KJ, Saad AF, Virella G, Argraves WS, Lopes-
Virella MF (2009): Oxidized LDL immune complexes and oxidized LDL 
differentially affect the expression of genes involved with inflammation and survival 
in human U937 monocytic cells. Atherosclerosis 202: 394-404. 
Hanh TTM, Komatsu T, Hung NT, Chuyen VN, Yoshimura Y, Tien PG, Yamamoto S 
(2001): Nutritional status of middle-aged Vietnamese in Ho Chi Minh City. J Am 
Coll Nutr 20: 616-622. 
Hardman AE (1999): Physical activity, obesity and blood lipids. Int J Obes Relat Metab 
Disord 23 Suppl 3: S64-71. 
Harris MI, Eastman RC (2000): Early detection of undiagnosed diabetes mellitus: a US 
perspective. Diabetes Metab Res Rev 16: 230-236. 
Harris SB, Zinman B, Hanley A, Gittelsohn J, Hegele R, Connelly PW, Shah B, Hux JE 
(2002): The impact of diabetes on cardiovascular risk factors and outcomes in a 
native Canadian population. Diabetes Res Clin Pract 55: 165-173. 
Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, Tall AR, 
Breslow JL (1993): Hypertriglyceridemia and cholesteryl ester transfer protein 
interact to dramatically alter high density lipoprotein levels, particle sizes, and 
metabolism. Studies in transgenic mice. J Clin Invest 92: 1143-1152. 
Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkand BM, Schonfeld G, Jacobs D, Frantz ID, 
Jr. (1980): Lipoprotein-cholesterol distributions in selected North American 
populations: the lipid research clinics program prevalence study. Circulation 61: 
302-315. 
Hennig B, Toborek M, McClain CJ (2001): High-energy diets, fatty acids and endothelial 
cell function: implications for atherosclerosis. J Am Coll Nutr 20: 97-105. 
Hertz RP, Unger AN, Ferrario CM (2006): Diabetes, hypertension, and dyslipidemia in 
Mexican Americans and non-Hispanic whites. Am J Prev Med 30: 103-110. 
 69 
 
Howard BV (1987): Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28: 613-628. 
Howard BV (1999): Insulin resistance and lipid metabolism. Am J Cardiol 84: 28J-32J. 
Hu D, Jablonski KA, Sparling YH, Robbins DC, Lee ET, Welty TK, Howard BV (2002): 
Accuracy of lipoprotein lipids and apoproteins in predicting coronary heart disease 
in diabetic American Indians. The Strong Heart Study. Ann Epidemiol 12: 79-85. 
Hulley SB, Rosenman RH, Bawol RD, Brand RJ (1980): Epidemiology as a guide to 
clinical decisions. The association between triglyceride and coronary heart disease. 
N Engl J Med 302: 1383-1389. 
Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C (2001): The impact of 
phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155: 
269-281. 
Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, 
Schoonmaker C, Wilson PW, D'Agostino RB, et al (2007): Clinical utility of 
different lipid measures for prediction of coronary heart disease in men and women. 
JAMA 298: 776-785. 
Ismail IS, Nazaimoon W, Mohamad W, Letchuman R, Singaraveloo M, Hew FL, Shuguna 
C, Khalid BA (2001): Ethnicity and glycaemic control are major determinants of 
diabetic dyslipidaemia in Malaysia. Diabet Med 18: 501-508. 
Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi 
Y (2001): Serum triglycerides and risk of coronary heart disease among Japanese 
men and women. Am J Epidemiol 153: 490-499. 
Jacobs MJ, Kleisli T, Pio JR, Malik S, L'Italien GJ, Chen RS, Wong ND (2005): Prevalence 
and control of dyslipidemia among persons with diabetes in the United States. 
Diabetes Res Clin Pract 70: 263-269. 
Janka HU (1985): Five-year incidence of major macrovascular complications in diabetes 
mellitus. Horm Metab Res Suppl 15: 15-19. 
Jensen T, Truong Q, Frandsen M, Dinesen B, Stender S (2002): Comparison of a 
homogeneous assay with a precipitation method for the measurement of HDL 
cholesterol in diabetic patients. Diabetes Care 25: 1914-1918. 
Jeppesen J, Hein HO, Suadicani P, Gyntelberg F (2001): Low triglycerides-high high-
density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 
161: 361-366. 
Jialal I (1998): Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density 
lipoprotein. Clin Chem 44: 1827-1832. 
Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB (2004): Non-HDL 
cholesterol and apolipoprotein B predict cardiovascular disease events among men 
with type 2 diabetes. Diabetes Care 27: 1991-1997. 
Johnson WJ, Bamberger MJ, Latta RA, Rapp PE, Phillips MC, Rothblat GH (1986): The 
bidirectional flux of cholesterol between cells and lipoproteins. Effects of 
phospholipid depletion of high density lipoprotein. J Biol Chem 261: 5766-5776. 
 70 
 
Jurado J, Ybarra J, Solanas P, Caula J, Gich I, Pou JM, Romeo JH (2009): Prevalence of 
cardiovascular disease and risk factors in a type 2 diabetic population of the North 
Catalonia diabetes study. J Am Acad Nurse Pract 21: 140-148. 
Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2005): Type 2 diabetes as a 
"coronary heart disease equivalent": an 18-year prospective population-based study 
in Finnish subjects. Diabetes Care 28: 2901-2907. 
Kannel WB (1985): Lipids, diabetes, and coronary heart disease: insights from the 
Framingham Study. Am Heart J 110: 1100-1107. 
Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, Sato H, Lang CC, Sitthi-
Amorn C, Pandey MR, et al (2009): Lipid profile, plasma apolipoproteins, and risk 
of a first myocardial infarction among Asians: an analysis from the INTERHEART 
Study. J Am Coll Cardiol 53: 244-253. 
Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN (2006): The importance of waist 
circumference in the definition of metabolic syndrome: prospective analyses of 
mortality in men. Diabetes Care 29: 404-409. 
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, 
Glasziou P, et al (2005): Effects of long-term fenofibrate therapy on cardiovascular 
events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised 
controlled trial. Lancet 366: 1849-1861. 
Kendall DM (2005): The dyslipidemia of diabetes mellitus: giving triglycerides and high-
density lipoprotein cholesterol a higher priority? Endocrinol Metab Clin North Am 
34: 27-48. 
Kinosian B, Glick H, Garland G (1994): Cholesterol and coronary heart disease: predicting 
risks by levels and ratios. Ann Intern Med 121: 641-647. 
Knopp RH, d'Emden M, Smilde JG, Pocock SJ (2006): Efficacy and safety of atorvastatin 
in the prevention of cardiovascular end points in subjects with type 2 diabetes: the 
Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-
insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29: 1478-1485. 
Kontush A, Chapman MJ (2006): Functionally defective high-density lipoprotein: a new 
therapeutic target at the crossroads of dyslipidemia, inflammation, and 
atherosclerosis. Pharmacol Rev 58: 342-374. 
Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH (1992): 
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. 
Diabetes Care 15: 820-825. 
Krauss RM (2004): Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 
27: 1496-1504. 
Krentz AJ (2003): Lipoprotein abnormalities and their consequences for patients with type 
2 diabetes. Diabetes Obes Metab 5 Suppl 1: S19-27. 
Kuller LH (2004): Ethnic differences in atherosclerosis, cardiovascular disease and lipid 
metabolism. Curr Opin Lipidol 15: 109-113. 
 71 
 
Laakso M, Lehto S, Penttila I, Pyorala K (1993): Lipids and lipoproteins predicting 
coronary heart disease mortality and morbidity in patients with non-insulin-
dependent diabetes. Circulation 88: 1421-1430. 
Laakso M (1996): Lipids and lipoproteins as risk factors for coronary heart disease in non-
insulin-dependent diabetes mellitus. Ann Med 28: 341-345. 
Langlois MR, Blaton VH (2006): Historical milestones in measurement of HDL-cholesterol: 
impact on clinical and laboratory practice. Clin Chim Acta 369: 168-178. 
LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM, Jr., Grundy SM, 
Rakita L, Robertson RM, Weisfeldt ML, et al (1990): The cholesterol facts. A 
summary of the evidence relating dietary fats, serum cholesterol, and coronary heart 
disease. A joint statement by the American Heart Association and the National Heart, 
Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart 
Association. Circulation 81: 1721-1733. 
Laws A, Marcus EB, Grove JS, Curb JD (1993): Lipids and lipoproteins as risk factors for 
coronary heart disease in men with abnormal glucose tolerance: the Honolulu Heart 
Program. J Intern Med 234: 471-478. 
Lehtonen A (1985): Effect of beta blockers on blood lipid profile. Am Heart J 109: 1192-
1196. 
Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais GR, 
Despres JP (2001): Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL 
cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec 
Cardiovascular Study. Arch Intern Med 161: 2685-2692. 
Lewis GF (1997): Fatty acid regulation of very low density lipoprotein production. Curr 
Opin Lipidol 8: 146-153. 
Li Z, Yang R, Xu G, Xia T (2005): Serum lipid concentrations and prevalence of 
dyslipidemia in a large professional population in Beijing. Clin Chem 51: 144-150. 
Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM (2005): Joint distribution 
of non-HDL and LDL cholesterol and coronary heart disease risk prediction among 
individuals with and without diabetes. Diabetes Care 28: 1916-1921. 
Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard 
BV (2003): Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 
diabetes: the strong heart study. Diabetes Care 26: 16-23. 
Mackness MI, Arrol S, Abbott C, Durrington PN (1993): Protection of low-density 
lipoprotein against oxidative modification by high-density lipoprotein associated 
paraoxonase. Atherosclerosis 104: 129-135. 
Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA (1996): Paraoxonase: 
biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7: 
69-76. 
Maeda K, Noguchi Y, Fukui T (2003): The effects of cessation from cigarette smoking on 
the lipid and lipoprotein profiles: a meta-analysis. Prev Med 37: 283-290. 
Maher VM, Brown BG (1995): Lipoprotein (a) and coronary heart disease. Curr Opin 
Lipidol 6: 229-235. 
 72 
 
Mahley RW, Ji ZS (1999): Remnant lipoprotein metabolism: key pathways involving cell-
surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40: 1-16. 
Mammas IN, Bertsias GK, Linardakis M, Tzanakis NE, Labadarios DN, Kafatos AG (2003): 
Cigarette smoking, alcohol consumption, and serum lipid profile among medical 
students in Greece. Eur J Public Health 13: 278-282. 
Mann JI, Lewis B, Shepherd J, Winder AF, Fenster S, Rose L, Morgan B (1988): Blood 
lipid concentrations and other cardiovascular risk factors: distribution, prevalence, 
and detection in Britain. Br Med J (Clin Res Ed) 296: 1702-1706. 
Mazza A, Tikhonoff V, Schiavon L, Casiglia E (2005): Triglycerides + high-density-
lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the 
CArdiovascular STudy in the ELderly. Intern Med J 35: 604-610. 
McGowan MW, Artiss JD, Strandbergh DR, Zak B (1983): A peroxidase-coupled method 
for the colorimetric determination of serum triglycerides. Clin Chem 29: 538-542. 
McKeigue PM, Shah B, Marmot MG (1991): Relation of central obesity and insulin 
resistance with high diabetes prevalence and cardiovascular risk in South Asians. 
Lancet 337: 382-386. 
McNamara DJ, Howell WH (1992): Epidemiologic data linking diet to hyperlipidemia and 
arteriosclerosis. Semin Liver Dis 12: 347-355. 
McNaughton SA, Mishra GD, Brunner EJ (2009): Food patterns associated with blood 
lipids are predictive of coronary heart disease: the Whitehall II study. Br J Nutr 102: 
619-624. 
McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, 
Sanderson JE, Hasani M, Volkova E, et al (2008): Lipids, lipoproteins, and 
apolipoproteins as risk markers of myocardial infarction in 52 countries (the 
INTERHEART study): a case-control study. Lancet 372: 224-233. 
Meigs JB, Nathan DM, D'Agostino RB, Sr., Wilson PW (2002): Fasting and postchallenge 
glycemia and cardiovascular disease risk: the Framingham Offspring Study. 
Diabetes Care 25: 1845-1850. 
Meisinger C, Loewel H, Mraz W, Koenig W (2005): Prognostic value of apolipoprotein B 
and A-I in the prediction of myocardial infarction in middle-aged men and women: 
results from the MONICA/KORA Augsburg cohort study. Eur Heart J 26: 271-278. 
Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J (2006): 
Different mechanisms for impaired fasting glucose and impaired postprandial 
glucose tolerance in humans. Diabetes Care 29: 1909-1914. 
Middeke M, Richter WO, Schwandt P, Beck B, Holzgreve H (1990): Normalization of lipid 
metabolism after withdrawal from antihypertensive long-term therapy with beta 
blockers and diuretics. Arteriosclerosis 10: 145-147. 
Millen BE, Quatromoni PA, Nam BH, O'Horo CE, Polak JF, D'Agostino RB (2002): 
Dietary patterns and the odds of carotid atherosclerosis in women: the Framingham 
Nutrition Studies. Prev Med 35: 540-547. 
Miller NE, La Ville A, Crook D (1985): Direct evidence that reverse cholesterol transport is 
mediated by high-density lipoprotein in rabbit. Nature 314: 109-111. 
 73 
 
Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D (2008): Primary prevention of 
cardiovascular mortality and events with statin treatments: a network meta-analysis 
involving more than 65,000 patients. J Am Coll Cardiol 52: 1769-1781. 
Mohan V, Deepa R, Haranath SP, Premalatha G, Rema M, Sastry NG, Enas EA (1998): 
Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM 
patients in South India. Diabetes Care 21: 1819-1823. 
Mora S, Rifai N, Buring JE, Ridker PM (2008): Fasting compared with nonfasting lipids 
and apolipoproteins for predicting incident cardiovascular events. Circulation 118: 
993-1001. 
Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H (1990): A prospective study 
of mortality among middle-aged diabetic patients (the London Cohort of the WHO 
Multinational Study of Vascular Disease in Diabetics) II: Associated risk factors. 
Diabetologia 33: 542-548. 
Morrish NJ, Stevens LK, Fuller JH, Jarrett RJ, Keen H (1991a): Risk factors for 
macrovascular disease in diabetes mellitus: the London follow-up to the WHO 
Multinational Study of Vascular Disease in Diabetics. Diabetologia 34: 590-594. 
Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ (1991b): Incidence of macrovascular 
disease in diabetes mellitus: the London cohort of the WHO Multinational Study of 
Vascular Disease in Diabetics. Diabetologia 34: 584-589. 
Mulukutla SR, Venkitachalam L, Marroquin OC, Kip KC, Aiyer A, Edmundowicz D, 
Ganesh S, Varghese R, Reis SE (2008): Population variation in atherogenic 
dyslipidemia: A report from the HeartSCORE and IndiaSCORE Studies. Journal of 
Clinical Lipidology 2: 410-417. 
Murakami K, Ishibashi S, Yoshida Y, Yamada N, Akanuma Y (1998): Lipoprotein(a) as a 
coronary risk factor in Japanese patients with Type II (non-insulin-dependent) 
diabetes mellitus. Relation with apolipoprotein(a) phenotypes. Diabetologia 41: 
1397-1398. 
Nakagami T (2004): Hyperglycaemia and mortality from all causes and from cardiovascular 
disease in five populations of Asian origin. Diabetologia 47: 385-394. 
Natarajan S, Glick H, Criqui M, Horowitz D, Lipsitz SR, Kinosian B (2003): Cholesterol 
measures to identify and treat individuals at risk for coronary heart disease. Am J 
Prev Med 25: 50-57. 
Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B 
(2007): Impaired fasting glucose and impaired glucose tolerance: implications for 
care. Diabetes Care 30: 753-759. 
Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, 
Wentworth D (1992): Serum cholesterol level and mortality findings for men 
screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor 
Intervention Trial Research Group. Arch Intern Med 152: 1490-1500. 
Nigon F, Lesnik P, Rouis M, Chapman MJ (1991): Discrete subspecies of human low 
density lipoproteins are heterogeneous in their interaction with the cellular LDL 
receptor. J Lipid Res 32: 1741-1753. 
 74 
 
Nobili A, D'Avanzo B, Santoro L, Ventura G, Todesco P, La Vecchia C (1994): Serum 
cholesterol and acute myocardial infarction: a case-control study from the GISSI-2 
trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-Epidemiologia 
dei Fattori di Rischio dell'Infarto Miocardico Investigators. Br Heart J 71: 468-473. 
Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A (2002): HDL 
and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161: 1-16. 
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007): Nonfasting triglycerides 
and risk of myocardial infarction, ischemic heart disease, and death in men and 
women. JAMA 298: 299-308. 
Novoa FJ, Boronat M, Saavedra P, Diaz-Cremades JM, Varillas VF, La Roche F, Alberiche 
MP, Carrillo A (2005): Differences in cardiovascular risk factors, insulin resistance, 
and insulin secretion in individuals with normal glucose tolerance and in subjects 
with impaired glucose regulation: the Telde Study. Diabetes Care 28: 2388-2393. 
Okafor CI, Fasanmade OA, Oke DA (2008): Pattern of dyslipidaemia among Nigerians 
with type 2 diabetes mellitus. Niger J Clin Pract 11: 25-31. 
Okazaki M, Sasamoto K, Muramatsu T, Hosaki S (1997): Evaluation of precipitation and 
direct methods for HDL-cholesterol assay by HPLC. Clin Chem 43: 1885-1890. 
Onat A, Surdum-Avci G, Senocak M, Ornek E, Gozukara Y (1992): Plasma lipids and their 
interrelationship in Turkish adults. J Epidemiol Community Health 46: 470-476. 
Onat A, Sari I, Yazici M, Can G, Hergenc G, Avci GS (2006): Plasma triglycerides, an 
independent predictor of cardiovascular disease in men: a prospective study based 
on a population with prevalent metabolic syndrome. Int J Cardiol 108: 89-95. 
Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Can G (2007): Determinants and 
definition of abdominal obesity as related to risk of diabetes, metabolic syndrome 
and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 
191: 182-190. 
Palaniappan LP, Kwan AC, Abbasi F, Lamendola C, McLaughlin TL, Reaven GM (2007): 
Lipoprotein abnormalities are associated with insulin resistance in South Asian 
Indian women. Metabolism 56: 899-904. 
Pang RW, Tam S, Janus ED, Siu ST, Ma OC, Lam TH, Lam KS (2006): Plasma lipid, 
lipoprotein and apolipoprotein levels in a random population sample of 2875 Hong 
Kong Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on 
cardiovascular risk assessment. Atherosclerosis 184: 438-445. 
Pankow JS, Kwan DK, Duncan BB, Schmidt MI, Couper DJ, Golden S, Ballantyne CM 
(2007): Cardiometabolic risk in impaired fasting glucose and impaired glucose 
tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 30: 325-
331. 
Papazafiropoulou A, Sotiropoulos A, Skliros E, Kardara M, Kokolaki A, Apostolou O, 
Pappas S (2009): Familial history of diabetes and clinical characteristics in Greek 
subjects with type 2 diabetes. BMC Endocr Disord 9: 12. 
Pastromas S, Terzi AB, Tousoulis D, Koulouris S (2008): Postprandial lipemia: an under-
recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol 126: 
3-12. 
 75 
 
Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M (2004): 
Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific 
region. Circulation 110: 2678-2686. 
Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM, 
Jr., Patsch W (1992): Relation of triglyceride metabolism and coronary artery 
disease. Studies in the postprandial state. Arterioscler Thromb 12: 1336-1345. 
Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais GR, Despres JP, Lamarche B (2002): 
Plasma free fatty acid levels and the risk of ischemic heart disease in men: 
prospective results from the Quebec Cardiovascular Study. Atherosclerosis 160: 
377-384. 
Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB (2005): Non-high-
density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary 
heart disease in men. Circulation 112: 3375-3383. 
Poapst M, Reardon M, Steiner G (1985): Relative contribution of triglyceride-rich 
lipoprotein particle size and number to plasma triglyceride concentration. 
Arteriosclerosis 5: 381-390. 
Pongchaiyakul C, Hongsprabhas P, Pisprasert V (2006): Rural-urban difference in lipid 
levels and prevalence of dyslipidemia: a population-based study in Khon Kaen 
province, Thailand. J Med Assoc Thai 89: 1835-1844. 
Proctor SD, Mamo JC (1998): Retention of fluorescent-labelled chylomicron remnants 
within the intima of the arterial wall--evidence that plaque cholesterol may be 
derived from post-prandial lipoproteins. Eur J Clin Invest 28: 497-503. 
Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LP, Lumley T, Robbins 
J, Burke G, Newman AB, et al (2004): The association between lipid levels and the 
risks of incident myocardial infarction, stroke, and total mortality: The 
Cardiovascular Health Study. J Am Geriatr Soc 52: 1639-1647. 
Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, 
Pedersen TR, Kjekshus J (2004): Reduction of cardiovascular events by simvastatin 
in nondiabetic coronary heart disease patients with and without the metabolic 
syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). 
Diabetes Care 27: 1735-1740. 
Rallidis LS, Pitsavos C, Panagiotakos DB, Sinos L, Stefanadis C, Kremastinos DT (2005): 
Non-high density lipoprotein cholesterol is the best discriminator of myocardial 
infarction in young individuals. Atherosclerosis 179: 305-309. 
Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C (2008): High 
prevalence of diabetes and cardiovascular risk factors associated with urbanization 
in India. Diabetes Care 31: 893-898. 
Rashid S, Watanabe T, Sakaue T, Lewis GF (2003): Mechanisms of HDL lowering in 
insulin resistant, hypertriglyceridemic states: the combined effect of HDL 
triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36: 421-
429. 
Razak F, Anand S, Vuksan V, Davis B, Jacobs R, Teo KK, Yusuf S (2005): Ethnic 
differences in the relationships between obesity and glucose-metabolic 
 76 
 
abnormalities: a cross-sectional population-based study. Int J Obes (Lond) 29: 656-
667. 
Rebolledo OR, Actis Dato SM (2005): Postprandial hyperglycemia and hyperlipidemia-
generated glycoxidative stress: its contribution to the pathogenesis of diabetes 
complications. Eur Rev Med Pharmacol Sci 9: 191-208. 
Reckless JP, Betteridge DJ, Wu P, Payne B, Galton DJ (1978): High-density and low-
density lipoproteins and prevalence of vascular disease in diabetes mellitus. Br Med 
J 1: 883-886. 
Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE (2005): Non-HDL cholesterol, 
apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk 
factors for cardiovascular disease in women. JAMA 294: 326-333. 
Rimm AA HA, Kalbfleisch JH, Anderson AJ & Hoffmann RG. (1980): Basic Biostatistics 
in Medicine and Epidemiology. New York: Appleton-Century-Crofts 
Roberto Robles N, Barroso S, Marcos G, Sanchez Munoz-Torrero JF (2009): [Lipid control 
in diabetic patients in Extremadura (Spain)]. Endocrinol Nutr 56: 112-117. 
Roberts WC (1989): Recent studies on the effects of beta blockers on blood lipid levels. Am 
Heart J 117: 709-714. 
Robinson JG, Wang S, Smith BJ, Jacobson TA (2009): Meta-analysis of the relationship 
between non-high-density lipoprotein cholesterol reduction and coronary heart 
disease risk. J Am Coll Cardiol 53: 316-322. 
Ronnemaa T, Laakso M, Kallio V, Pyorala K, Marniemi J, Puukka P (1989): Serum lipids, 
lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart 
disease in non-insulin-dependent diabetic patients. Am J Epidemiol 130: 632-645. 
Roselli della Rovere G, Lapolla A, Sartore G, Rossetti C, Zambon S, Minicuci N, Crepaldi 
G, Fedele D, Manzato E (2003): Plasma lipoproteins, apoproteins and 
cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr 
Metab Cardiovasc Dis 13: 46-51. 
Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L (1989): Impact of cardiovascular risk 
factors on coronary heart disease and mortality among middle aged diabetic men: a 
general population study. BMJ 299: 1127-1131. 
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, 
Schaefer EJ, Schectman G, et al (1999): Gemfibrozil for the secondary prevention of 
coronary heart disease in men with low levels of high-density lipoprotein cholesterol. 
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study 
Group. N Engl J Med 341: 410-418. 
Ruixing Y, Jinzhen W, Yaoheng H, Jing T, Hai W, Muyan L, Yiyang L, Dongmei F, 
Hanjun Y, Yuming C (2008): Associations of diet and lifestyle with hyperlipidemia 
for middle-aged and elderly persons among the Guangxi Bai Ku Yao and Han 
populations. J Am Diet Assoc 108: 970-976. 
Rye KA, Clay MA, Barter PJ (1999): Remodelling of high density lipoproteins by plasma 
factors. Atherosclerosis 145: 227-238. 
 77 
 
Rywik SL, Manolio TA, Pajak A, Piotrowski W, Davis CE, Broda GB, Kawalec E (1999): 
Association of lipids and lipoprotein level with total mortality and mortality caused 
by cardiovascular and cancer diseases (Poland and United States collaborative study 
on cardiovascular epidemiology). Am J Cardiol 84: 540-548. 
Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer HB, Jr. (2000): Lecithin-cholesterol 
acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and 
atherosclerosis. Curr Opin Lipidol 11: 267-275. 
Santen RJ, Willis PW, 3rd, Fajans SS (1972): Atherosclerosis in diabetes mellitus. 
Correlations with serum lipid levels, adiposity, and serum insulin level. Arch Intern 
Med 130: 833-843. 
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, 
Khaw KT, Gudnason V (2007): Triglycerides and the risk of coronary heart disease: 
10,158 incident cases among 262,525 participants in 29 Western prospective studies. 
Circulation 115: 450-458. 
Schulze MB, Shai I, Manson JE, Li T, Rifai N, Jiang R, Hu FB (2004): Joint role of non-
HDL cholesterol and glycated haemoglobin in predicting future coronary heart 
disease events among women with type 2 diabetes. Diabetologia 47: 2129-2136. 
Semenkovich CF (2006): Insulin resistance and atherosclerosis. J Clin Invest 116: 1813-
1822. 
Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, 
Kristinsson A, McInnes GT, et al (2005): Reduction in cardiovascular events with 
atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac 
Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care 28: 1151-1157. 
Seviour PW, Teal TK, Richmond W, Elkeles RS (1988): Serum lipids, lipoproteins and 
macrovascular disease in non-insulin-dependent diabetics: a possible new approach 
to prevention. Diabet Med 5: 166-171. 
Seyum B, Mebrahtu G, Usman A, Mufunda J, Tewolde B, Haile S, Kosia A, Negassi E 
(2010): Profile of patients with diabetes in Eritrea: results of first phase registry 
analyses. Acta Diabetol 47: 23-27. 
Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J 
(2004a): Multivariate assessment of lipid parameters as predictors of coronary heart 
disease among postmenopausal women: potential implications for clinical guidelines. 
Circulation 110: 2824-2830. 
Shai I, Rimm EB, Schulze MB, Rifai N, Stampfer MJ, Hu FB (2004b): Moderate alcohol 
intake and markers of inflammation and endothelial dysfunction among diabetic 
men. Diabetologia 47: 1760-1767. 
Sharma MD, Pavlik VN (2001): Dyslipidaemia in African Americans, Hispanics and whites 
with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 3: 41-45. 
Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W (2001): 
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, 
lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The 
Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104: 1108-1113. 
 78 
 
Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, 
LaRosa J, Grundy S, et al (2006): Effect of lowering LDL cholesterol substantially 
below currently recommended levels in patients with coronary heart disease and 
diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29: 1220-1226. 
Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, 
Walldius G, Hellenius ML, Hamsten A (2009): Concentration of apolipoprotein B is 
comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than 
routine clinical lipid measurements in predicting coronary heart disease mortality: 
findings from a multi-ethnic US population. Eur Heart J 30: 710-717. 
Singh IM, Shishehbor MH, Ansell BJ (2007): High-density lipoprotein as a therapeutic 
target: a systematic review. JAMA 298: 786-798. 
Sisson SB, Camhi SM, Church TS, Martin CK, Tudor-Locke C, Bouchard C, Earnest CP, 
Smith SR, Newton RL, Jr., Rankinen T, et al (2009): Leisure time sedentary 
behavior, occupational/domestic physical activity, and metabolic syndrome in U.S. 
men and women. Metab Syndr Relat Disord 7: 529-536. 
Smaoui M, Hammami S, Chaaba R, Attia N, Hamda KB, Masmoudi AS, Mahjoub S, 
Bousslama A, Farhat MB, Hammami M (2004): Lipids and lipoprotein(a) 
concentrations in Tunisian type 2 diabetic patients; Relationship to glycemic control 
and coronary heart disease. J Diabetes Complications 18: 258-263. 
Snehalatha C, Ramachandran A (2009): Cardiovascular risk factors in the normoglycaemic 
Asian-Indian population--influence of urbanisation. Diabetologia 52: 596-599. 
Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Gareeboo H, 
Alberti KG, Shaw JE (2005): Increasing prevalence of Type 2 diabetes mellitus in 
all ethnic groups in Mauritius. Diabet Med 22: 61-68. 
Sorkin JD, Muller DC, Fleg JL, Andres R (2005): The relation of fasting and 2-h 
postchallenge plasma glucose concentrations to mortality: data from the Baltimore 
Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 
28: 2626-2632. 
Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, 
Horvath T, Doerries C, Heinemann M, et al (2010): Endothelial-vasoprotective 
effects of high-density lipoprotein are impaired in patients with type 2 diabetes 
mellitus but are improved after extended-release niacin therapy. Circulation 121: 
110-122. 
Spady DK, Dietschy JM (1985): Dietary saturated triacylglycerols suppress hepatic low 
density lipoprotein receptor activity in the hamster. Proc Natl Acad Sci U S A 82: 
4526-4530. 
Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993): Diabetes, other risk factors, and 
12-yr cardiovascular mortality for men screened in the Multiple Risk Factor 
Intervention Trial. Diabetes Care 16: 434-444. 
Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH (1996): A 
prospective study of triglyceride level, low-density lipoprotein particle diameter, and 
risk of myocardial infarction. JAMA 276: 882-888. 
 79 
 
Stein EA, Steiner PM (1989): Triglyceride measurement and its relationship to heart disease. 
Clin Lab Med 9: 169-185. 
Steiner G, Schwartz L, Shumak S, Poapst M (1987): The association of increased levels of 
intermediate-density lipoproteins with smoking and with coronary artery disease. 
Circulation 75: 124-130. 
Steinhagen-Thiessen E, Bramlage P, Losch C, Hauner H, Schunkert H, Vogt A, Wasem J, 
Jockel KH, Moebus S (2008): Dyslipidemia in primary care--prevalence, 
recognition, treatment and control: data from the German Metabolic and 
Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 7: 31. 
Stone NJ (1994): Secondary causes of hyperlipidemia. Med Clin North Am 78: 117-141. 
Sumi M, Sata M, Miura S, Rye KA, Toya N, Kanaoka Y, Yanaga K, Ohki T, Saku K, Nagai 
R (2007): Reconstituted high-density lipoprotein stimulates differentiation of 
endothelial progenitor cells and enhances ischemia-induced angiogenesis. 
Arterioscler Thromb Vasc Biol 27: 813-818. 
Surana SP, Shah DB, Gala K, Susheja S, Hoskote SS, Gill N, Joshi SR, Panikar V (2008): 
Prevalence of metabolic syndrome in an urban Indian diabetic population using the 
NCEP ATP III guidelines. J Assoc Physicians India 56: 865-868. 
Syvanne M, Taskinen MR (1997): Lipids and lipoproteins as coronary risk factors in non-
insulin-dependent diabetes mellitus. Lancet 350 Suppl 1: SI20-23. 
Tall AR (1998): An overview of reverse cholesterol transport. Eur Heart J 19 Suppl A: 
A31-35. 
Talmud PJ, Hawe E, Miller GJ, Humphries SE (2002): Nonfasting apolipoprotein B and 
triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged 
UK men. Arterioscler Thromb Vasc Biol 22: 1918-1923. 
Tan CE, Emmanuel SC, Tan BY, Jacob E (1999): Prevalence of diabetes and ethnic 
differences in cardiovascular risk factors. The 1992 Singapore National Health 
Survey. Diabetes Care 22: 241-247. 
Tan CE, Tai ES, Tan CS, Chia KS, Lee J, Chew SK, Ordovas JM (2003): APOE 
polymorphism and lipid profile in three ethnic groups in the Singapore population. 
Atherosclerosis 170: 253-260. 
Tanasescu M, Cho E, Manson JE, Hu FB (2004): Dietary fat and cholesterol and the risk of 
cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr 79: 999-
1005. 
Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C (2005): Enlarged 
waist combined with elevated triglycerides is a strong predictor of accelerated 
atherogenesis and related cardiovascular mortality in postmenopausal women. 
Circulation 111: 1883-1890. 
Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M 
(2009): Extended-release niacin or ezetimibe and carotid intima-media thickness. N 
Engl J Med 361: 2113-2122. 
 80 
 
Tekes-Manova D, Israeli E, Shochat T, Swartzon M, Gordon S, Heruti R, Ashkenazi I, 
Justo D (2006): The prevalence of reversible cardiovascular risk factors in Israelis 
aged 25-55 years. Isr Med Assoc J 8: 527-531. 
Temelkova-Kurktschiev TS, Kurktschiev DP, Vladimirova-Kitova LG, Vaklinova I, 
Todorova BR (2009): Prevalence and type of dyslipidaemia in a population at risk 
for cardiovascular death in Bulgaria. Folia Med (Plovdiv) 51: 26-32. 
Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK (2006): Primary prevention of 
cardiovascular diseases with statin therapy: a meta-analysis of randomized 
controlled trials. Arch Intern Med 166: 2307-2313. 
The DECODA Study Group (2007): Prevalence of the metabolic syndrome in populations 
of Asian origin. Comparison of the IDF definition with the NCEP definition. 
Diabetes Res Clin Pract 76: 57-67. 
The DECODE Study Group (2001): Glucose tolerance and cardiovascular mortality: 
comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: 397-405. 
The DECODE Study Group (2003): Age- and sex-specific prevalences of diabetes and 
impaired glucose regulation in 13 European cohorts. Diabetes Care 26: 61-69. 
The DECODE Study Group (2005): Are insulin resistance, impaired fasting glucose and 
impaired glucose tolerance all equally strongly related to age? Diabet Med 22: 1476-
1481. 
The DECODE Study Group (2006): Comparison of different definitions of the metabolic 
syndrome in relation to cardiovascular mortality in European men and women. 
Diabetologia 49: 2837-2846. 
Thomas GN, Chook P, Qiao M, Huang XS, Leong HC, Celermajer DS, Woo KS (2004): 
Deleterious impact of "high normal" glucose levels and other metabolic syndrome 
components on arterial endothelial function and intima-media thickness in 
apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc 
Biol 24: 739-743. 
Thomas GN, Jiang CQ, McGhee SM, Zhang WS, Lao XQ, Schooling M, Adab P, Lam TH, 
Cheng KK (2006): Association of vascular risk factors with increasing glycemia 
even in normoglycemic subjects in an older Chinese population: the Guangzhou 
Biobank Cohort Study. Metabolism 55: 1035-1041. 
Tolonen H, Keil U, Ferrario M, Evans A (2005): Prevalence, awareness and treatment of 
hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. 
Int J Epidemiol 34: 181-192. 
Tseng CH, Tseng CP, Chong CK, Cheng JC, Tai TY (2006): Independent association 
between triglycerides and coronary artery disease in Taiwanese type 2 diabetic 
patients. Int J Cardiol 111: 80-85. 
Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK (1997): 
Comparison of the prediction by 27 different factors of coronary heart disease and 
death in men and women of the Scottish Heart Health Study: cohort study. BMJ 315: 
722-729. 
 81 
 
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR (1998): 
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: 
United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823-828. 
U.K. Prospective Diabetes Study Investigators (1997): U.K. Prospective Diabetes Study 27. 
Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes 
Care 20: 1683-1687. 
Umeda T, Kono S, Sakurai Y, Shinchi K, Imanishi K, Nishikawa H, Ogawa S, Katsurada M, 
Wakabayashi K, Honjo S, et al (1998): Relationship of cigarette smoking, alcohol 
use, recreational exercise and obesity with serum lipid atherogenicity: a study of 
self-defense officials in Japan. J Epidemiol 8: 227-234. 
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K (1993): Ten-year 
cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein 
composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. 
Diabetologia 36: 1175-1184. 
Vaessen SF, Schaap FG, Kuivenhoven JA, Groen AK, Hutten BA, Boekholdt SM, Hattori 
H, Sandhu MS, Bingham SA, Luben R, et al (2006): Apolipoprotein A-V, 
triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk 
Population Study. J Lipid Res 47: 2064-2070. 
Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001): High 
apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal 
myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026-2033. 
Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J (2007): The 
metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in 
elderly non-diabetic Finns. Eur Heart J 28: 857-864. 
Warnick GR, Remaley AT (2001): Measurement of cholesterol in plasma and other body 
fluids. Curr Atheroscler Rep 3: 404-411. 
Wasada T, Kuroki H, Katsumori K, Arii H, Sato A, Aoki K (2004): Who are more insulin 
resistant, people with IFG or people with IGT? Diabetologia 47: 758-759. 
Venkatesan A, Hemalatha A, Bobby Z, Selvaraj N, Sathiyapriya V (2006): Effect of 
smoking on lipid profile and lipid peroxidation in normal subjects. Indian J Physiol 
Pharmacol 50: 273-278. 
Werk EE, Jr., Gonzalez JJ, Ranney JE (1993): Lipid level differences and hypertension 
effect in blacks and whites with type II diabetes. Ethn Dis 3: 242-249. 
West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, 
Grabauskas V, Jarrett RJ, Kosaka K, et al (1983): The role of circulating glucose 
and triglyceride concentrations and their interactions with other "risk factors" as 
determinants of arterial disease in nine diabetic population samples from the WHO 
multinational study. Diabetes Care 6: 361-369. 
Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ 
(2010): The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the 
Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in 
Atherosclerosis) Final Results and the Impact of Medication Adherence, Dose, and 
Treatment Duration. J Am Coll Cardiol doi:10.1016/j.jacc.2010.1003.1017. 
 82 
 
Wilson PW, Abbott RD, Castelli WP (1988): High density lipoprotein cholesterol and 
mortality. The Framingham Heart Study. Arteriosclerosis 8: 737-741. 
Wilson PW (1994): Established risk factors and coronary artery disease: the Framingham 
Study. Am J Hypertens 7: 7S-12S. 
Vlajinac H, Ilic M, Marinkovic J (1992): Cardiovascular risk factors and prevalence of 
coronary heart disease in type 2 (non-insulin-dependent) diabetes. Eur J Epidemiol 8: 
783-788. 
Wood PD, Stern MP, Silvers A, Reaven GM, von der Groeben J (1972): Prevalence of 
plasma lipoprotein abnormalities in a free-living population of the Central Valley, 
California. Circulation 45: 114-126. 
World Health Organization (2007): Prevention of cardiovascular disease: guideline for 
assessment and management of cardiovascular risk. WHO Press. 
Wu DM, Pai L, Sun PK, Hsu LL, Sun CA (2001): Joint effects of alcohol consumption and 
cigarette smoking on atherogenic lipid and lipoprotein profiles: results from a study 
of Chinese male population in Taiwan. Eur J Epidemiol 17: 629-635. 
Yarnell JW, Patterson CC, Sweetnam PM, Thomas HF, Bainton D, Elwood PC, Bolton CH, 
Miller NE (2001): Do total and high density lipoprotein cholesterol and triglycerides 
act independently in the prediction of ischemic heart disease? Ten-year follow-up of 
Caerphilly and Speedwell Cohorts. Arterioscler Thromb Vasc Biol 21: 1340-1345. 
Zaman MM, Yoshiike N, Rouf MA, Syeed MH, Khan MR, Haque S, Mahtab H, Tanaka H 
(2001): Cardiovascular risk factors: distribution and prevalence in a rural population 
of Bangladesh. J Cardiovasc Risk 8: 103-108. 
Zaninotto P, Mindell J, Hirani V (2007): Prevalence of cardiovascular risk factors among 
ethnic groups: results from the Health Surveys for England. Atherosclerosis 195: 
e48-57. 
Zhang X, Sun Z, Zhang D, Zheng L, Li J, Liu S, Xu C, Hu D, Sun Y (2009): Prevalence 
and association with diabetes and obesity of lipid phenotypes among the 
hypertensive Chinese rural adults. Heart Lung 38: 17-24. 
Zhao WH, Zhang J, Zhai Y, You Y, Man QQ, Wang CR, Li H, Li Y, Yang XG (2007): 
Blood lipid profile and prevalence of dyslipidemia in Chinese adults. Biomed 
Environ Sci 20: 329-335. 
Zimmet P, Alberti KG, Shaw J (2001): Global and societal implications of the diabetes 
epidemic. Nature 414: 782-787. 
 
 
 
 
 
 83 
 
APPENDIX 1 Measures of lipid components in each study 
Countries and studies Blood sample Total cholesterol High-density lipoprotein cholesterol Triglycerides 
China     
Hong Kong Cardiovascular 
Disease  Risk Factor 
Prevalence Study 
Plasma Cholesterol oxidase (CHOD) 
method; Hitachi 717 analyser 
(Hitachi Instruments, California, 
USA). 
Measured after precipitation of very-
low density lipoprotein (VLDL) and 
low-density lipoprotein (LDL) by 
polyethylene glycol PEG 6000. 
Lipase/glycerol kinase method; 
Hong Kong Workforce 
Survey on CVD Risk 
Factors  
Venous 
Plasma 
Enzymatic method, with reagents 
(Baker Instruments Corporation, 
Allentown, PA 18103, USA) with 
Cobas Mira analyzer (Hoffman-La 
Roche and Co., Basle Switzerland).  
Enzymatic method after 
precipitation with dextran sulphate-
MgCl2 on Cobas Mira analyzer 
(Hoffman-La Roche and Co., Basle 
Switzerland) 
Enzymatic method, with 
reagents (Baker Instruments 
Corporation, Allentown, PA 
18103, USA) with Cobas Mira 
analyzer (Hoffman-La Roche 
and Co., Basle Switzerland) 
Qingdao Diabetes Survey 
2002 
Venous 
Plasma 
Enzymatic method (AMS Analyzer 
Medical System, SABA-18, Rome, 
Italy) 
 
Enzymatic method after 
precipitation (AMS Analyzer 
Medical System, SABA-18, Rome, 
Italy) 
 
Enzymatic method (AMS 
Analyzer Medical System, 
SABA-18, Rome, Italy) 
Qingdao Diabetes Study 
2006 
Serum Enzymatic method (Olympus 
reagent) With OLYMPUS-AU640 
Automatic Analyzers (Olympus 
Optical. Tokyo, Japan) 
Direct method (Olympus reagent) 
with OLYMPUS-AU640 Automatic 
Analyzers (Olympus Optical. 
Tokyo, Japan) 
Enzymatic method (Olympus 
reagent) with OLYMPUS-
AU640 Automatic Analyzers 
(Olympus Optical. Tokyo, 
Japan) 
Finland     
East-West men Serum Enzymatic techniques (Monotest, 
Boehringer Mannheim GmbH, FRG) 
Enzymetic method after 
precipitation of VLDL and LDL by 
Enzymatic techniques 
(Monotest, Boehringer 
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Olli C3000 photometer (Kone Oy, 
Finland) 
 
means of dextran-magnesium-
chloride, with Olli C3000 
photometer (Kone Oy, Finland) 
Mannheim GmbH, FRG) 
Olli C3000 photometer (Kone 
Oy, Finland) 
National FINRISK Study 
87, 92 
Serum Enzymatic techniques (Cholesterol 
oxidase-peroxidase-amidopyrine, 
CHOD-PAP, Boehringer-
Mannheim, Mannheim, Germany) 
 
Enzymatic method after dextran 
sulfate magnesium chloride 
precipitation of apolipoprotein B 
(apoB)-containing lipoproteins 
Enzymatic techniques (CHOD-
PAP, Boehringer-Mannheim, 
Mannheim, Germany) 
National FINRISK Study 
2002 
Serum Enzymatic method (CHOD-PAP; 
Thermo Elektron Oy, Finland); 
 
Enzymatic method (CHOD-PAP; 
Thermo Elektron Oy, Finland) after 
precipitation by the PTA-
precipitation method 
Enzymatic techniques 
(Glycerol phosphate oxidase-
peroxidase-amidopyrine, GPO-
PAP; Thermo Elektron Oy) 
Oulu Study Serum Enzymatic method (CHOD-PAP, 
Boehringer Mannheim, Mannheim, 
Germany).  
 
Enzymatic CHOD-PAP method 
after precipitation of LDL and 
VLDL with a reagent containing 
phosphotungstic acid and MgCl2 
(Boehringer Mannheim) 
Enzymatic method (CHOD-
PAP, Boehringer Mannheim, 
Mannheim, Germany) 
Savitaipale Study Plasma Enzymatic colorimetric method 
(CHOD-PAP) Cobas Integra 
400/700 analyzer 
Enzymatic colorimetric method 
(CHOD-PAP) Cobas Integra 
400/700 analyzer 
Enzymatic colorimetric method 
(CHOD-PAP) Cobas Integra 
400/700 analyzer 
Vantaa Study Serum Enzymatic techniques (Boehringer-
Mannheim) 
Enzymatic method after 
precipitation with polyethylenglycol 
Enzymatic techniques 
(Boehringer-Mannheim) 
India     
Chennai 94 Serum Enzymatic method; 
Hitachi 704 autoanalyser, using 
Boehringer Mannheim (Mannheim, 
Germany) reagents 
Phosphotungstate-magnesium 
precipitation method. 
Hitachi 704 autoanalyser, using 
Boehringer Mannheim (Mannheim, 
Enzymatic method. 
Hitachi 704 autoanalyser, using 
Boehringer Mannheim 
(Mannheim, Germany) 
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Germany) reagents reagents 
Chennai 97 Venous 
Plasma 
CHOD-PAP method (Boehringer 
Mannheim, Germany);   
Corning Express Plus Auto Analyser 
(Corning, medfied, MA, USA) 
Phosphotungstic acid method after 
precipitation of LDL and 
chylomicrons (Boehringer 
Mannheim, Germany);  
Corning Express Plus Auto Analyser 
(Corning, medfied, MA, USA) 
GPO-PAP method (Boehringer 
Mannheim, Germany);  
Corning Express Plus Auto 
Analyser (Corning, medfied, 
MA, USA) 
CURES Serum CHOD-PAP method with Hitachi-
912 Autoanalyser (Hitachi, 
Mannheim, Germany) using kits 
supplied by Roche Diagnostics 
(Mannheim, Germany).  
 
Direct method (polyethylene glycol–
pretreated enzymes) with Hitachi-
912 Autoanalyser (Hitachi, 
Mannheim, Germany) using kits 
supplied by Roche Diagnostics 
(Mannheim, Germany).  
GPO-PAP method; 
Hitachi-912 Autoanalyser 
(Hitachi, Mannheim, Germany) 
using kits supplied by Roche 
Diagnostics (Mannheim, 
Germany).  
 
Chennai 2006 Serum Standard enzymatic procedures  
(Roche Diagnostics, Mannheim, 
Germany)  
Direct assay method (Roche 
Diagnostics, Mannheim, Germany) 
Standard enzymatic procedures 
(Roche Diagnostics, 
Mannheim, Germany) 
Italy     
Cremona Study Plasma Enzymatic techniques (Boehringer-
Mannheim, Mannheim, Germany) 
with CIBA Corning 550 Express 
Auto-analyser  
Precipitation with PEG using a 
Colortest kit (Roche, Basel, 
Switzerland). 
Enzymatic techniques 
(Boehringer-Mannheim, 
Mannheim, Germany) with 
CIBA Corning 550 Express 
Auto-analyser 
Japan     
Funagata Study Plasma Cholesterol oxidase method (L-type 
Wako CHO-H [Wako Pure 
Chemical Industries, Osaka, Japan]) 
Direct method (Cholesterol N HDL 
[Daiichi Pure Chemicals, Tokyo, 
Japan]) with TBA 80FR (Toshiba 
GPO HDAOS method 
(Pureauto S TG-N [Daiichi 
Pure Chemicals, Tokyo, 
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with TBA 80FR (Toshiba medical 
system corporation, Tokyo) 
medical system corporation, Tokyo) Japan]) with TBA 80FR 
(Toshiba medical system 
corporation, Tokyo) 
Hisayama Study Serum Enzymatic techniques (TBA-80S; 
Toshiba Inc., Tokyo, Japan) 
Enzymatic method after 
precipitation of of VLDL and LDL 
with dextran sulfate and magnesium 
(TBA-80S; Toshiba Inc., Tokyo, 
Japan) 
Enzymatic techniques (TBA-
80S; Toshiba Inc., Tokyo, 
Japan) 
Mauritius     
Mauritius 1987 Venous 
plasma 
Manual enzymatic colorimetric 
method (Coulter Minikem 
Spectrophotometer), (Boeringer Cat 
no 701912) 
 
Manual enzymatic colorimetric 
method (Coulter Minikem 
Spectrophotometer), (Boeringer Cat 
no 701912) 
Precipitation method (Biomerieux) 
Manual enzymatic colorimetric 
method(Coulter Minikem 
Spectrophotometer) (Boeringer 
Cat nr 400971) 
Mauritius 1992 Venous 
plasma 
Automated enzymatic method with 
Chemistry Profile Analyser Model 
LS (Coulter- France) 
Automated enzymatic method, 
Chemistry Profile Analyser Model 
LS (Coulter- France) 
Precipitation method (Biomerieux) 
Automated enzymatic method 
with Chemistry Profile 
Analyser Model LS (Coulter- 
France) 
Mauritius 1998 Venous 
plasma 
Automated enzymatic methods; 
Cobas Mira analyzer (Roche 
Diagnostics, France) 
Automated enzymatic methods; 
Cobas Mira analyzer (Roche 
Diagnostics, France) 
Direct method (Biomerieux) 
Automated enzymatic 
methods; Cobas Mira analyzer 
(Roche Diagnostics, France) 
Poland     
POLMONICA Serum Direct Liebermann-Burchard 
method (Boehringer-Mannheim) 
Determined in the supernatant after 
precipitation with heparin 
manganese (Boehringer-Mannheim) 
Enzymatic method 
(Boehringer-Mannheim) 
 
Republic of Cyprus     
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Nicosia Diabetes Study Whole Blood Cobas Micra Plus Roche Cobas Micra Plus Roche Cobas Micra Plus Roche 
Spain     
The Guía Study Plasma Standard enzymatic methods 
(Boehringer-Mannheim Hitachi 717 
autoanalyser, Tokyo, Japan) 
Phosphotungstate precipitation 
(Boehringer-Mannheim Hitachi 717 
autoanalyser, Tokyo, Japan) 
Standard enzymatic methods 
(Boehringer-Mannheim 
Hitachi 717 autoanalyser, 
Tokyo, Japan) 
The Viva Study Plasma Enzymatic techniques (Boehringer-
Mannheim) 
Enzymatic techniques (Boehringer-
Mannheim) 
Enzymatic techniques 
(Boehringer-Mannheim) 
Sweden     
MONICA Serum Enzymatic techniques (Boehringer-
Mannheim GmbH, Germany) 
 
Phosphotungstate-Mg2+ precipitation 
method 
Enzymatic method (CHOD-
PAP, Boehringer-Mannheim 
GmbH, Germany) 
The Uppsala Longitudinal 
Study of Adult Men 
(ULSAM) 
Serum Enzymatic techniques using IL Test 
Cholesterol Trinders's Method and 
IL Test Enzymatic-colorimetric 
Method for use in a Monarch 
apparatus (Instrumentation 
Laboratories, Lexington, USA).  
(http://www.pubcare.uu.se/ULSAM/
invest/70yrs/meth70.htm#09) 
Separated by precipitation with 
magnesium 
chloride/phosphotumgstate. 
Enzymatic techniques using IL 
Test Cholesterol Trinders's 
Method and IL Test 
Enzymatic-colorimetric 
Method for use in a Monarch 
apparatus (Instrumentation 
Laboratories, Lexington, 
USA). 
The Netherlands     
The Hoorn Study Serum Enzymatic techniques (Boehringer-
Mannheim, Mannheim, Germany); 
 
Enzymatic techniques after 
precipitation of the low and very 
low-density lipoproteins 
(Boehringer-Mannheim, Mannheim, 
Germany) 
Enzymatic techniques 
(Boehringer-Mannheim, 
Mannheim, Germany); 
Zutphen Serum Enzymatic techniques (CHOD-PAP Enzymatic method after Enzymatic techniques (CHOD-
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mono-test kit,  Boehringer-
Mannheim) 
 
precipitation of apoB-containing 
particles by means of dextran 
magnesium sulphate. 
PAP mono-test kit,  
Boehringer-Mannheim) 
U.K.     
Isle of ELY Diabetes 
Project  
Plasma Enzymatic techniques, RA 1000 
(Bayer Diagnostics, Basingstoke, 
Hants, UK) 
Enzymatic methods 
 
Standard automated enzymatic 
method with the RA1000 
(Bayer Diagnostics, Suffolk, 
U.K.), 
Newcastle Heart Project Plasma Cholesterol oxidase/peroxidase 
method with Cobas Bio centrifugal 
analyzer (Roche Products Ltd, 
Welwyn Garden City, UK) 
Measuring the supernatant 
cholesterol concentration after 
precipitation of apoB-containing 
lipoproteins with heparin and 
manganese. 
Cobas Bio centrifugal analyzer 
(Roche Products Ltd, Welwyn 
Garden City, UK) 
Lipase/glycerol kinase method. 
Cobas Bio centrifugal analyzer 
(Roche Products Ltd, Welwyn 
Garden City, UK)  
 
The Goodinge Study Plasma Cholesterol esterase method 
(Boehringer Mannheim, Lewes, 
Sussex, U.K.) 
 
Enzymatic spectrophotometric 
method (Roche Diagnostics, 
Hatfield, Herts, U.K.) after 
precipitation of LDL by the addition 
of phosphotungstic acid in the 
presence of magnesium ions. 
Enzymatic spectrophotometric 
method (Roche Diagnostics, 
Hatfield, Herts, U.K.).  
 
 
 
